triazoles has been researched along with HIV Infections in 546 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (0.92) | 18.2507 |
| 2000's | 131 (23.99) | 29.6817 |
| 2010's | 356 (65.20) | 24.3611 |
| 2020's | 54 (9.89) | 2.80 |
| Authors | Studies |
|---|---|
| Challenger, E; Else, L; Imaz, A; Khoo, S; Niubó, J; Penchala, SD; Podzamczer, D; Prieto, P; Rigo-Bonin, R; Saumoy, M; Scévola, S; Silva-Klug, A; Soriano, I; Tiraboschi, J | 1 |
| Appiah-Kubi, P; Iwuchukwu, EA; Soliman, MES | 1 |
| Asante-Appiah, E; Grobler, JA; Hazuda, D; Lai, J; Martin, EA; Petropoulos, CJ; Sklar, P; Walworth, C; Wan, H; Yang, D | 1 |
| Canziani, GA; Chaiken, IM; Dick, A; Enríquez Rodríguez, L; Holmes, AP; Rashad, AA; Root, MJ; Zhang, S | 1 |
| Akari, H; Irie, K; Kikumori, M; Murata, M; Seki, Y; Tan, W; Tang, Y; Wardani, NP; Washizaki, A | 1 |
| Khoo, S; Stockdale, AJ | 1 |
| Antinori, S; Baldelli, S; Bisinella, GC; Cattaneo, D; Cossu, MV; Fusi, M; Gervasoni, C; Meraviglia, P; Micheli, V; Resnati, C; Vimercati, S | 1 |
| Cattelan, AM; Leoni, D; Mazzitelli, M; Putaggio, C; Sasset, L | 1 |
| Cai, W; Chen, M; Lan, G; Lan, Y; Liang, S; Ma, Y; Ni, M; Sun, Z; Wang, J; Yan, L; Yu, F; Zhang, F; Zhang, H; Zhang, X | 1 |
| Bailón, L; Curran, A; Else, L; Graterol, F; Imaz, A; Khoo, S; Moltó, J; Paredes, R; Pérez, F; Ramos, N; Sandoval, D | 1 |
| Bociąga-Jasik, M; Hlebowicz, M; Jakubowski, P; Parczewski, M; Raczyńska, A; Scheibe, K; Szetela, B; Szymczak, A; Urbańska, A; Łojewski, W | 1 |
| Carrozzo, G; Cattaneo, D; Gervasoni, C; Poloni, A; Riva, A | 1 |
| G Ang, C; M Chaiken, I; P Carter, E | 1 |
| Antoni, MD; Castelli, F; Cattelan, AM; Fabbiani, M; Ferraresi, A; Lapadula, G; Mazzitelli, M; Putaggio, C; Quiros-Roldan, E; Ripamonti, D; Zuglian, G | 1 |
| Afani Saud, A; Bettacchi, C; Chahin Anania, C; Correll, T; Eves, K; Grandhi, A; Hanna, GJ; Hepler, D; Hwang, C; Klopfer, SO; Molina, JM; Robertson, MN; Yazdanpanah, Y | 1 |
| Chen, H; Chen, L; Li, J; Liu, H; Luo, RH; Ma, D; Peng, P; Wang, J; Xie, X; Yang, LM; Zhang, S; Zheng, CB; Zheng, YG; Zheng, YT | 1 |
| Bolzenius, J; Chow, D; Clements, DM; De Gruttola, V; Kallianpur, K; Matos, M; Ndhlovu, LC; Paul, R; Premeaux, TA; Rodriguez-Benitez, RJ; Shikuma, CM; Shiramizu, B; Siriwardhana, C; Souza, SA; Turner, EH; Wojna, V | 1 |
| Blevins, SR; Chastain, DB; Cluck, DB; Hester, EK | 1 |
| Badshah, C; DeJesus, E; Goldstein, D; Hanna, GJ; Hepler, D; Hwang, C; Johnson, M; Kumar, S; Mallolas, J; Molina, JM; Pozniak, A; Rodgers, A; Sklar, P; Teal, V; Teppler, H; Wong, A | 1 |
| Hazuda, D; Hwang, C; Lai, MT | 1 |
| Grobler, JA; Markowitz, M | 1 |
| Cahn, P; DeJesus, E; Hanna, GJ; Hwang, C; Kumar, S; Lai, MT; Lombaard, J; Lupinacci, L; Martin, EA; Molina, JM; Rodgers, A; Sax, PE; Sklar, P; Squires, K | 1 |
| Abdi, B; Andreoni, M; Antinori, A; Armenia, D; Bertoli, A; Calvez, V; Ceccherini-Silberstein, F; Charpentier, C; Descamps, D; Forbici, F; Gennari, W; Jary, A; Marcelin, AG; Mussini, C; Perno, CF; Santoro, MM; Soulie, C; Storto, A | 1 |
| Aguilera, A; Alejos, B; Álvarez, M; Blanco, JR; Caballero, E; Espinosa, N; García, F; García-Álvarez, M; García-Bujalance, S; García-Fraile, LJ; Gómez-Sirvent, JL; Guerrero-Beltrán, C; Iborra, A; Imaz, A; Iribarren, JA; Martínez, M; Martínez-Sanz, J; Masiá, M; Montero, M; Moreno, S; Olalla, J; Peraire, J; Portilla, J; Rivero, M; Rodríguez, C; Vidal-Ampurdanes, MC | 1 |
| DiBenedetto, A; Fackler, P; Fan, L; Iwamoto, M; Khalilieh, S; Stoch, SA; Triantafyllou, I; Vallee, MH; Yee, KL | 1 |
| Alves Saldanha, S; André, P; Buclin, T; Cavassini, M; Choong, E; Courlet, P; Csajka, C; Decosterd, LA; Desfontaine, V; Günthard, HF; Marzolini, C | 1 |
| Talwani, R; Temesgen, Z | 1 |
| Cocklin, S; Karadsheh, R; Meuser, ME | 1 |
| Barat, C; Drouin, J; Gagnon, MT; Leboeuf, M; Proust, A; Tremblay, MJ; Vanasse, F | 1 |
| Kraft, WK; Lam, E; Schaefer, J; Zhan, T; Zheng, R | 1 |
| Azeem, SM; Frey, KM; Muwonge, AN; Tabassum, T | 1 |
| Calvi, RM; Chiarella, J; Deeks, SG; Ho, YC; Hoh, R; Jenike, KM; Yeh, YJ | 1 |
| Fulco, PP; Herity, LB | 1 |
| Hewlett, K; Hughes, SH; Pauly, GT; Schneider, JP; Smith, SJ | 1 |
| Arduino, RC; Bauch, T; Chen, M; Graviss, EA; Kimata, JT; Li, M; Liu, W; Wang, J | 1 |
| Iwamoto, M; Khalilieh, S; Sanchez, R; Stoch, SA; Wenning, L; Yee, KL | 1 |
| Alam, SM; Anasti, K; Cronin, K; Desaire, H; Ding, H; Eaton, A; Go, EP; Haynes, BF; Kappes, J; Montefiori, D; Parks, R; Saunders, KO; Sodroski, J | 1 |
| Kandala, B; Vaddady, P; Yee, KL | 1 |
| Arribas, JR; Battegay, M; Béguelin, C; Bhagani, S; Cinque, P; Collins, S; Cotter, A; De Miguel, R; Guaraldi, G; Kirk, O; Kowalska, JD; Mallon, P; Marzolini, C; Molina, JM; Podlekareva, D; Rauch, A; Ryom, L; Winston, A | 1 |
| Asante-Appiah, E; Feng, M; Graham, D; Hazuda, DJ; Hwang, C; Kumar, S; Lai, MT; Martin, EA; Ngo, W; Sklar, P | 1 |
| Feng, LS; Liu, D; Zhao, F; Zheng, MJ | 1 |
| Boccuto, A; Dragoni, F; Giammarino, F; Giannini, A; Hosseini, BA; Saladini, F; Shafer, RW; Vicenti, I; Zazzi, M | 1 |
| Alvarez Bognar, F; Elion, R; Hwang, C; Martin, EA; Orkin, C; Rockstroh, JK; Sklar, P; Thompson, M; Xu, ZJ | 1 |
| Abdel-Daim, MM; Afify, MA; Ahmed, IGG; Alkahtani, TA; Alrowili, ASM; Altulayhi, RI; Bin-Jumah, M; Ghozy, S | 1 |
| Hanna, GJ; Hwang, C; Kumar, S; Lin, G; Martin, E; Molina, JM; Orkin, C; Sax, PE; Squires, KE; Sussmann, O; Teppler, H | 1 |
| Chinen, M; Hayashida, T; Hirano, A; Kobayashi, M; Masuda, J; Watanabe, K | 1 |
| Bassa, A; Hill, A; Kumar, S; Mngqibisa, R; Nelson, M; Orkin, C; Rassool, M; Rodgers, A; Teal, V; Teppler, H; Winston, A | 1 |
| Bickel, M; Cahn, P; Greaves, W; Johnson, M; Kumar, P; Molina, JM; Morais, C; Rizzardini, G; Sklar, P; Wan, H; Xu, ZJ | 1 |
| Brenner, BG; Ibanescu, RI; Oliveira, M; Routy, JP; Thomas, R | 1 |
| Hans, L; Moorhouse, M; Steegen, K; Venter, WD; Wensing, AM | 1 |
| Afani Saud, A; Bettacchi, C; Chahin Anania, C; Correll, T; DeJesus, E; Eves, K; Grandhi, A; Hanna, GJ; Hwang, C; Molina, JM; Olsen Klopfer, S; Robertson, MN; Sklar, P; Yazdanpanah, Y | 1 |
| Ciccullo, A; D'Angelillo, A; Di Giambenedetto, S; Farinacci, D; Iannone, V; Lombardi, F; Tamburrini, E; Visconti, E | 1 |
| Bieniasz, P | 1 |
| Arenas-Pinto, A; Benn, P; Brima, N; Clarke, A; Copas, A; Fisher, M; Gilson, R; Hawkins, D; Milinkovic, A; Schembri, G; Williams, A | 1 |
| Benko, E; Huibner, S; Kandel, G; Kaul, R; Kim, CJ; Kovacs, C; Ostrowski, M; Rousseau, R; Shahabi, K | 1 |
| Abagyan, R; Cherezov, V; Han, GW; Handel, TM; Kufareva, I; Stevens, RC; Wu, B; Zheng, Y | 1 |
| Alberto Arnaiz, J; Amin, J; Andrade-Villanueva, J; Belloso, W; Clark, A; Clarke, A; Cooper, D; Emery, S; Gatell, J; Gill, J; Harrigan, R; Horban, A; Kaiser, R; Kelleher, A; Losso, M; Madero, JS; Mallon, P; Pett, SL; Porteiro, N; Prazuck, T; Rockstroh, JK; Ruxrungtham, K; Silk, D; Sugiura, W; Tu, E; Wolff, M; Woolley, I | 1 |
| Borm, K; Cashin, K; Churchill, M; Duncan, R; Ellenberg, P; Ellett, A; Flynn, JK; Gorry, PR; Gray, LR; Jubb, B; Lee, B; Lewin, SR; Lewis, M; Roche, M; Sterjovski, J; Westby, M; Zhou, J | 1 |
| Amico, KR; Andrade, A; Andrew, P; Chege, W; Chen, YQ; Cottle, LM; Eshleman, SH; Frank, I; Gulick, RM; Hendrix, CW; Ho, K; Hodder, S; Klingman, KL; Landovitz, RJ; Manabe, YC; Marcus, C; Marzinke, MA; Mayer, KH; McCauley, M; McGowan, I; Richardson, P; Rinehart, AR; Rooney, JF; Salata, RA; Santana, J; Siegel, M; Stekler, JD; Swaminathan, S; Wilkin, TJ; Young, AM | 1 |
| Belarbi, L; Chaix, ML; Dulioust, E; Duvivier, C; Ghosn, J; Launay, O; Lê, MP; Mahjoub, N; Peytavin, G; Salmon, D; Viard, JP | 1 |
| Asmuth, DM; Chun, TW; Garcia, JC; Kashuba, AD; Landay, A; Ma, ZM; Mann, S; Miller, CJ; Pollard, RB; Sainz, T; Serrano-Villar, S; Thompson, CG; Troia-Cancio, P; Utay, NS | 1 |
| Antinori, A; Canovari, B; Colafigli, M; Colangeli, V; D'Arminio Monforte, A; D'Avino, A; De Luca, A; Di Biagio, A; Di Giambenedetto, S; Fantauzzi, A; Francisci, D; Gagliardini, R; Ghisetti, V; Grima, P; Lamonica, S; Latini, A; Lisi, L; Mastroianni, C; Meini, G; Micheli, V; Navarra, P; Orofino, G; Re, MC; Rossetti, B; Rusconi, S; Sterrantino, G; Trezzi, M; Vignale, F; Vullo, V; Zazzi, M | 1 |
| Abner, E; Chen, HC; Fanunza, E; Filion, GJ; Izquierdo-Bouldstridge, A; Jordan, A; Konuma, T; Mahmoudi, T; Stoszko, M; Zeng, L; Zhang, Q; Zhou, MM; Zorita, E | 1 |
| Bruckman, RS; Campbell, GR; Durden, DL; Herns, SD; Joshi, S; Spector, SA | 1 |
| Aralaguppe, SG; Ashokkumar, M; Hanna, LE; Neogi, U; Tripathy, SP | 1 |
| Cahn, P; DeJesus, E; Hanna, GJ; Hwang, C; Kumar, S; Lai, MT; Lombaard, J; Lupinacci, L; Molina, JM; Nguyen, BY; Rodgers, A; Sax, PE; Sklar, P; Squires, K; Xu, X | 1 |
| Chen, CH; Daelemans, D; De Clercq, E; Huang, B; Kang, D; Lee, KH; Liu, J; Liu, X; Liu, Z; Pannecouque, C; Tian, Y; Zhan, P; Zhang, H | 1 |
| Anderson, JL; Harty, L; Jacobson, J; Khoury, G; Lee, MY; Lewin, SR; Li, S; Mota, TM; Purcell, DFJ; Tumpach, C | 1 |
| Colombier, MA; Molina, JM | 1 |
| Álvarez, H; Llibre, JM; Yzusqui, M | 1 |
| Deeks, ED | 1 |
| Cary, DC; Peterlin, BM | 1 |
| Calvez, V; Ceccherini-Silberstein, F; Charpentier, C; Descamps, D; Di Carlo, D; Gennari, W; Marcelin, AG; Paraskevis, D; Perno, CF; Santoro, MM; Soulie, C; Sterrantino, G; Storto, A; Zazzi, M | 1 |
| Claussen, A; de Greef, R; Ouerdani, A; Wenning, L; Yee, KL | 1 |
| Andreoni, M; Antinori, A; Bagnarelli, P; Borghi, V; Bruzzone, B; Callegaro, AP; De Gennaro, M; Gianotti, N; Maffongelli, G; Maggiolo, F; Saladini, F; Sterrantino, G; Vergori, A; Zaccarelli, M; Zazzi, M | 1 |
| Bouhajib, M; Fan, L; Iwamoto, M; Khalilieh, S; Sanchez, RI; Searle, S; Vaynshteyn, K; Yee, KL | 1 |
| Cahn, P; Hanna, G; Hwang, C; Kumar, S; Martin, E; Molina, JM; Orkin, C; Rodgers, A; Sax, P; Squires, K; Teppler, H; Thompson, M; Xu, X | 1 |
| DeJesus, E; Hanna, G; Hwang, C; Kumar, S; Lombaard, J; Martin, E; Molina, JM; Orkin, C; Rodgers, A | 1 |
| Bordin-Wosk, T; Chun, V; Dhamija, A; Kadakia, A; Lin, AY | 1 |
| Alamer, E; Ananworanich, J; Chen, H; Endsley, J; Fan, X; Gelman, BB; Hu, H; Kim, JH; Liu, Z; Michael, NL; Niu, Q; Robb, ML; Tian, B; Zhou, J | 1 |
| Arastéh, K; Dretler, R; Frobose, C; Gatell, JM; Hagins, DP; Harvey, C; Hoffmann, C; Hwang, C; Kumar, S; Morales-Ramirez, JO; Osiyemi, O; Plettenberg, A; Portilla, J; Raffi, F; Rodgers, A; Rugina, S; Smith, DE; Teppler, H; Thompson, M; Wan, H; Xu, X | 1 |
| Boyle, A; Khoo, S; Marzolini, C; Moss, CE | 1 |
| Chapman, D; Demarest, J; Dong, WW; Ellery, S; Harrigan, PR; Heera, J; Mo, T; Poon, AF; Swenson, LC; Valdez, H | 1 |
| Abi-Habib, S; Abrol, R; Berro, R; Goddard, WA; Grunbeck, A; Klasse, PJ; Lascano, D; Moore, JP; Sakmar, TP; Trzaskowski, B; Yasmeen, A | 1 |
| Abrams, CF; Bewley, CA; Chaiken, IM; Emileh, A; Lalonde, JM; Moreira, DR; Tuzer, F; Umashankara, M; Yeh, H | 1 |
| Archer, J; Arts, EJ; Gibson, RM; Henry, K; King, K; Olivo, PD; Poveda, E; Quiñones-Mateu, ME; Rhea, AM; Robertson, DL; Rose, JD; Soriano, V; Vazquez, AC; Weber, J; Winner, D; Wright, A; Wylie, D | 1 |
| Bonora, S; Calcagno, A; Chiappetta, S; D'Avolio, A; Di Perri, G; Galli, A; Gonzalez de Requena, D; Lazzarin, A; Nozza, S; Simiele, M | 1 |
| Arts, EJ; Dudley, DM; Lobritz, MA; Marozsan, AJ; Ratcliff, AN; Tilton, JC | 1 |
| Bonora, S; Calcagno, A; D'Avolio, A; Di Perri, G; Ghisetti, V; Marinaro, L; Montrucchio, C; Trentini, L | 1 |
| Adeyemi, O; Clagett, B; Dahl, V; Deeks, SG; Funderburg, NT; Gilman, LE; Hayes, TL; Hunt, PW; Landay, AL; Lederman, MM; Martin, JN; McLaughlin, B; Palmer, S; Rodriguez, B; Schacker, TW; Shacklett, BL; Shulman, NS; Somsouk, M | 1 |
| Emery, S; Harrigan, R; Kaiser, R; Kaye, S; Kelleher, AD; Land, S; Marks, K; Pett, S; Schuelter, E; Swenson, LC; Tu, E | 1 |
| Bon, I; Borderi, M; Calza, L; Clò, A; Colangeli, V; Cricca, M; Gibellini, D; Miserocchi, A; Morini, S; Re, MC | 1 |
| Chikere, K; Churchill, MJ; Duncan, R; Ellett, A; Flynn, JK; Gorry, PR; Gray, LR; Jubb, B; Lee, B; Lewin, SR; Moore, MS; Payne, RJ; Ramsland, PA; Roche, M; Salimi, H; Sterjovski, J; Webb, NE; Westby, M; Wilkinson, BL; Zappi, H | 1 |
| Hanna, GJ; Healy, MD; Hwang, C; Krystal, M; Lataillade, M; Ray, N; Whitcomb, J; Wind-Rotolo, M | 1 |
| Khamadi, SA; Muigai, AW; Ng'ang'a, Z; Nyamache, AK | 1 |
| Aoki, R; Blauvelt, A; Gatanaga, H; Kawamura, T; Koyanagi, Y; Matsuzawa, T; Moriishi, K; Ogawa, Y; Shimada, S; Takahashi, M | 1 |
| Dong, W; Harrigan, PR; Hoepelman, AI; McGovern, RA; Nijhuis, M; Poon, AF; Symons, J; van Ham, PM; van Lelyveld, SF; Wensing, AM | 1 |
| Bicudo, EL; Cassoli, LM; da Eira, M; de Andrade Neto, JL; Furtado, J; Leite, OH; Lewi, DS; Lima, MP; Lopes, MI; Machado, AA; Madruga, JV; Miranda, AF; Netto, EM; Pedro, Rde J; Portsmouth, S; Santini-Oliveira, M; Santos, BR; Tupinambas, U; Wajsbrot, DB | 1 |
| Cai, YD; Chen, L; Huang, T; Jiang, M; Kong, XY; Li, BQ; Lu, J; Niu, B; Wei, ZJ; Zheng, MY | 1 |
| Cazabat, M; Coassin, L; Delobel, P; Izopet, J; Loiseau, C; Marchou, B; Massip, P; Raymond, S; Requena, M; Saliou, A | 1 |
| Acosta, EP; Adeyemi, O; Berzins, B; Castro, J; Eron, JJ; Kuritzkes, DR; Lalezari, J; Lu, D; Ryscavage, P; Swindells, S; Taiwo, B; Tsibris, A | 1 |
| Guo, H; Kong, X; Liu, B; Liu, C; Wood, C | 1 |
| Feucht, N; Hadeler, J; Lanzl, I; Loos, D; Schmid, RM; Schwerdtfeger, C; Spinner, CD | 1 |
| Bumpus, NN; Hendrix, CW; To, EE | 1 |
| Bellazzi, LI; Bianco, C; Bruzzone, B; Colao, G; Corsi, P; De Luca, A; Monno, L; Pagano, G; Paolucci, S; Punzi, G; Rossetti, B; Setti, M; Zazzi, M | 1 |
| Degli Antoni, A; Ferrari, C; Fragola, V; Manfredi, R; Weimer, LE | 1 |
| Autran, B; Barbuat, C; Corbeau, P; Cuzin, L; Flandre, P; Ghosn, J; Lascoux-Combe, C; Lavigne, JP; Psomas, C; Reynes, J; Trabelsi, S | 1 |
| Deeks, SG; Hunt, PW; Lederman, MM | 1 |
| Brumme, CJ; Chan, D; Chapman, D; Chui, CK; Demarest, JF; Dong, W; Goodrich, J; Harrigan, PR; Heera, J; James, I; Lewis, M; Mo, T; Portsmouth, S; Swenson, LC; Valdez, H; Woods, CK | 1 |
| Eggers, B; Fan, L; Fang, H; Hanna, GJ; Healy, M; Hwang, C; Krystal, M; Langley, DR; Lataillade, M; McAuliffe, B; Nowicka-Sans, B; Ray, N; Zhou, N | 1 |
| Gianella, S; Jordan, PS; Karris, MY; Little, SJ; Massanella, M; Patel, D; Pérez-Santiago, J; Richman, DD; Smith, DM; Spina, CA; Var, SR; Young, JA | 1 |
| Ballestero, M; Blanco, J; Boix, J; Buzon, MJ; Clotet, B; Esteve, A; Gatell, JM; Llibre, JM; Manzardo, C; Martinez-Picado, J; Massanella, M; Miró, JM; Ouchi, D; Puertas, MC | 1 |
| Banerjea, AC; Gupta, S; Neogi, U; Shet, A; Srinivasa, H | 1 |
| Alcami, J; Pérez-Olmeda, M | 1 |
| Piguet, V | 1 |
| Abeli, C; Adorni, F; Bai, F; Bonora, S; Buonomini, AR; Butini, L; Capetti, A; Colafigli, M; Colella, E; D'Annunzio, M; d'Ettorre, G; Di Biagio, A; Di Nardo Stuppino, S; Di Pietro, M; Focà, E; Francisci, D; Marchetti, G; Meraviglia, P; Merlini, E; Montano, M; Morosi, M; Mosti, S; Orofino, G; Parruti, G; Rusconi, S; Soria, A; Tau, P; Tommasi, C; Vitiello, P | 1 |
| Asante-Appiah, E; Burch, J; Campeau, LC; Cauchon, E; Côté, B; DiStefano, D; Ducharme, Y; Falgueyret, JP; Feng, M; Grobler, J; Hazuda, DJ; Lai, MT; Li, Y; Lu, M; Miller, MD; Sachs, N; Tawa, P; Witmer, M; Yan, Y | 1 |
| Abad-Fernández, M; Díaz, L; Dronda, F; Gutiérrez, C; Hernández-Novoa, B; Madrid, N; Moreno, A; Moreno, S; Muñoz-Fernández, MA; Serrano-Villar, S; Vallejo, A; Zamora, J | 1 |
| Burnside, R; Fatkenheuer, G; Goodrich, J; Gulick, RM; Hardy, WD; Heera, JR; Mukwaya, G; Nelson, MR; Portsmouth, S | 1 |
| Kravchenko, AV | 1 |
| Caskey, M; Evering, TH; Garmon, D; La Mar, M; Markowitz, M; Mohri, H; Palmer, S; Prada, N; Rodriguez, K; Sahi, V | 1 |
| Bigoloni, A; Bonora, S; Calcagno, A; Carbone, A; Castagna, A; D'Avolio, A; Galli, L; Lazzarin, A; Nozza, S; Pignataro, AR; Ripa, M | 1 |
| Blanco, J; Brander, C; Bravo, I; Clotet, B; Escrig, R; Gatell, JM; Iwamoto, A; Kawana-Tachikawa, A; Llibre, JM; Manzardo, C; Martinez-Picado, J; Miro, JM; Mothe, B; Pozniak, AL; Puertas, MC; Puig, J | 1 |
| Bozzano, F; Cenderello, G; De Maria, A; Dentone, C; Di Biagio, A; Fenoglio, D; Filaci, G; Fraccaro, P; Mantia, E; Orofino, G; Parodi, A; Signori, A | 1 |
| Mitra, AK; Pal, D; Patel, M; Paturi, DK; Vadlapatla, RK | 1 |
| Assoumou, L; Chablais, L; Costagliola, D; Duvivier, C; Katlama, C; Kolta, S; Marcelin, AG; Mercié, P; Peytavin, G; Pialoux, G; Simon, A; Soulié, C; Valantin, MA | 1 |
| Audino, A; Baietto, L; Bonora, S; D'Avolio, A; Di Perri, G; Sciandra, M; Simiele, M | 1 |
| Bancalero, P; Chueca, N; García, C; Jiménez, P; Macías, J; Márquez, M; Merino, D; Muñoz, L; Ojeda, G; Pasquau, J; Pineda, JA; Recio, E | 1 |
| Evans, A; Forbes, CJ; Malcolm, RK; McCoy, CF; Moore, JP; Murphy, DJ; Shattock, RJ; Woolfson, AD | 1 |
| Casado, JL; Dronda, F; Estébanez, M; González, J; Hernández-Novoa, B; Madrid-Elena, N; Moreno, A; Moreno, S; Pérez-Elias, MJ; Pérez-Molina, JA; Zamora, J | 1 |
| McGowan, I | 1 |
| Panos, G; Watson, DC | 1 |
| Leal, M; Martínez-Bonet, M; Méndez-Lagares, G; Muñoz-Fernández, MA; Pacheco, YM; Pozo-Balado, MM; Rodríguez-Méndez, MM; Rosado, I; Ruiz-Mateos, E; Vidal, F | 1 |
| Bullen, CK; Durand, CM; Laird, GM; Siliciano, JD; Siliciano, RF | 1 |
| Siegel, MO | 1 |
| Baldelli, F; Baroncelli, S; Cecchini, E; Falcinelli, E; Floridia, M; Francisci, D; Gresele, P; Petito, E; Weimer, LE | 1 |
| Beliakova-Bethell, N; Dubé, MP; Goicoechea, M; Haubrich, R; Jain, S; Lada, SM; Rought, SE; Spina, CA; Sun, X; Witt, MD; Woelk, CH | 1 |
| Caballero, E; Cabezas, T; De Mendoza, C; Eiros, JM; Lopez, M; Parra, P; Poveda, E; Roc, L; Rodríguez, C; Soriano, V; Treviño, A | 1 |
| Bonora, S; Calcagno, A; Chiappetta, S; D'Avolio, A; Di Perri, G; Ghisetti, V; Lazzarin, A; Milia, MG; Nozza, S; Simiele, M | 1 |
| Bigoloni, A; Carbone, A; Castagna, A; Chiappetta, S; Galli, L; Gianotti, N; Lazzarin, A; Nozza, S; Ripa, M; Spagnuolo, V; Tambussi, G | 1 |
| Ajassa, C; Ermocida, A; Lichtner, M; Mastroianni, CM; Mengoni, F; Rossi, R; Sauzullo, I; Vullo, V | 1 |
| Colby-Germinario, SP; Kramer, VG; Mesplède, T; Oliviera, M; Varsaneux, O; Wainberg, MA | 1 |
| Ball, C; Woodrow, KA | 1 |
| Back, D; Boffito, M; Else, L; Gazzard, B; Jackson, A; Nelson, M; Newell, S; Rockwood, N; Waters, L | 1 |
| Botes, M; Burnside, R; Clumeck, N; Cooper, DA; Dejesus, E; Heera, J; Ive, P; Lazzarin, A; Mukwaya, G; Saag, M; van Der Ryst, E; Walmsley, S | 1 |
| Abid, S; Adnot, S; Amsellem, V; Bobe, R; Combadière, C; Delcroix, M; Dubois-Randé, JL; Gary-Bobo, G; Gladwin, MT; Houssaini, A; Lipskaia, L; Marcos, E; Mouraret, N; Norris, KA; Parpaleix, A; Poupel, L; Quarck, R; Saker, M | 1 |
| Chen, XQ; Gu, WG | 1 |
| Akkina, R; Kashuba, ADM; LeCureux, J; Remling-Mulder, L; Sykes, C; Veselinovic, M; Yang, KH | 1 |
| Booth, C; Conibear, T; Garcia-Diaz, A; Herman, OM; Irish, D; Johnson, MA; Macartney, M; McCormick, A; Smith, C; Webster, DP; Wyatt, H | 1 |
| Gilchrist, A; Karash, A; Mazzoni, MR | 1 |
| Guo, J; Wu, Y; Xu, GG | 1 |
| Abad-Carrillo, MA; Alvarez-Ríos, AI; Benhnia, MR; Bernal-Morell, E; Bravo-Urbieta, J; de Pablo-Bernal, RS; Galera-Peñaranda, C; Genebat, M; Leal, M; Romero-Sánchez, MC; Ruiz-Mateos, E; Vera, F | 1 |
| Brun-Vézinet, F; Charpentier, C; Damond, F; Descamps, D; Fagard, C; Glohi, D; Matheron, S; Rouard, C; Tubiana, R; Visseaux, B | 1 |
| Calvez, V; Charpentier, C; Descamps, D; Désiré, N; Fofana, DB; Katlama, C; Lambert-Niclot, S; Maïga, AI; Marcelin, AG; Sayon, S; Simon, A; Soulié, C; Yazdanpanah, Y | 1 |
| Bai, Q; Chen, W; Li, X; Liu, H; Yao, X; Zhang, Y | 1 |
| Calvez, V; Charpentier, C; Descamps, D; Katlama, C; Lambert-Niclot, S; Marcelin, AG; Peytavin, G; Sayon, S; Simon, A; Soulie, C; Visseaux, B; Yazdanpanah, Y | 1 |
| Cohen, MS; Emerson, CW; Fedoriw, Y; Geller, EJ; Kashuba, AD; Nelson, JA; Nicol, MR; Patterson, KB; Prince, HM; Sykes, C | 1 |
| Al-Abdullah, ES; Alanazi, AM; Almutairi, MS; El-Emam, AA; Pathak, SK; Prasad, O; Sinha, L; Srivastava, R | 1 |
| Averseng-Peaureaux, D; Bauer, J; Biotti, D; Bonneville, F; Brassat, D; Dumas, H; Fabre, N; Lassmann, H; Liblau, RS; Marchou, B; Martin-Blondel, G; Uro-Coste, E | 1 |
| Baccarani, U; Bassetti, M; Bonora, S; Dal Zoppo, S; Della Siega, P; Delle Foglie, P; Giglio, O; Londero, A; Nasta, P; Pea, F; Righi, E; Villa, G | 1 |
| Alcaro, S; Alteri, C; Aquaro, S; Artese, A; Balestra, E; Ceccherini-Silberstein, F; Chapman, D; Clotet, B; Costa, G; Harrigan, R; Lewis, M; Martinez-Picado, J; Parrotta, L; Perno, CF; Puertas, MC; Saccomandi, P; Surdo, M; Svicher, V; Swenson, L; Valdez, H | 1 |
| Antinori, A; Bonora, S; Chiappetta, S; De Battista, D; Di Pietro, M; Galli, L; Lazzarin, A; Malnati, M; Mazzotta, F; Nozza, S; Ottou, S; Pogliaghi, M; Ripa, M; Zaccarelli, M | 1 |
| Amiel, C; Bellecave, P; Delaugerre, C; Desbois, D; Descamps, D; Izopet, J; Maillard, A; Marcelin, AG; Peytavin, G; Raymond, S; Soulie, C; Trabaud, MA | 1 |
| Cashin, K; Churchill, MJ; Demarest, JF; Drummond, F; Gorry, PR; Gray, LR; Harrigan, PR; Harvey, KL; Lee, GQ; Perez-Bercoff, D; Roche, M; Sterjovski, J | 1 |
| Assoumou, L; Autran, B; Campillo-Gimenez, L; Capeau, J; Costagliola, D; Guihot, A; Katlama, C; Marcelin, AG; Pajanirassa, P; Soulié, C; Valantin, MA; Villemonteix, J | 1 |
| Acharya, P; Bewley, CA; Kwong, PD; Lusvarghi, S | 1 |
| Cao, Y; Gauthier, DR; Humphrey, G; Itoh, T; Journet, M; Mangion, I; Sherry, BD; Tschaen, DM | 1 |
| Appolloni, L; Calza, L; Cascavilla, A; Colangeli, V; Manfredi, R; Marinacci, G; Martelli, G; Puggioli, C; Salvadori, C; Viale, P | 1 |
| Bullen, CK; Durand, CM; Hill, AL; Laird, GM; Martin, AR; Rosenbloom, DI; Siliciano, JD; Siliciano, RF | 1 |
| De La Mata, FJ; Gómez, R; Jiménez, JL; Muñoz-Fernández, MÁ; Sánchez-Rodríguez, J; Sepúlveda-Crespo, D; Serramía, MJ | 1 |
| Biswas, P; Cozzi, P; García-Sastre, A; Ghezzi, S; Guzzo, C; Jabes, D; Lusso, P; Malnati, M; Martínez-Romero, C; Mongelli, N; Sironi, F | 1 |
| Assoumou, L; Calvez, V; Chas, J; Duvivier, C; Katlama, C; Lê, MP; Marcelin, AG; Peytavin, G; Ponscarme, D; Soulié, C; Valantin, MA | 1 |
| Glisic, S; Radi, M; Tassini, S; Veljkovic, N; Veljkovic, V; Vucicevic, J | 1 |
| Best, C; Laciny, E; Reeds, DN; Royal, M; Struthers, H; Yarasheski, KE | 1 |
| Demarest, J; Heera, J; Knirsch, C; van der Ryst, E | 1 |
| Ahmed, N; Ainsworth, J; Okoli, C | 1 |
| Dybowski, JN; Esser, S; Fätkenheuer, G; Güney, L; Heider, D; Hoffmann, D; Jensen, B; Kaiser, R; Lengauer, T; Pfister, H; Pironti, A; Reuter, S; Sierra, S; Thielen, A | 1 |
| Arroyo, D; Blanco, JR; Crespo, M; Garcia Del Toro, M; Herrero, C; Llibre, JM; Masiá, M; Moreno, S; Pasquau, J; Pineda, JA; Rivero, A; Rojas, JF | 1 |
| Cavarelli, M; Chiappetta, S; Cossarizza, A; De Battista, D; De Biasi, S; Galli, L; Lazzarin, A; Malnati, M; Nozza, S; Pensieroso, S; Pogliaghi, M; Ripa, M; Scarlatti, G; Tambussi, G | 1 |
| Arroyo-Manzano, D; Blanco, JR; Bravo, I; Crespo, M; Garcia Del Toro, M; Herrero, C; Llibre, JM; Moreno, S; Pasquau, J; Rivero, A; Rojas-Liévano, JF | 1 |
| Berzins, B; Brown, T; Chan, ES; Eron, JJ; Fichtenbaum, CJ; Klingman, KL; Landay, A; Ofotokun, I; Ribaudo, H; Robertson, K; Taiwo, BO; Tsibris, A | 1 |
| Shah, M; Shahani, L; Tavakoli-Tabasi, S | 1 |
| Bellecave, P; Calvez, V; Charpentier, C; Descamps, D; Flandre, P; Marcelin, AG; Masquelier, B; Pawlotsky, JM; Recordon-Pinson, P; Rodriguez, C; Soulié, C | 1 |
| Brown, ER; Devlin, B; Dezzutti, CS; Moncla, B; Nuttall, J; Rohan, LC; Teeple, EA; Wang, L; Yandura, S | 1 |
| Abad, MA; de Pablo-Bernal, RS; Genebat, M; Jiménez-Mejías, ME; Leal, M; Martínez, O; Pacheco, YM; Pulido, I; Raffi-El-Idrissi Benhia, M; Ruiz-Mateos, E | 1 |
| Boonchawalit, S; Gatanaga, H; Harada, S; Matsushita, S; Oka, S; Shirai, N; Yoshimura, K | 1 |
| Aguilera-Lizarraga, J; Blanco, JR; Oteo, JA; Pérez-Martínez, L; Pérez-Matute, P | 1 |
| Best, B; Burchett, S; Burger, D; Capparelli, E; Colbers, A; Haberl, A; Hawkins, D; Hidalgo Tenorio, C; Kabeya, K; Kreitchmann, R; Mirochnick, M; Schalkwijk, S; Smith, E; Stek, A; Taylor, G; van Kasteren, M; Wang, J | 1 |
| Borghans, JA; Brinkman, K; Drylewicz, J; Hoepelman, AI; Krikke, M; Kroon, F; Middel, A; Mulder, JW; Nijhuis, M; Otto, SA; Prins, JM; Richter, C; Soetekouw, R; Symons, J; Tesselaar, K; van Lelyveld, SF; Veel, EM; Wensing, AM | 1 |
| Cai, I; Dandekar, S; Fenton, A; Hildreth, JE; Jiang, G; Kaiser, P; Melcher, GP; Mendes, EA; Tang, Y; Thompson, GR; Wong, DP; Wong, JK | 1 |
| Bertine, M; Brun-Vézinet, F; Charpentier, C; Collin, G; Damond, F; Descamps, D; Lefebvre, E; Matheron, S; Peytavin, G; Visseaux, B | 1 |
| Craig, C; Feyertag, F; Jiang, X; Lewis, M; McCormack, GP; Meehan, CJ; Robertson, DL; Travers, SA; Westby, M | 1 |
| DeVico, AL; Fouts, TR; Heredia, A; Lakowicz, JR; Latinovic, OS; Redfield, RR; Schneider, K; Tagaya, Y; Zhang, J | 1 |
| Barnett, C; Cuffe, R; Granier, C; Machida, M; Roger, J; Wang, C | 1 |
| Anderson, MS; Butterton, JR; De Lepeleire, I; Gilmartin, J; Guo, Y; Liu, R; Robberechts, M; Schürmann, D; Sobotha, C; Wagner, F; Wagner, JA; Yee, KL | 1 |
| Council, OD; Garcia, JV; Spagnuolo, RA; Swanson, MD; Wahl, A | 1 |
| Assoumou, L; Caby, F; Calvez, V; Canestri, A; Costagliola, D; Darty, M; Donati, F; Katlama, C; Marcelin, AG; Peytavin, G; Rodriguez, C; Sayon, S; Schneider, L; Soulié, C; Valantin, MA | 1 |
| Kanmogne, GD; Woollard, SM | 2 |
| Garvey, L; Rojas, JH; Taylor-Robinson, S; Vigneswaran, S; Winston, A | 1 |
| Blanco, JR; Ochoa-Callejero, L | 1 |
| Back, D; Boix, J; Cabrera, C; Carrillo, A; Clotet, B; Coll, J; Else, L; Escrig, R; García, E; Gómez-Mora, E; Moltó, J; Ouchi, D; Paredes, R | 1 |
| Briz, V; De Ory, SJ; Espiau, M; Gómez, ML; González-Tomé, MI; Guasch, CF; Guillén, SM; Guruceta, IP; Hoyos, SP; León-Leal, JA; Méndez, M; Moreno-Pérez, D; Palladino, C; Sierra, AM; Soler-Palacín, P | 1 |
| Cillo, AR; Coombs, RW; Currier, JS; Fox, L; Gandhi, RT; Gulick, RM; Hilldorfer, BB; Lalama, CM; McKinnon, JE; Mellors, JW; Ribaudo, H; Tenorio, AR; Wilkin, TJ | 1 |
| Connell, BJ; Hoepelman, AI; Nijhuis, M; Symons, J; van Ham, P; van Lelyveld, SF; Wensing, AM | 1 |
| Carcenac, R; Cazabat, M; Delobel, P; Dubois, M; Izopet, J; Jeanne, N; Lefebvre, C; Loiseau, C; Nicot, F; Raymond, S; Saliou, A | 1 |
| Azzoni, L; Fair, MG; Joseph, J; Montaner, LJ; Patro, SC; Rassool, MS; Sanne, I; Sierra-Madero, JG | 1 |
| Ball, C; Hamlyn, E; Jarosz, J; Post, FA; Sudhanva, M | 1 |
| Armanasco, N; Fletcher, P; Herrera, C; Nuttall, J; Shattock, RJ | 1 |
| Aubin, C; Costagliola, D; Ferry, T; Finkielsztejn, L; Potard, V; Reynes, J; Yazdanpanah, Y | 1 |
| Fu, M; Gong, L; He, H; Li, H; Wang, TT | 1 |
| Carcenac, R; Cazabat, M; Cuzin, L; Delobel, P; Izopet, J; Jeanne, N; Nicot, F; Raymond, S; Requena, M | 1 |
| Albanese, A; Asmuth, DM; Chun, TW; Deeks, SG; Kashuba, AD; Landay, A; Ma, ZM; Mann, S; Miller, CJ; Moreno, S; Pollard, RB; Sainz, T; Serrano-Villar, S; Siewe, B; Sinclair, E; Somasunderam, A; Troia-Cancio, P; Utay, NS; Wook-Chun, T; Yotter, T | 1 |
| Benhnia, MR; Leal, M; Méndez-Lagares, G; Muñoz-Fernández, MA; Pacheco, YM; Pozo-Balado, MM; Rodríguez-Méndez, MM; Rosado-Sánchez, I; Ruiz-Mateos, E | 1 |
| Brew, BJ; Chaganti, J; Cysique, LA; Gates, TM; Moffat, KJ; Siefried, KJ | 1 |
| Carlson, D; Mattioni, J; Moore, JE; Portnoy, JE; Sataloff, RT | 1 |
| Chen, BA; Cheng, H; Hoesley, CJ; Horn, S; Husnik, MJ; Laborde, N; Nel, A; Panther, L; Soto-Torres, L; van der Straten, A | 1 |
| Genebat, M; Gonzalez-Serna, A; Leal, M; Ruiz-Mateos, E | 1 |
| Alcamí, J; Armanasco, N; García-Pérez, J; Herrera, C; Nuttall, J; Olejniczak, N; Shattock, RJ; Ziprin, P | 1 |
| Altamirano, R; Córdoba, S; Davel, G; Isla, MG; Szusz, W; Vivot, W | 1 |
| Abu Tarif, M; Bertz, RJ; Boulton, DW; Hanna, GJ; Hruska, M; Joshi, S; Landry, I; Lataillade, M; Pitsiu, M; Sadler, BM; Zhu, L | 1 |
| Garvey, LJ; Mora-Peris, B; Scott, J; Underwood, J; Winston, A | 1 |
| Woodland, DL | 1 |
| Fukutake, K | 1 |
| Dirks, M; Dittmer, U; Esser, S; Joedicke, JJ; Verheyen, J | 1 |
| Amin, J; Andrade-Villanueva, J; Arnaiz, JA; Belloso, W; Clark, A; Clarke, A; Cooper, D; Emery, S; Fisher, M; Gatell, J; Gill, J; Harrigan, R; Horban, A; Kaiser, R; Kelleher, A; Losso, M; Mallon, P; Pett, SL; Porteiro, N; Prazuck, T; Rockstroh, JK; Ruxrungtham, K; Sierra Madero, J; Silk, D; Sugiura, W; Tu, E; Wolff, M; Woolley, I | 1 |
| Baum, MM; Butkyavichene, I; Churchman, SA; Easley, JT; Fanter, R; Gunawardana, M; Hendrix, CW; Marzinke, MA; Miller, CS; Moss, JA; Smith, TJ; Yang, F | 1 |
| Akram, A; Ambrose, Z; Hughes, SH; Melody, K; Pauly, GT; Schneider, JP; Smith, SJ | 1 |
| Ajana, F; Alidjinou, EK; Bocket, L; Calvez, V; Charpentier, C; Choisy, P; Descamps, D; Katlama, C; Lê, M; Marcelin, AG; Peytavin, G; Simon, A; Soulie, C; Yazdanpanah, Y | 1 |
| Brown, TT; Chan, ES; Eron, JJ; Fichtenbaum, CJ; Klingman, KL; Landay, AL; Martinson, J; Mirmonsef, P; Ofotokun, I; Plants, J; Ribaudo, HJ; Taiwo, BO; Weitzmann, MN | 1 |
| Hancianu, M; Kolecka, A; Marangoci, N; Mares, M; Minea, B; Nastasa, V; Pinteala, M; Rosca, I | 1 |
| Berzins, B; Brown, TT; Chan, ES; Eron, JJ; Lee, A; Miyahara, S; Robertson, KR; Rusin, D; Taiwo, BO | 1 |
| Clerici, M; Cossu, M; Masetti, M; Piconi, S; Pocaterra, D; Rainone, V; Rizzardini, G; Trabattoni, D | 1 |
| Cao, Y; Gauthier, DR; Helmy, R; Sheng, H; Yang, R; Zhang, LK; Zheng, J | 1 |
| Chen, BA; Dezzutti, CS; Hoesley, CJ; Johnson, S; Marzinke, MA; Nel, A; Nuttall, JP; Panther, L; Richardson-Harman, N; Rohan, LC | 1 |
| Brochier, C; Cottalorda-Dufayard, J; Cotte, L; Dellamonica, P; Durant, J; Gagnieu, MC; Gatey, C; Izopet, J; Jacomet, C; Lucht, F; Pradat, P; Raffi, F; Trabaud, MA; Vassallo, M | 1 |
| Achhra, AC; Amin, J; Boyd, MA; Mwasakifwa, G | 1 |
| Alteri, C; Boeri, E; Castagna, A; Clementi, M; Galli, L; Lazzarin, A; Nozza, S; Perno, CF; Pignataro, AR; Ripa, M; Sampaolo, M; Svicher, V | 1 |
| Arnatt, CK; El-Hage, N; Falls, BA; Hauser, KF; Knapp, PE; Masvekar, RR; Nicola, AV; Raborg, TJ; Selley, DE; Yuan, Y; Zhang, Y | 1 |
| Back, D; Boffito, M; Dickinson, L; Egan, D; Else, L; Fox, J; Herrera, C; Jackson, A; Khoo, S; Olejniczak, N; Shattock, R; Tiraboschi, JM | 1 |
| Kaku, Y; Minami, R; Takahama, S; Yamamoto, M | 1 |
| Giesler, KE; Kim, MB; Liotta, DC; Tahirovic, YA; Truax, VM; Wilson, LJ | 1 |
| Borm, K; Cashin, K; Churchill, MJ; Ellenberg, P; Flynn, JK; Gorry, PR; Jakobsen, MR; Lee, B; Ostergaard, L; Roche, M | 1 |
| Amico, KR; Andrade, A; Andrew, P; Chege, W; Chen, YQ; Cottle, LM; Eshleman, SH; Farley, JE; Frank, I; Gulick, RM; Hendrix, CW; Ho, K; Klingman, KL; Landovitz, RJ; Liu, A; Magnus, M; Marcus, C; Marzinke, MA; Mayer, KH; McCauley, M; McGowan, I; Richardson, P; Rinehart, AR; Rooney, JF; Salata, RA; Santana, J; Stekler, JD; Wilkin, TJ; Young, AM | 1 |
| Karris, MY; Little, S; Richman, D; Smith, D; Umlauf, A; Vaida, F | 1 |
| Chiappetta, S; Coppalini, G; Nozza, S; Pogliaghi, M; Ripa, M; Rovelli, C; Soria, A; Tambussi, G | 1 |
| Cason, J; Davies, O; Fidler, S; Fox, J; Frater, J; Hopkins, E; Kaye, S; Klenerman, P; Mant, C; Meyerowitz, J; Pace, M; Patel, K; Phalora, P; Ray, S; Robinson, N; Sanderson, J; Tiraboschi, J; Wang, Y | 1 |
| Asmuth, DM; Bansal, M; Fätkenheuer, G; Heera, J; Pialoux, G; Pineda, JA; Plonski, F; Rockstroh, JK; Small, CB; Wang, R; Zhang-Roper, R | 1 |
| Foster, C; Fraser-Taliente, T; Kaye, S; Mackie, NE; Nyirenda, M | 1 |
| Angarano, G; Bruno, G; Ladisa, N; Maggi, P; Perilli, F; Santoro, C; Saracino, A; Volpe, A | 1 |
| Archin, NM; Bosque, A; Ireland, CM; Macedo, AB; Margolis, DM; Martins, LJ; Nilson, KA; Novis, CL; Planelles, V; Price, DH; Spivak, AM; Szaniawski, MA; Van Wagoner, RM | 1 |
| Capetti, AF; Carenzi, L; Dedivitiis, G; Landonio, S; Micale, M; Niero, F; Rizzardini, G; Vimercati, S | 1 |
| Atieno, N; Atieno, S; Fleming, E; Gaines, J; Kamb, ML; O'Connor, K; Ogutu, J; Quick, R | 1 |
| MacArthur, RD; Novak, RM | 1 |
| Barber, T; Hughes, A; Nelson, M | 1 |
| Collins, C; Dickins, M; Hyland, R; Jones, B; Jones, H | 1 |
| Bandres, JC; Fung, HB; Lieberman-Blum, SS | 1 |
| Emmelkamp, JM; Rockstroh, JK | 1 |
| Edmunds-Ogbuokiri, T | 1 |
| Dolin, R | 1 |
| Bellos, N; Cooper, DA; Dunne, MW; Fätkenheuer, G; Felstead, S; Hirschel, B; Hoepelman, AI; Konourina, I; Lampiris, H; Lazzarin, A; Mayer, H; Nelson, M; Raffi, F; Ridgway, C; Saag, M; Sullivan, JF; Tawadrous, M; Tebas, P; Trottier, B; van der Ryst, E; Westby, M | 1 |
| Clotet, B; Clumeck, N; DeJesus, E; Dunne, MW; Felstead, S; Goodrich, J; Gulick, RM; Horban, A; Karlsson, A; Lalezari, J; Mayer, H; McHale, M; Montana, JB; Nadler, J; Ridgway, C; Sullivan, J; van der Ryst, E; Wohlfeiler, M | 1 |
| Cervera, C; Crespo, G; Marco, F; Michelena, J; Moreno, A; Navasa, M | 1 |
| Alcamí, J; Calvez, V; Fätkenheuer, G; Geretti, AM; Perno, CF; Pillay, D; Reynes, J; Rockstroh, J; Soriano, V; Tambussi, G | 1 |
| Caldwell, DJ; Evans, JD | 1 |
| Melby, T; Westby, M | 1 |
| Boyle, B; Cohen, C; DeJesus, E; Elion, R; Frank, I; Moyle, G; Sax, P | 1 |
| Alcamí, J | 2 |
| Arenzana-Seisdedos, F | 1 |
| Poveda, E; Soriano, V | 1 |
| Delsol, E; Gutiérrez, C; Hernández, B; Moreno, S | 1 |
| Arribas López, JR | 1 |
| Delgado, R | 1 |
| Camacho, A; Genebat, M; Leal, M; Rivero, A | 1 |
| Barber, CG; Blakemore, DC; Chiva, JY; Eastwood, RL; Middleton, DS; Paradowski, KA | 1 |
| Allen, SH; Foster, SA; Garvey, EP; Jeffrey, JL; Johns, BA; Miller, WH; Thompson, JB; Weatherhead, JG | 2 |
| Hunt, JS; Romanelli, F | 1 |
| Sax, PE | 2 |
| Pasquale, TR; Sahloff, EG; Yost, R | 1 |
| Lanzafame, M; Lattuada, E; Vento, S | 1 |
| Vandekerckhove, L; Verhofstede, C; Vogelaers, D | 2 |
| Aguirre, JM; Carrillo-Muñoz, AJ; Eraso, E; Gaitán-Cepeda, LA; Quindós, G; Sánchez Vargas, LO | 1 |
| Archer, J; Braverman, MS; Desany, B; Harrigan, PR; James, I; Lewis, M; Robertson, DL; Taillon, BE | 1 |
| Clotet, B; Clumeck, N; Fätkenheuer, G; Goodrich, J; Mayer, H; Saag, M; Sullivan, J; van der Ryst, E; Westby, M | 1 |
| Able, S; Dorr, P; Griffin, P; Irvine, B; James, I; Macartney, M; Mansfield, R; Miller, K; Mills, J; Napier, C; Navratilova, I; Perros, M; Rickett, G; Root, H; van der Ryst, E; Westby, M | 1 |
| Pett, SL | 1 |
| Andrews, E; Damle, B; Dumond, JB; Kashuba, AD; Patterson, KB; Pecha, AL; Tressler, R; Werner, RE; Worsley, J | 1 |
| Arribas, JR | 1 |
| Chiang, TS; Dever, LL; Eng, RH; Paez, SL; Perez, G; Smith, SM; Stepanyuk, O | 1 |
| Khanlou, H; Sayana, S | 1 |
| Goodrich, J; Mayer, H; Moyle, G; Rajicic, N; Valdez, H | 1 |
| Ferrando-Martínez, S; Genebat, M; González-Serna, A; Leal, M; León, JA; Muñoz-Fernández, MA; Pulido, I; Rivas, I; Ruiz-Mateos, E; Sánchez, B | 1 |
| Doms, RW; Tilton, JC | 1 |
| Costa, CR; de Aquino Lemos, J; de Fátima Lisboa Fernandes, O; do Rosário Rodrigues Silva, M; Hasimoto e Souza, LK; Jesuíno, RS; Passos, XS | 1 |
| Abel, S; Back, DJ; Vourvahis, M | 1 |
| Edmunds-Ogbuokiri, J | 1 |
| McFadyen, L; Weatherley, B | 1 |
| Fätkenheuer, G; Kümmerle, T; Lehmann, C; Meuer, K | 1 |
| Calvez, V; di Perri, G; Gatell, JM; Geretti, AM; Kaiser, R; Perno, CF; Pillay, D; Rockstroh, J; Soriano, V | 1 |
| Hogan, BK; Lewis, JS; Nierenberg, NE; Patterson, TF; Thompson, GR | 1 |
| Aiuti, F; Esposito, A; Fantauzzi, A; Isgro, A; Leti, W; Mezzaroma, I; Pastori, D | 1 |
| Else, L; Gisslèn, M; Watson, V; Yilmaz, A | 1 |
| Alvarez, M; Cuvinciuc, V; Cuzin, L; Delobel, P; Dumas, H; Marchou, B; Martin-Blondel, G; Massip, P | 1 |
| Louie, M; Marfatia, S; Mear, I; Meunier, J; Regnault, A; Viala-Danten, M | 1 |
| Manga, V; Sivan, SK | 1 |
| Baietto, L; Bonora, S; D'Avolio, A; Di Perri, G; Patanella, S; Sciandra, M; Siccardi, M; Simiele, M | 1 |
| McKinnell, JA; Saag, MS | 1 |
| Andrews, E; Crownover, P; Damle, B; Fang, J; Glue, P; Tressler, R | 1 |
| Clumeck, N; Coakley, E; Cooper, DA; Dejesus, E; Goodrich, J; Hackman, F; Heera, J; Horban, A; Ive, P; Mayer, H; Mingrone, H; Mohapi, L; Reeves, JD; Reyes-Teran, G; Saag, M; Sullivan, J; Tawadrous, M; Ting, N; Van Der Ryst, E; Walmsley, S; Westby, M | 1 |
| Bigoloni, A; Canducci, F; Castagna, A; Galli, L; Gianotti, N; Lazzarin, A; Nozza, S; Salpietro, S; Soria, A; Tambussi, G; Torre, LD; Visco, F | 1 |
| Larue, V; Lecourt, T; Micouin, L; Moumné, R; Seijo, B; Tisné, C | 1 |
| Rotstein, DM; Yang, H | 1 |
| Armstrong-James, D; Ferns, B; Nelson, M; Pillay, D; Scourfield, A; Smit, E; Stebbing, J | 1 |
| Altamura, M; Angarano, G; Brindicci, G; Lagioia, A; Monno, L; Punzi, G; Saracino, A; Trillo, G | 1 |
| Boekhout, T; Bouza, E; Guinea, J; Hagen, F; Peláez, T; Tahoune, H; Torres-Narbona, M | 1 |
| Baroncelli, S; Cicalini, S; Cusato, M; Floridia, M; Francisci, D; Galluzzo, C; Ladisa, N; Preziosi, R; Regazzi, M; Tommasi, C; Villani, P; Vullo, V; Weimer, LE | 1 |
| Huitema, AD; Kromdijk, W; Mulder, JW | 1 |
| Poizot-Martin, I | 1 |
| Perry, CM | 1 |
| Charpentier, C; Cottalorda, J; Desbois, D; Descamps, D; Ferré, V; Flandre, P; Izopet, J; Lazrek, M; Macé, M; Marcelin, AG; Masquelier, B; Montes, B; Morand-Joubert, L; Pallier, C; Raymond, S; Recordon-Pinson, P; Reynes, J; Ruffault, A; Schneider, V; Soulié, C; Tamalet, C; Trabaud, MA; Vabret, A | 1 |
| Alvarez, M; Cazabat, M; Delobel, P; Izopet, J; Marchou, B; Massip, P; Mavigner, M; Raymond, S | 1 |
| Fang, J; Heera, J; Huyghe, I; Vourvahis, M | 1 |
| Bouvier-Alias, M; Calvez, V; Canestri, A; Clavel, C; Katlama, C; Lascaux, AS; Lelievre, JD; Levy, Y; Melica, G; Peytavin, G | 1 |
| Dufour, J; Green, LC; Ketas, TJ; Klasse, PJ; Moore, JP; Moroney-Rasmussen, T; Veazey, RS | 1 |
| Ferrando-Martínez, S; García-Pergañeda, A; Genebat, M; González-Serna, A; Leal, M; Méndez, G; Pulido, I; Romero-Sánchez, MC; Ruiz-Mateos, E | 1 |
| Chaiken, I; Contarino, M; Freire, E; Kuriakose, SA; Lalonde, J; McFadden, K; Rajagopal, S; Schön, A; Tuzer, F; Umashankara, M; Zentner, I | 1 |
| Balduin, M; Braken, P; Häussinger, D; Jensen, B; Kaiser, R; Oette, M; Reuter, S; Sierra-Aragon, S | 1 |
| Agrawal-Gamse, C; Bushman, FD; Deeks, SG; Didigu, CA; Doms, RW; Harrison, JE; Henning, EA; Martin, JN; Sinha, R; Tilton, JC; Wilen, CB | 1 |
| Fätkenheuer, G; Goodrich, J; Gulick, RM; Hardy, WD; Heera, J; Mayer, H; Nelson, M; Rajicic, N | 1 |
| Curto, J; Niubo, J; Podzamczer, D; Tiraboschi, JM | 2 |
| Abbate, I; Bartolini, B; Bruselles, A; Capobianchi, MR; Chillemi, G; Ippolito, G; Narciso, P; Nicastri, E; Rozera, G; Tommasi, C | 1 |
| Chapman, D; Dong, W; Harrigan, PR; Heera, J; James, I; Lewis, M; McGovern, RA; Mo, T; Thielen, A; Valdez, H; Woods, CK | 1 |
| Hirano, A; Kaneda, T; Kinoshita, E; Nomura, T; Okubo, N; Takahashi, M | 1 |
| D'Avolio, A; Fuchs, D; Gisslén, M; Hagberg, L; Svennerholm, B; Verhofstede, C; Watson, V; Yilmaz, A | 1 |
| Henrich, TJ; Konstantinidis, I; Kuritzkes, DR; Leopold, KE; Lewine, NR; Sagar, M; Tsibris, AM | 1 |
| Alston, S; Ayoub, A; Goodrich, J; Heera, J; Hoepelman, AI; Lalezari, J; Mayer, H; Mchale, M; Nelson, M; van der Ryst, E | 1 |
| Aguilera, A; de Mendoza, C; del Romero, J; González, Mdel M; Lapaz, M; Poveda, E; Rodríguez, C; Seclén, E; Soriano, V | 1 |
| Abad, MA; Ferrando-Martinez, S; Garcia-Perganeda, A; Genebat, M; Gonzalez-Serna, A; Leal, M; Ruiz-Mateos, E | 1 |
| Eason, J; Funderburg, N; Goodrich, J; Heera, J; Kalinowska, M; Lederman, MM; Mayer, H; Rajicic, N; Valdez, H | 1 |
| Anders, M; Jochmans, D; Keuleers, I; Kraus, G; Kräusslich, HG; Müller, B; Smeulders, L | 1 |
| Baietto, L; Bertucci, R; Calcagno, A; D'Avolio, A; De Rosa, FG; Di Perri, G; Libanore, V; Tettoni, MC | 1 |
| Assoumou, L; Autran, B; Canestri, A; Carcelain, G; Guihot, A; Katlama, C; Krivine, A; Le Corre, M; Marcelin, AG; Rozenberg, F; Samri, A; Schneider, L | 1 |
| Alencar, CS; Diaz, RS; Ferreira, S; Giret, MT; Nishiya, AS; Sabino, EC | 1 |
| Chan, PL; Jacqmin, P; Lavielle, M; McFadyen, L; Weatherley, B | 1 |
| Becker, D; Chancellor, J; Contreras-Hernandez, I; Kühne, F; Marfatia, S; Mould-Quevedo, J; Vega, G | 1 |
| Alcami, J; Arenzana-Seisdedos, F; Garcia-Perez, J; Kellenberger, E; Lagane, B; Rueda, P; Staropoli, I | 1 |
| Ferrando-Martínez, S; Genebat, M; González-Serna, A; Leal, M; Muñoz-Fernández, MÁ; Pulido, I; Ruiz-Mateos, E | 1 |
| Hizue, M | 1 |
| Archer, J; Harrigan, PR; Lewis, M; Rambaut, A; Robertson, DL; Taillon, BE | 1 |
| De Wit, S; Demecheleer, E; Florence, E; Fransen, K; Geretti, AM; Kabeya, K; Mackie, N; Mostmans, W; Moutschen, M; Plum, J; Stuyver, LJ; Vaira, D; Van Baelen, K; Van Eygen, V; Van Marck, H; Vandekerckhove, L; Vandenbroucke, I; Verhofstede, C; Vogelaers, D | 1 |
| Akkina, R; Habu, Y; Ndolo, T; Neff, CP; Tandon, A | 1 |
| Gilliam, BL; Redfield, RR; Riedel, DJ | 1 |
| Chapman, D; Dong, WW; Harrigan, PR; Heera, J; James, I; Jensen, MA; Lewis, M; Mo, T; Swenson, LC; Thielen, A; Valdez, H; Woods, CK; Zhong, X | 1 |
| Giguère, P; Kravcik, S; la Porte, CJ; Toy, J | 1 |
| Casado, MA; González, J; Lekander, I; Martí, B; Moreno, S; Oyagüez, I; Sánchez-de la Rosa, R | 1 |
| Kaptur, PE; Mertenskoetter, T | 1 |
| Chen, CH; Huang, L; Lai, WH | 1 |
| Aerssens, J; Andreoni, M; Aquaro, S; Balestra, E; Buonomini, AR; Ceccherini-Silberstein, F; Cento, V; D'Arrigo, R; Dori, L; Mostmans, W; Perno, CF; Saccomandi, P; Sarmati, L; Stuyver, LJ; Surdo, M; Svicher, V; Van Marck, H; Vandenbroucke, I | 1 |
| Bigoloni, A; Castagna, A; Cossarini, F; Della Torre, L; Galli, A; Galli, L; Lazzarin, A; Nicola, G; Nozza, S; Pogliaghi, M; Salpietro, S; Tambussi, G | 1 |
| Zhang, XQ | 1 |
| Bernard, J; Ferain, T; Fraser, G; Hoveyda, H; Ooms, F; Schols, D | 1 |
| de Jong, D; Hoepelman, AI; Nijhuis, M; Symons, J; van Ham, PM; van Lelyveld, SF; Wensing, AM | 1 |
| DeVico, A; Foulke, JS; Heredia, A; Latinovic, O; Le, N; Pal, R; Redfield, RR; Reitz, M | 1 |
| Nweze, EI; Ogbonnaya, UL | 1 |
| Dong, WW; Harrigan, PR; Heera, J; James, I; Lengauer, T; Lewis, M; McGovern, RA; Swenson, LC; Thielen, A; Valdez, H | 1 |
| Boucher, CA; Chapman, D; Delogne, C; Kuritzkes, DR; Lewis, M; Llibre, JM; McFadyen, L; Perros, M; Schapiro, JM; Simpson, P; Valdez, H; van de Vijver, DA; van der Ryst, E; Westby, M | 1 |
| Bargalló, E; Espiau, M; Figueras, C; Martín-Nalda, A; Paredes, R; Soler-Palacín, P | 1 |
| Alonso-Villaverde, C; Berenguer, J; Blanco, JL; Domingo, P; Dronda, F; Galera, C; Gutiérrez, F; Kindelán, JM; Knobel, H; Leal, M; López-Aldeguer, J; Mariño, A; Miralles, C; Moltó, J; Ortega, E; Oteo, JA; Parra, J; Portilla, J; Pulido, F; Sánchez-de la Rosa, R | 1 |
| Zorn, F | 1 |
| van Lunzen, J | 2 |
| Bonora, S; Calcagno, A; Castagna, A; D'Avolio, A; Di Perri, G; Gonzalez de Requena, D; Lazzarin, A; Nozza, S | 1 |
| Akkina, R; Fox, K; Kurisu, T; Ndolo, T; Neff, CP | 1 |
| Anderson, DD; Ghosh, AK | 1 |
| Ferrando-Martinez, S; Genebat, M; González-Serna, A; Leal, M; Machmach, K; Muñoz-Fernández, A; Ruiz-Mateos, E; Vidal, F | 1 |
| Abbate, I; Capobianchi, MR; D'Offizi, G; Giombini, E; Ippolito, G; Narciso, P; Nicastri, E; Rozera, G | 1 |
| Doyle, LA; Forbes, CJ; Geer, L; Goldman, L; Klasse, PJ; Lowry, D; Malcolm, RK; Mitchnick, M; Moore, JP; Muldoon, BC; Shattock, RJ; Veazey, RS; Woolfson, AD | 1 |
| Chen, W; Chen, X; De Clercq, E; Li, D; Li, X; Liu, X; Pannecouque, C; Tian, Y; Zhan, P | 1 |
| Chapman, D; Dong, WW; Harrigan, PR; Heera, J; James, I; Jensen, MA; Knapp, DJ; Lewis, M; Mo, T; Portsmouth, S; Swenson, LC; Thielen, A; Valdez, H; Woods, CK; Zhong, X | 1 |
| De Rosa, A; Lichtner, M; Massetti, AP; Mastroianni, CM; Mengoni, F; Rossi, R; Sauzullo, I; Vullo, V | 1 |
| Allsop, JM; Back, D; Erlwein, OW; Garvey, L; Kaye, S; Latch, N; Mitchell, A; Nelson, M; Taylor-Robinson, SD; Watson, V; Winston, A | 1 |
| De Luca, A; Dello Russo, C; Lisi, L; Navarra, P; Tramutola, A | 1 |
| Arendt, V; Baatz, F; De Landtsheer, S; Lemaire, M; Perez Bercoff, D; Schmit, JC; Servais, JY; Struck, D | 1 |
| Cui, Y; Jin, C; Li, X; Wu, N | 1 |
| Machala, L; Perlík, F; Slanar, O; Stanková, M; Vondracková, H | 1 |
| Gulick, RM; Wilkin, TJ | 1 |
| Churchill, MJ; Ellett, A; Gorry, PR; Jakobsen, MR; Jubb, B; Lee, B; Lewin, SR; Roche, M; Salimiseyedabad, H; Westby, M | 1 |
| Bahlaoui, A; Bakhatar, A; Chakib, A; El Fane, M; El Filali, KM; Ouladlahsen, A; Sodqi, M | 1 |
| Antoine, R; Brun-Vézinet, F; Charpentier, C; Damond, F; Descamps, D; Hurtado-Nedelec, M; Matheron, S; Peytavin, G; Storto, A; Visseaux, B | 1 |
| Hardy, WD; Rockstroh, JK; Wasmuth, JC | 1 |
| Abad, MA; Ferrando-Martinez, S; Genebat, M; Gonzalez-Serna, A; Harrigan, PR; Leal, M; McGovern, RA; Poon, AF; Ruiz-Mateos, E; Vidal, F | 1 |
| Back, DJ; Else, LJ; Khoo, SH; Taylor, S | 1 |
| Ainsworth, J; Cook, R; Dufty, N; Gandhi, K; Hickinbottom, G; Khonyongwa, K; Okoli, C; Owen, A; Siccardi, M; Taylor, S; Thomas-William, S; Watson, J | 1 |
| Abad, M; Casado, JL; Dahl, V; Díaz, L; Dronda, F; Gutiérrez, C; Hernández-Novoa, B; Madrid, N; Moreno, AM; Moreno, S; Muñoz, E; Muñoz-Fernández, MÁ; Navas, E; Palmer, S; Pérez-Elías, MJ; Rubio, R; Vallejo, A; Zamora, J | 1 |
| Belvisi, V; Branà, MT; Di Bari, G; Gramegna, P; Latronico, T; Lichtner, M; Liuzzi, GM; Mascellino, MT; Mastroianni, CM; Mengoni, F; Vullo, V | 1 |
| Genebat, M; Leal, M; Machmach, K; Mendez-Lagares, G; Pulido, I; Romero-Sánchez, MC; Ruiz-Mateos, E | 1 |
| Arrowsmith, J; Drummond, KS; Feltner, DE; Morgan, P; Street, SD; Van Der Graaf, PH; Wegner, CD | 1 |
| Berro, R; Gulick, RM; Henrich, TJ; Kuritzkes, DR; Lee, SH; Lewine, NR; Moore, JP; Rao, SS; Tsibris, AM | 1 |
| Camacho, A; de los Santos, I; Di Lello, F; Gómez-Mateos, J; Macías, J; Márquez, M; Mata, R; Ojeda, G; Pineda, JA; Portilla, J; Rivero, A; Sanz-Sanz, J; Viloria, MM | 1 |
| Brudney, D; Garcia, A; Geretti, AM; Johnson, M; MacCartney, M; Marshall, N; Smith, C; Vitiello, P | 1 |
| Antunes, F; Barroso, H; Bártolo, I; Borrego, P; Caixas, U; Calado, R; Cavaco-Silva, P; Doroana, M; Maltez, F; Marcelino, JM; Rocha, C; Taveira, N | 1 |
| Bujan, L; Daudin, M; Izopet, J; Massip, P; Moinard, N; Pasquier, C; Sauné, K; Trancart, S | 1 |
| García, F; Gutiérrez, F; Poveda, E; Rodríguez, JC | 1 |
| Best, BM; Clifford, DB; Collier, AC; Croteau, D; Ellis, RJ; Gelman, BB; Grant, I; Letendre, S; McArthur, JC; McCutchan, JA; Morgello, S; Rossi, SS | 1 |
| Boyd, P; Doyle, LA; Fetherston, SM; Geer, L; Goldman, L; Ketas, TJ; Klasse, PJ; Lowry, D; Major, I; Malcolm, RK; Moore, JP; Murphy, DJ; Rasmussen, KK; Shattock, RJ; Veazey, RS | 1 |
| Baroncelli, S; Bucciardini, R; Cavalli, A; Degli Antoni, A; Floridia, M; Fragola, V; Francisci, D; Galluzzo, CM; Ladisa, N; Mercuri, A; Monno, L; Pirillo, MF; Volpe, A; Weimer, LE | 1 |
| Boyd, SD; McLaughlin, M; Morse, CG; Pau, AK; Penzak, SR | 1 |
| Aouri, M; Buclin, T; Calmy, A; Decosterd, LA; Hirschel, B; Livio, F | 1 |
| Chen, L; Chen, Z; Cheung, AK; Kang, Y; Lau, TC; Li, B; Li, S; Liang, J; Liu, L; Lu, X; Ng, J; Tan, Z; Wang, H; Wu, Z; Zheng, B | 1 |
| Abrol, R; Goddard, WA; Grunbeck, A; Huber, T; Sakmar, TP; Trzaskowski, B | 1 |
| Bustos Terol, S; Cama-Barbieri, J; Caro-Martínez, E; Reus-Bañuls, S | 1 |
| Das, D; Maeda, K; Mitsuya, H; Nakata, H | 1 |
| Abad, MA; Ferrando-Martinez, S; Genebat, M; Gonzalez-Serna, A; Leal, M; Muñoz-Fernández, MÁ; Romero-Sánchez, MC; Ruiz-Mateos, E; Vidal, F | 1 |
| Barouch, DH; Dufour, J; Klasse, PJ; Moore, JP; Veazey, RS | 1 |
| Bigoloni, A; Castagna, A; Cossarini, F; Della Torre, L; Galli, A; Galli, L; Gianotti, N; Lazzarin, A; Nozza, S; Salpietro, S; Spagnuolo, V; Vinci, C | 1 |
| Chiappetta, S; Faioni, EM; Fontana, G; Nozza, S; Pogliaghi, M; Razzari, C; Spagnuolo, V; Tambussi, G | 1 |
| Caixas, U; Faustino, I; Ferreira, J; Germano, I; Grilo, NM; Lampreia, F; Marinho, AT; Monteiro, EC; Pereira, SA | 1 |
| Fang, J; Jadhav, PR | 1 |
| Currier, JS; Fox, L; Gandhi, RT; Gulick, R; Lalama, CM; Landay, A; Lin, N; McKinnon, J; Mellors, JW; Ribaudo, H; Tenorio, AR; Wilkin, TJ | 1 |
| Ferrando-Martínez, S; Genebat, M; González-Serna, A; Leal, M; Machmach, K; Muñoz-Fernández, MÁ; Pacheco, YM; Pulido, I; Romero-Sánchez, MC; Ruiz-Mateos, E | 1 |
| Dhiver, C; Durant, J; Gagnieu, MC; Garraffo, R; Katlama, C; Lê, MP; Muret, P; Peytavin, G; Poizot-Martin, I; Solas, C; Yeni, P | 1 |
| Briz, V; de José, MI; de Mulder, M; García, D; González-Tomé, MI; Leal, M; León-Leal, JA; Mellado, MJ; Méndez-Lagares, G; Moreno-Pérez, D; Muñoz-Fernández, MA; Navarro, ML; Ramos, JT; Ruiz-Mateos, E | 1 |
| Anders, M; Bozek, K; Eckhardt, M; Kaiser, R; Kräusslich, HG; Lengauer, T; Müller, B; Sierra, S | 1 |
| Boesecke, C; Pett, SL | 1 |
| Murray, JM; Savkovic, B; Symonds, G | 1 |
| Imami, N; Jackson, A; Mandalia, S; Moyle, G; Nelson, M; Westrop, SJ | 1 |
| Mugavero, MJ; Napolitano, LA; Nevin, CR; Raper, JL; Saag, MS; Tamhane, A; Wilkins, SA; Willig, JH | 1 |
| Alvarez-Ríos, AI; Ferrando-Martinez, S; García-García, M; Genebat, M; Gonzalez-Serna, A; Leal, M; Machmach, K; Pulido, I; Romero-Sánchez, MC; Ruiz-Mateos, E | 1 |
| Berghs, HAM; Carvalho, LR; Kacew, S; Martins, MA; Melhem, MSC; Mendes, RP; Moris, DV; Pimenta-Rodrigues, MV; Souza, LR; Szeszs, MW | 1 |
| Gamaletsou, MN; Kontos, AN; Kontoyiannis, DP; Kordossis, T; Sipsas, NV; Stefanou, I; Tsiakalos, A | 1 |
| Allavena, C; Barbuat, C; Corbeau, P; Cuzin, L; Delobel, P; Flandre, P; Ghosn, J; Lascoux-Combe, C; Peytavin, G; Psomas, C; Reynes, J; Trabelsi, S | 1 |
| Biswas, P; Chapman, DS; Johnson, EP; Kagan, RM; Pesano, RL; Platt, JL; Siaw, M; Su, Z | 1 |
| Abad Fernández, M; Díaz, L; Dronda, F; Gutiérrez, C; Hernández-Novoa, B; Madrid, N; Moreno, S; Muñoz-Fernández, MÁ; Serrano-Villar, S; Vallejo, A; Zamora, J | 1 |
| Cardoso, SW; Grinsztejn, B; Guimarães, ML; Morgado, MG; Passaes, CP; Pilotto, JH; Veloso, V | 1 |
| Brumme, CJ; Chapman, D; Dong, W; Harrigan, PR; Heera, J; James, I; Lewis, M; McGovern, RA; Mo, T; Portsmouth, S; Thielen, A; Valdez, H; Woods, CK; Zhong, X | 1 |
| Hoepelman, AI; van Lelyveld, SF; Wensing, AM | 1 |
| Craig, C; Fätkenheuer, G; Heera, J; Leal, M; McFadyen, L; Mildvan, D; Mills, A; Podzamczer, D; Portsmouth, S; Rinehart, AR; Than, S; Valdez, H; Valluri, SR; Vourvahis, M | 1 |
| Bellecave, P; Calvez, V; Descamps, D; Fleury, H; Harrigan, PR; Izopet, J; Marcelin, AG; Masquelier, B; Raymond, S; Recordon-Pinson, P; Soulie, C | 1 |
| Aneja, R; Bailey, LD; Chaiken, IM; Contarino, M; Duffy, C; Freire, E; Holmes, A; Kamanna, K; Kubinski, P; McFadden, K; Rodrigo Moreira, D; Schön, A; Tuzer, F | 1 |
| Dufty, NE; Else, LJ; Gilleran, G; Hawkins, D; Taylor, S | 1 |
| Aull, K; Boehm, D; Bradner, JE; Calvanese, V; Dar, RD; Li, PC; Martins, L; Ott, M; Planelles, V; Schroeder, S; Siliciano, RF; Verdin, E; Weinberger, L; Xing, S; Zhou, MM | 1 |
| Goodwin, SR; Laciny, E; Reeds, DN; Royal, M; Struthers, H; Yarasheski, KE | 1 |
| Ampofo, S; Boyd, P; Edwards, KL; Fetherston, SM; Malcolm, RK; McBride, MC; McCoy, CF | 1 |
| Berro, R; Chikere, KC; Didigu, CA; Doms, RW; Hahn, BH; Iyer, SS; Klasse, PJ; Lee, B; Lee, FH; Moore, JP; Parker, ZF; Parrish, NF; Shaw, GM; Wilen, CB | 1 |
| Boonchawalit, S; Harada, S; Matsushita, S; Yamaguchi, A; Yoshimura, K; Yusa, K | 1 |
| Henrich, TJ; Kuritzkes, DR | 1 |
| Ferrando-Martínez, S; Genebat, M; Leal, M; Méndez-Lagares, G; Muñoz-Fernández, MÁ; Pacheco, YM; Romero-Sánchez, MC; Ruiz-Mateos, E | 1 |
| Antoniou, T; Brunetta, J; Halpenny, R; Hasan, S; Kovacs, C; La Porte, C; Loutfy, MR; Smith, G | 1 |
| Baraki, B; Benko, E; Brumme, ZL; Danroth, R; Huibner, S; Kaul, R; Kovacs, C; Le, AQ; Mazzulli, T; Osborne, BJ; Porte, Cl; Sheth, PM; Yi, TJ | 1 |
| Bellido, R; Bonjoch, A; Casadellà, M; Clotet, B; Negredo, E; Noguera-Julian, M; Paredes, R; Pérez-Álvarez, N; Pou, C; Puig, J | 1 |
| Back, D; Croucher, A; Else, LJ; Khoo, S; Mora-Peris, B; Scullard, G; Vera, JH; Winston, A | 1 |
| Ait-Arkoub, Z; Calvez, V; Fofana, DB; Fourati, S; Katlama, C; Lambert-Niclot, S; Marcelin, AG; Sayon, S; Simon, A; Soulié, C | 1 |
| Aharchi, F; Hoetelmans, RM; Kakuda, TN; Nijs, S; Smedt, GD; Van Solingen-Ristea, R; Vyncke, V; Witek, J | 1 |
| Billich, A | 1 |
| Albougy, HA; Naidoo, S | 1 |
| Brown, N; Chau, AS; DiDomenico, B; Hare, RS; Li, X; Loebenberg, D; López-Ribot, JL; McNicholas, PM; Mendrick, CA; Quindos, G; Ruesga, MT | 1 |
| del Palacio, A; Garau, M; Garcí, J; Gené, J; Molina, L; Perkins, A | 1 |
| De Clercq, E; De Maeyer, M; Debyser, Z; Fikkert, V; Hombrouck, A; Pannecouque, C; Van Remoortel, B; Witvrouw, M | 1 |
| Arvieux, C; Chapplain, JM; Tattevin, P | 1 |
| Abel, S; Dezube, BJ; Fätkenheuer, G; Goebel, FD; Hoepelman, AI; James, IT; Jenkins, TM; Johnson, MA; Medhurst, C; Plettenberg, A; Pozniak, AL; Ridgway, C; Rockstroh, JK; Saag, MS; Staszewski, S; Sullivan, JF; van der Ryst, E; Youle, M | 1 |
| Dorr, P; Hitchcock, C; Jacqmin, P; Rosario, MC; van der Ryst, E | 1 |
| Clausen, RP | 1 |
| Poland, B; Rosario, MC; Sullivan, J; van der Ryst, E; Westby, M | 1 |
| James, IT; Jenkins, TM; Lewis, M; Perros, M; Pozniak, AL; van der Ryst, E; Westby, M; Whitcomb, J; Youle, M | 1 |
| Goebel, FD; Horster, S | 1 |
| Archimandritis, A; Filiotou, A; Giannaris, M; Kaloterakis, A; Mitroussia, A; Pirounaki, M; Velegraki, A | 1 |
| Boffito, M; Mallon, PW; Winston, A | 1 |
| Cepero de García, MC; Espinel-Ingroff, A; Rincón, S | 1 |
| Girardet, JL; Hamatake, RK; Hong, Z; Koh, YH; Shim, JH; Xu, W; Yeh, LT; Zhang, Z | 1 |
| Temesgen, Z | 1 |
| Elder, JH; Fokin, VV; Lin, YC; Lindstrom, W; Olson, AJ; Sharpless, KB; Tripp, JC; Whiting, M | 1 |
| Ciaramella, G; Dorr, P; Lewis, M; Mori, J; Mosley, M; Perros, M; Smith-Burchnell, C; Stockdale, M; Westby, M | 1 |
| Ampel, NM | 1 |
| Stephenson, J | 2 |
| Ajisawa, A; Honma, M; Imamura, A; Negishi, M; Suganuma, A; Suzuki, T; Takeshita, N; Yanagisawa, N | 1 |
| Opar, A | 1 |
| Aoun, N; Baixench, MT; Bretagne, S; Dannaoui, E; Desnos-Ollivier, M; Garcia-Hermoso, D; Piketty, C; Ramires, S | 1 |
| Egger, M; Telenti, A | 1 |
| Jackson, V; McHale, M; Penny, M; Wheeler, J | 1 |
| Laurence, J | 1 |
| Boyle, BA; Cohen, CJ; Elion, R; Frank, I; Moyle, GJ; Sax, P | 1 |
| Vazquez, JA | 1 |
| Kadow, JF; Meanwell, NA | 1 |
| Granowitz, E; Iarikov, D; Robertson, D; Skiest, D | 1 |
| Kuritzkes, DR | 1 |
| Groeschen, HM | 1 |
| Carter, NJ; Keating, GM | 1 |
| Mosier, DE | 1 |
| Lorenzen, T; Plettenberg, A; Stoehr, A; Walther, I | 1 |
| Bredeek, UF; Harbour, MJ | 1 |
| Bogner, JR; Mueller, MC | 1 |
| Delfraissy, JF; Ghosn, J; Méchai, F; Quertainmont, Y; Sahali, S | 1 |
| Ndegwa, S | 1 |
| Meessen, NE; Oosten, AW; Sprenger, HG; van Assen, S; van Leeuwen, JT | 1 |
| Fadel, H; Temesgen, Z | 1 |
| Abel, S; Boffito, M | 1 |
| Abel, S; Medhurst, CG; Muirhead, GJ; Ridgway, CE; Rosario, MC; Taylor-Worth, RJ; van der Ryst, E | 1 |
| Abel, S; Muirhead, GJ; Ridgway, CE; Russell, D; Whitlock, LA | 2 |
| Abel, S; Muirhead, GJ; Ridgway, CE; Russell, D; Taylor-Worth, RJ | 1 |
| Abel, S; Jenkins, TM; Muirhead, GJ; Ridgway, CE; Whitlock, LA | 1 |
| Boffito, M; Muirhead, GJ; Pozniak, AL; Ridgway, CE; Russell, D | 1 |
| Chan, PL; McFadyen, L; Weatherley, B | 1 |
| Abel, S; Dorr, P; Jacqmin, P; James, I; Jenkins, TM; Rosario, MC; van der Ryst, E | 1 |
| Jacqmin, P; McFadyen, L; Wade, JR | 1 |
| Taéron, C | 1 |
| Brunel, AS; Fraisse, T; Lechiche, C; Mauboussin, JM; Pinzani, V; Sotto, A | 1 |
| de la Tribonnière, X; Reynes, J; Yazdanpanah, Y | 1 |
| Peytavin, G | 1 |
| Chidiac, C; Katlama, C; Yeni, P | 1 |
| al-Haidary, AD; Catanzaro, A; Cloud, GA; Graybill, JR; Hostetler, JS; Larsen, RA; Rinaldi, MG; Sharkey, PK; Stevens, DA; Tucker, RM | 1 |
| Chiritescu, ME; Chiritescu, MM; Scher, RK | 1 |
| Ruhnke, M; Schmidt-Westhausen, A; Trautmann, M | 1 |
| Cantu, RA; Fothergill, AW; Kirkpatrick, WR; Lopez-Ribot, JL; Mcatee, RK; McCarthy, DI; Patterson, TF; Revankar, SG; Rinaldi, MG; Sanche, SE | 1 |
| Krcmery, V | 1 |
| Müller, FM; Weig, M | 1 |
| Arzeni, D; Barchiesi, F; D'Angelo, M; Falconi Di Francesco, L; Giuliana, G; Milici, ME; Pizzo, G; Scalise, G | 1 |
| Fothergill, AW; Gonzalez, G; Perea, S; Rinaldi, MG; Sutton, DA | 1 |
| Graybill, JR; Hardin, TC; Lam, YF; Rinaldi, MG; Sharkey, PK; Wallace, JE | 1 |
89 review(s) available for triazoles and HIV Infections
| Article | Year |
|---|---|
Doravirine: its role in HIV treatment.
Topics: Anti-HIV Agents; HIV Infections; Humans; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2022 |
Peptide Triazole Inhibitors of HIV-1: Hijackers of Env Metastability.
Topics: Binding Sites; HIV Infections; HIV-1; Humans; Peptides; Sulfhydryl Compounds; Triazoles | 2023 |
Doravirine: A Return of the NNRTI Class?
Topics: Anti-HIV Agents; HIV Infections; HIV-1; Humans; Pyridones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Treatment Outcome; Triazoles | 2020 |
Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1.
Topics: Animals; Anti-HIV Agents; Deoxyadenosines; Drug Combinations; Drug Evaluation, Preclinical; HIV Infections; HIV-1; Humans; Lamivudine; Macaca mulatta; Pre-Exposure Prophylaxis; Pyridones; Reverse Transcriptase Inhibitors; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Triazoles; Viral Load | 2020 |
Doravirine: a new non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection.
Topics: Anti-HIV Agents; Cytochrome P-450 CYP3A; HIV Infections; HIV-1; Humans; Japan; Pyridones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Triazoles | 2020 |
Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Area Under Curve; Drug Interactions; Female; Food-Drug Interactions; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Triazoles; Young Adult | 2020 |
Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; In Vitro Techniques; Pyridones; Rilpivirine; Triazoles | 2020 |
1,2,3-Triazole hybrids with anti-HIV-1 activity.
Topics: Anti-HIV Agents; HIV Infections; Humans; Structure-Activity Relationship; Triazoles | 2021 |
Efficacy and safety of doravirine in treatment-naive HIV-1-infected adults: a systematic review and meta-analysis.
Topics: Adult; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Pyridones; Triazoles | 2021 |
Doravirine: a review.
Topics: Anti-HIV Agents; HIV Infections; Humans; Pyridones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Triazoles | 2018 |
Clinical Impact of Virological Failure and Resistance Analysis Definitions used in Pivotal Clinical Trials of Initial Antiretroviral Treatment: A Systematic Review
Topics: Amides; Anti-Retroviral Agents; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Resistance, Viral; Genotype; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Quinolones; Rilpivirine; RNA, Viral; Triazoles; Viral Load | 2018 |
Doravirine: First Global Approval.
Topics: Anti-HIV Agents; Drug Approval; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Reverse Transcriptase Inhibitors; Tablets; Tenofovir; Triazoles | 2018 |
Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Interactions; HIV Infections; HIV-1; Humans; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2019 |
Determination of HIV tropism and its use in the clinical practice.
Topics: Biological Assay; Cyclohexanes; Genotype; HIV Fusion Inhibitors; HIV Infections; HIV-1; Host-Pathogen Interactions; Humans; Maraviroc; Molecular Typing; Phenotype; Receptors, CCR5; Receptors, CXCR4; Sensitivity and Specificity; Triazoles; Viral Tropism | 2013 |
[Use of maraviroc, the first CCR5 receptor antagonist, in HIV treatment regimens].
Topics: CCR5 Receptor Antagonists; Cyclohexanes; HIV; HIV Infections; Humans; Maraviroc; Treatment Outcome; Triazoles | 2013 |
Clinically relevant drug-drug interactions between antiretrovirals and antifungals.
Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-Retroviral Agents; Antifungal Agents; Benzoxazines; Carbamates; Cyclopropanes; Drug Interactions; Drug Monitoring; Echinocandins; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Itraconazole; Mycoses; Organophosphates; Pyrimidines; Ritonavir; Sulfonamides; Triazoles; Voriconazole | 2014 |
An overview of antiretroviral pre-exposure prophylaxis of HIV infection.
Topics: Adenine; Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; Female; HIV Infections; Humans; Male; Maraviroc; Medication Adherence; Nitriles; Organophosphonates; Pre-Exposure Prophylaxis; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Triazoles | 2014 |
Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
Topics: CCR5 Receptor Antagonists; CD4 Antigens; Cyclohexanes; Disease Progression; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CCR5; Receptors, CXCR4; Triazoles; Viral Tropism; Virus Internalization | 2015 |
Targeting CCR5 for anti-HIV research.
Topics: Anti-HIV Agents; Biological Therapy; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Drug Discovery; HIV Infections; Humans; Maraviroc; Receptors, CCR5; Triazoles | 2014 |
Pharmacological intervention at CCR1 and CCR5 as an approach for cancer: help or hindrance.
Topics: Animals; Antineoplastic Agents; Cyclohexanes; HIV Infections; Humans; Maraviroc; Molecular Structure; Neoplasms; Receptors, CCR1; Receptors, CCR5; Triazoles | 2014 |
Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Drug Discovery; HIV; HIV Infections; Humans; Maraviroc; Receptors, CCR5; Structure-Activity Relationship; Triazoles; Virus Replication | 2014 |
HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth.
Topics: Animals; Anti-HIV Agents; Cyclohexanes; Drug Design; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Maraviroc; Molecular Targeted Therapy; Receptors, CCR5; Triazoles | 2015 |
Immune reconstitution inflammatory syndrome in a patient with progressive multifocal leukoencephalopathy.
Topics: CCR5 Receptor Antagonists; CD8-Positive T-Lymphocytes; Cyclohexanes; Disease Progression; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; JC Virus; Leukoencephalopathy, Progressive Multifocal; Male; Maraviroc; Middle Aged; Treatment Outcome; Triazoles | 2015 |
Maraviroc: a review of its use in HIV infection and beyond.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Interactions; Drug Resistance, Viral; Genotype; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Mutation; Phenotype; Polypharmacy; Treatment Outcome; Triazoles | 2015 |
Off-label use of maraviroc in clinical practice.
Topics: Animals; Arthritis, Rheumatoid; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Graft vs Host Disease; Hematologic Neoplasms; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Mice; Off-Label Use; Sarcoidosis; Triazoles | 2016 |
[Companion Diagnostics for Selecting Antiretroviral Drugs against HIV-1].
Topics: Alleles; Anti-Retroviral Agents; CCR5 Receptor Antagonists; Cyclohexanes; Dideoxynucleosides; HIV Infections; HIV-1; HLA-B Antigens; Humans; Maraviroc; Pharmacogenetics; Precision Medicine; Reverse Transcriptase Inhibitors; Triazoles; Viral Tropism | 2015 |
Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis.
Topics: Anti-HIV Agents; Cyclohexanes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Male; Maraviroc; Middle Aged; Odds Ratio; Reverse Transcriptase Inhibitors; Risk; Triazoles; Viral Load | 2016 |
CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV.
Topics: Animals; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Design; HIV Infections; Humans; Imidazoles; Maraviroc; Sulfoxides; Triazoles | 2016 |
Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents.
Topics: Anti-HIV Agents; Biological Assay; CCR5 Receptor Antagonists; CD4-Positive T-Lymphocytes; Clinical Trials as Topic; Cyclohexanes; Cytochrome P-450 CYP3A; Drug Interactions; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CCR5; Triazoles; Tropism; Virus Internalization | 2008 |
New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Darunavir; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Maraviroc; Nitriles; Pyridazines; Pyridines; Pyrimidines; Pyrones; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Salvage Therapy; Sulfonamides; Treatment Outcome; Triazoles | 2008 |
Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Interactions; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Maraviroc; Triazoles | 2008 |
Maraviroc, risks and benefits: a review of the clinical literature.
Topics: CCR5 Receptor Antagonists; Clinical Trials, Phase III as Topic; Cyclohexanes; Drug Resistance, Multiple, Viral; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Triazoles | 2008 |
Optimal use of maraviroc in clinical practice.
Topics: Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Drug Interactions; Drug Resistance, Viral; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Receptors, CCR5; Triazoles; Tropism; Viral Load | 2008 |
Developing clinical role of a CCR5 co-receptor antagonist in HIV-1 infection.
Topics: Anti-Retroviral Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Therapy, Combination; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles; Virus Replication | 2008 |
Inhibitors of viral entry.
Topics: Animals; Chemokines; Cyclohexanes; Drug Resistance, Viral; Enfuvirtide; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Peptide Fragments; Triazoles; Virus Attachment; Virus Internalization | 2009 |
[Viral entry as therapeutic target. Current situation of entry inhibitors].
Topics: Adult; Amides; Benzoates; CCR5 Receptor Antagonists; CD4 Antigens; Chemokines, CC; Chemokines, CXC; Clinical Trials as Topic; Cyclohexanes; Diketopiperazines; Drug Design; env Gene Products, Human Immunodeficiency Virus; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Membrane Fusion; Models, Molecular; Piperazines; Pyrimidines; Quaternary Ammonium Compounds; Receptors, CCR5; Receptors, CXCR4; Spiro Compounds; Structure-Activity Relationship; Triazoles; Virus Attachment; Virus Internalization | 2008 |
[Pharmacokinetics, interactions and mechanism of action of maraviroc].
Topics: Adolescent; Adult; Aged; Biological Availability; Biotransformation; CCR5 Receptor Antagonists; Chemokines, CC; Clinical Trials as Topic; Cyclohexanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Design; Drug Interactions; env Gene Products, Human Immunodeficiency Virus; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Kidney Diseases; Liver Diseases; Maraviroc; Membrane Fusion; Receptors, CCR5; Triazoles; Virus Attachment; Virus Internalization; Virus Replication | 2008 |
[Maraviroc efficacy in clinical studies on the development of the molecule].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Cyclohexanes; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Design; Drug Resistance, Multiple, Viral; env Gene Products, Human Immunodeficiency Virus; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Multicenter Studies as Topic; Salvage Therapy; Treatment Outcome; Triazoles | 2008 |
[Secondary effects of treatment with maraviroc and other CCR5 antagonists. Potential impact of the CCR5 blocker].
Topics: Adult; Benzoates; CCR5 Receptor Antagonists; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Comorbidity; Cyclohexanes; Diketopiperazines; Disease Susceptibility; Drug Design; env Gene Products, Human Immunodeficiency Virus; HIV Fusion Inhibitors; HIV Infections; Homozygote; Humans; Hyperlipidemias; Incidence; Infections; Maraviroc; Membrane Fusion; Neoplasms; Piperazines; Receptors, CCR5; Sequence Deletion; Spiro Compounds; Triazoles; Virus Attachment; Virus Internalization | 2008 |
[Mechanisms of resistance and failure of treatment with maraviroc].
Topics: Amino Acid Sequence; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Viral; env Gene Products, Human Immunodeficiency Virus; Genes, env; HIV; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Membrane Fusion; Molecular Sequence Data; Multicenter Studies as Topic; Peptide Fragments; Receptors, CXCR4; Selection, Genetic; Treatment Failure; Triazoles; Virus Attachment; Virus Internalization | 2008 |
[At what time and with which combinations should maraviroc be indicated in the new antiretroviral treatment scenario?].
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Anti-Infective Agents; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; HIV; HIV Infections; Humans; Maraviroc; Membrane Fusion; Receptors, CXCR4; Salvage Therapy; Triazoles; Viral Load; Virus Attachment | 2008 |
[Conclusions and perspectives. Maraviroc].
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Drug Design; Drug Resistance, Viral; Drug Therapy, Combination; Gene Products, env; HIV; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Membrane Fusion; Peptide Fragments; Receptors, CXCR4; Salvage Therapy; Selection, Genetic; Triazoles; Virus Attachment; Virus Internalization | 2008 |
Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CCR5; Receptors, CXCR4; Triazoles; Virus Internalization | 2009 |
Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection.
Topics: Animals; CCR5 Receptor Antagonists; Cyclohexanes; Disease Management; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CCR5; Triazoles | 2009 |
Immunotherapies in HIV-1 infection.
Topics: Cyclohexanes; HIV Infections; HIV-1; Humans; Immunologic Factors; Immunotherapy; Interleukin-2; Maraviroc; Treatment Outcome; Triazoles | 2009 |
[Role of the new molecules in antiretroviral therapy. Position of raltegravir].
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Enfuvirtide; Forecasting; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; Humans; Maraviroc; Nitriles; Peptide Fragments; Pyridazines; Pyridines; Pyrimidines; Pyrones; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Sulfonamides; Triazoles | 2008 |
Maraviroc: a new CCR5 antagonist.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Child; Clinical Trials as Topic; Cyclohexanes; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Pregnancy; Treatment Outcome; Triazoles | 2009 |
Entry inhibitors in the treatment of HIV-1 infection.
Topics: Cyclohexanes; Drug Resistance, Viral; Enfuvirtide; History, 20th Century; History, 21st Century; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Peptide Fragments; Triazoles | 2010 |
Maraviroc: pharmacokinetics and drug interactions.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Anti-Infective Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Reverse Transcriptase Inhibitors; Triazoles; Young Adult | 2009 |
When and how to use maraviroc in HIV-infected patients.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Drug Resistance, Viral; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Triazoles; Viral Tropism | 2009 |
Novel drug classes: entry inhibitors [enfuvirtide, chemokine (C-C motif) receptor 5 antagonists].
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Enfuvirtide; HIV; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Peptide Fragments; Piperazines; Pyrimidines; Salvage Therapy; Triazoles; Virus Internalization | 2009 |
Novel CCR5 antagonists for the treatment of HIV infection: a review of compounds patented in 2006 - 2008.
Topics: AIDS Vaccines; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Delivery Systems; Drug Resistance, Viral; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Patents as Topic; Triazoles | 2010 |
Treatment of HIV infection with the CCR5 antagonist maraviroc.
Topics: CCR5 Receptor Antagonists; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclohexanes; Drug Resistance, Viral; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Triazoles; Viral Tropism | 2010 |
[CCR5-antagonists: contribution of a new antiretroviral class to the management of HIV infection].
Topics: Anti-Retroviral Agents; CCR5 Receptor Antagonists; Cyclohexanes; HIV; HIV Infections; Humans; Maraviroc; Triazoles; Viral Tropism | 2010 |
Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; Cyclohexanes; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Randomized Controlled Trials as Topic; Receptors, CCR5; Treatment Failure; Treatment Outcome; Triazoles; Viral Load; Viral Tropism; Young Adult | 2010 |
[Pharmacological profile and clinical findings of Maraviroc (Celsentri® Tablets)].
Topics: Animals; Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Antigens; Clinical Trials as Topic; Cyclohexanes; Drug Resistance, Viral; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Maraviroc; Protein Binding; Tablets; Triazoles | 2010 |
Maraviroc first-line therapy for HIV infection. Too risky.
Topics: Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Risk Factors; Triazoles | 2010 |
Clinical use of CCR5 inhibitors in HIV and beyond.
Topics: Animals; Antiviral Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Disease Models, Animal; Encephalitis, Tick-Borne; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Protein Binding; Triazoles; West Nile Fever | 2011 |
Update on microbicide research and development - seeking new HIV prevention tools for women.
Topics: Adenine; Administration, Intravaginal; Adult; Africa South of the Sahara; Anti-HIV Agents; Anti-Infective Agents; Clinical Trials as Topic; Cyclohexanes; Drug Discovery; Female; HIV Infections; Humans; Male; Maraviroc; Organophosphonates; Pyridines; Pyrimidines; Tenofovir; Triazoles; Urea | 2011 |
HIV entry inhibitors: progress in development and application.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Antigens; Cyclohexanes; Drug Resistance, Viral; Enfuvirtide; HIV Envelope Protein gp120; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Molecular Structure; Peptide Fragments; Receptors, CCR5; Receptors, Chemokine; Receptors, CXCR4; Triazoles | 2010 |
[The newest developments in anti-HIV-1 drugs].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Drug Resistance, Viral; Enfuvirtide; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Maraviroc; Molecular Structure; Peptide Fragments; Pyrrolidinones; Raltegravir Potassium; Saquinavir; Triazoles; Virus Replication; Zidovudine | 2010 |
Clinical utility of maraviroc.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CCR5; Triazoles | 2011 |
Tetrahydrofuran, tetrahydropyran, triazoles and related heterocyclic derivatives as HIV protease inhibitors.
Topics: Furans; Heterocyclic Compounds; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Pyrans; Structure-Activity Relationship; Triazoles | 2011 |
CCR5 antagonism in HIV infection: current concepts and future opportunities.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Drug Discovery; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CCR5; Triazoles | 2012 |
Drug safety evaluation of maraviroc for the treatment of HIV infection.
Topics: Animals; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclohexanes; Drug Monitoring; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Time Factors; Triazoles | 2012 |
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
Topics: Adenine; Adult; Amniotic Fluid; Anti-HIV Agents; Cyclohexanes; Enfuvirtide; Female; Fetal Blood; Fetus; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Maraviroc; Nevirapine; Organophosphonates; Peptide Fragments; Placenta; Pregnancy; Pregnancy Complications, Infectious; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Triazoles; Viral Load; Zidovudine | 2011 |
[Methods for determination of HIV tropism and their clinical use].
Topics: Algorithms; Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Europe; Genes, env; Genotype; HIV Envelope Protein gp120; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Maraviroc; Peptide Fragments; Phenotype; Practice Guidelines as Topic; Receptors, CCR5; Receptors, CXCR4; Retrospective Studies; Triazoles; Viral Tropism; Virology; Virus Internalization | 2011 |
CCR5 inhibitors: emergence, success, and challenges.
Topics: Animals; Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclohexanes; HIV Infections; Humans; Maraviroc; Receptors, CXCR4; Triazoles | 2012 |
Clinical studies with chemokine receptor-5 (CCR5)-inhibitors.
Topics: Antibodies, Monoclonal; Antiviral Agents; CCR5 Receptor Antagonists; Coinfection; Cyclohexanes; Hepatitis C, Chronic; HIV; HIV Antibodies; HIV Infections; Humans; Maraviroc; Molecular Diagnostic Techniques; Triazoles; Viral Tropism; Virology | 2012 |
The MOTIVATE trials: maraviroc therapy in antiretroviral treatment-experienced HIV-1-infected patients.
Topics: Anti-Retroviral Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Maraviroc; Randomized Controlled Trials as Topic; Triazoles; Viral Tropism | 2012 |
HIV-1 entry inhibitors: recent development and clinical use.
Topics: Antibodies, Monoclonal; Chemoprevention; Clinical Trials as Topic; Cyclohexanes; Disease Transmission, Infectious; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Organophosphates; Piperazines; Triazoles; Virus Internalization | 2013 |
S-1360 Shionogi-GlaxoSmithKline.
Topics: Anti-HIV Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Furans; HIV Infections; HIV Integrase Inhibitors; Humans; Triazoles | 2003 |
A systematic review of the management of oral candidiasis associated with HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Antifungal Agents; Candidiasis, Oral; Comorbidity; HIV Infections; Humans; Practice Guidelines as Topic; Treatment Outcome; Triazoles | 2002 |
Serious doubts on safety and efficacy of CCR5 antagonists : CCR5 antagonists teeter on a knife-edge.
Topics: Benzoates; CCR5 Receptor Antagonists; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cyclohexanes; Diketopiperazines; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Piperazines; Pyrimidines; Spiro Compounds; Treatment Outcome; Triazoles | 2006 |
The clinical pharmacology of antiretrovirals in development.
Topics: Animals; Anti-Retroviral Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Darunavir; Drug Evaluation, Preclinical; Drug Interactions; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Maraviroc; Nitriles; Organic Chemicals; Protease Inhibitors; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Receptors, CCR5; Reverse Transcriptase Inhibitors; Sulfonamides; Triazoles | 2006 |
Coccidioidomycosis in persons infected with HIV-1.
Topics: Amphotericin B; Antifungal Agents; CD4-Positive T-Lymphocytes; Coccidioidomycosis; HIV Infections; HIV-1; Humans; Patient Compliance; Recurrence; Triazoles | 2007 |
[Voriconazole as an effective therapy against pulmonary aspergillosis in a man with immunodeficiency virus-infection: a case report].
Topics: Antifungal Agents; Aspergillosis; HIV Infections; Humans; Lung Diseases, Fungal; Male; Middle Aged; Pyrimidines; Triazoles; Voriconazole | 2007 |
Assessing theoretical risk and benefit suggested by genetic association studies of CCR5: experience in a drug development programme for maraviroc.
Topics: Adult; Arthritis, Rheumatoid; CCR5 Receptor Antagonists; Cyclohexanes; Drug Design; Female; Genotype; Hepatitis C; HIV Fusion Inhibitors; HIV Infections; Humans; Male; Maraviroc; Multiple Sclerosis; Mutation; Pharmacogenetics; Receptors, CCR5; Risk Assessment; Risk Factors; Triazoles | 2007 |
Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-HIV Agents; Anti-Inflammatory Agents; Arthritis, Rheumatoid; CCR5 Receptor Antagonists; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclohexanes; HIV Infections; Humans; Maraviroc; Receptors, CCR5; Structure-Activity Relationship; Triazoles | 2007 |
Maraviroc.
Topics: Animals; Anti-HIV Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclohexanes; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Maraviroc; Triazoles | 2007 |
CCR5 antagonists in the treatment of treatment-experienced patients infected with CCR5 tropic HIV-1.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; HIV Infections; HIV-1; Humans; Maraviroc; Piperazines; Pyrimidines; Triazoles | 2007 |
CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1.
Topics: Adolescent; Adult; Anti-HIV Agents; Benzoates; CCR5 Receptor Antagonists; Cyclohexanes; Diketopiperazines; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic; Spiro Compounds; Triazoles | 2007 |
How will CCR5 antagonists influence the recommendations for the antiretroviral treatment of HIV-1 infection.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Patient Selection; Practice Guidelines as Topic; Triazoles | 2007 |
Treatment with CCR5 antagonists: which patient may have a benefit?
Topics: Anti-Retroviral Agents; CCR5 Receptor Antagonists; Cyclohexanes; HIV Infections; HIV-1; Humans; Maraviroc; Patient Selection; Treatment Outcome; Triazoles | 2007 |
Bilateral renal aspergillosis in a patient with AIDS: a case report and review of reported cases.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Antiretroviral Therapy, Highly Active; Aspergillosis; Aspergillus fumigatus; HIV Infections; Humans; Kidney Diseases; Male; Pyrimidines; Radiography; Tomography Scanners, X-Ray Computed; Triazoles; Voriconazole | 2008 |
Maraviroc.
Topics: Animals; Controlled Clinical Trials as Topic; Cyclohexanes; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Female; Food-Drug Interactions; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Triazoles | 2007 |
A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects.
Topics: Adolescent; Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; Computer Simulation; Cyclohexanes; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Models, Biological; Models, Statistical; Randomized Controlled Trials as Topic; Triazoles | 2008 |
Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Computer Simulation; Cyclohexanes; HIV Infections; Humans; Maraviroc; Models, Biological; Models, Statistical; Randomized Controlled Trials as Topic; Triazoles; Viral Load | 2008 |
Newer systemic antifungal drugs for the treatment of onychomycosis.
Topics: Aged; Antifungal Agents; Child; Enzyme Inhibitors; Female; Griseofulvin; HIV Infections; Humans; Imidazoles; Male; Naphthalenes; Onychomycosis; Terbinafine; Triazoles | 1996 |
104 trial(s) available for triazoles and HIV Infections
| Article | Year |
|---|---|
Removal of doravirine by haemodialysis in people living with HIV with end-stage renal disease.
Topics: Chromatography, Liquid; Dialysis Solutions; HIV Infections; Humans; Kidney Failure, Chronic; Male; Pyridones; Renal Dialysis; Tandem Mass Spectrometry; Triazoles | 2022 |
Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine.
Topics: Adult; Anti-HIV Agents; Deoxyadenosines; Drug Combinations; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Reverse Transcriptase Inhibitors; RNA; Tenofovir; Triazoles | 2022 |
Impact of antiretroviral therapy intensification with C-C motif chemokine receptor 5 antagonist maraviroc on HIV-associated neurocognitive impairment.
Topics: Antiretroviral Therapy, Highly Active; Cyclohexanes; HIV Infections; Humans; Maraviroc; Triazoles | 2023 |
Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Pyridones; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Triazoles | 2019 |
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
Topics: Adult; Anti-HIV Agents; Darunavir; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pyridones; Ritonavir; Triazoles; Young Adult | 2020 |
Comparative Bioavailability of Oral Granule Formulations of the HIV Antiretroviral Drugs Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Biological Availability; Cross-Over Studies; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Tablets; Tenofovir; Triazoles; Young Adult | 2020 |
Twice-Daily Doravirine Overcomes the Interaction Effect from Once-Weekly Rifapentine and Isoniazid in Healthy Volunteers.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Drug Administration Schedule; Drug Interactions; Female; Healthy Volunteers; HIV Infections; Humans; Isoniazid; Male; Middle Aged; Prospective Studies; Pyridones; Reverse Transcriptase Inhibitors; Rifampin; Triazoles; Tuberculosis; Young Adult | 2020 |
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Emtricitabine; Fumarates; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Tenofovir; Treatment Outcome; Triazoles | 2021 |
Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Pyridones; Tenofovir; Treatment Outcome; Triazoles | 2021 |
Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Triazoles; Weight Gain; Weight Loss | 2021 |
Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial.
Topics: Adult; Anti-HIV Agents; Deoxyadenosines; Drug Dosage Calculations; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Pyridones; Triazoles; Young Adult | 2021 |
Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial).
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cyclohexanes; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Maraviroc; Medication Adherence; Post-Exposure Prophylaxis; Ritonavir; Triazoles; Young Adult | 2017 |
Impact of intensified antiretroviral therapy during early HIV infection on gut immunology and inflammatory blood biomarkers.
Topics: Adult; Anti-HIV Agents; Biomarkers; Canada; Cyclohexanes; Double-Blind Method; Drug Therapy, Combination; Fibrin Fibrinogen Degradation Products; Flow Cytometry; HIV Infections; Humans; Immunity, Mucosal; Inflammation; Intestinal Mucosa; Lymphocyte Activation; Male; Maraviroc; Middle Aged; Prospective Studies; Raltegravir Potassium; Th17 Cells; Treatment Outcome; Triazoles; Young Adult | 2017 |
Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study.
Topics: Adult; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; Cyclohexanes; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Maraviroc; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Triazoles; Viral Load | 2018 |
Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial.
Topics: Adolescent; Adult; Cyclohexanes; Double-Blind Method; Female; Follow-Up Studies; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Middle Aged; Patient Dropouts; Pre-Exposure Prophylaxis; Prospective Studies; Treatment Outcome; Triazoles; Young Adult | 2017 |
Tissue Pharmacologic and Virologic Determinants of Duodenal and Rectal Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution in HIV-Infected Patients Initiating Antiretroviral Therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclohexanes; Cyclopropanes; DNA, Viral; Duodenum; Female; HIV Infections; Humans; Lymphoid Tissue; Male; Maraviroc; Raltegravir Potassium; Rectum; RNA, Viral; Triazoles | 2017 |
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Ritonavir; Treatment Outcome; Triazoles; Viral Load | 2017 |
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pyridones; Ritonavir; RNA, Viral; Treatment Outcome; Triazoles; Viral Load | 2018 |
Evaluation of the Pharmacokinetic Interaction Between Doravirine and Methadone.
Topics: Adult; Analgesics, Opioid; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders; Outcome Assessment, Health Care; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2020 |
Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety Analysis.
Topics: Adult; Anti-HIV Agents; Emtricitabine; HIV Infections; HIV-1; Humans; Pyridones; Tenofovir; Triazoles | 2020 |
Once-daily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Emtricitabine; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Treatment Outcome; Triazoles | 2020 |
Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pyridones; Treatment Outcome; Triazoles; Viral Load; Young Adult | 2019 |
The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial.
Topics: Adult; CCR5 Receptor Antagonists; CD4-Positive T-Lymphocytes; Cyclohexanes; Female; Gastrointestinal Tract; Graft vs Host Disease; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Immunophenotyping; Lymphocyte Activation; Lymphoid Tissue; Male; Maraviroc; Middle Aged; Rectum; RNA, Viral; Triazoles; Viral Load | 2013 |
Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Disease Susceptibility; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Mutation, Missense; Organophosphates; Piperazines; Prodrugs; RNA, Viral; Treatment Outcome; Triazoles; Viral Load | 2013 |
Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study.
Topics: Adult; Anti-HIV Agents; Brazil; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Darunavir; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Maraviroc; Middle Aged; Protease Inhibitors; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Sulfonamides; Treatment Failure; Triazoles; Viral Load; Young Adult | 2013 |
Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.
Topics: Adolescent; Adult; Aged; CCR5 Receptor Antagonists; Cyclohexanes; Female; Gene Expression; Genotype; High-Throughput Nucleotide Sequencing; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Peptide Fragments; Receptors, CCR5; Receptors, CXCR4; Treatment Failure; Triazoles; Viral Tropism | 2013 |
Gut Lactobacillales are associated with higher CD4 and less microbial translocation during HIV infection.
Topics: Adult; Anti-Retroviral Agents; Bacteria; Bacterial Translocation; Biota; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclohexanes; Double-Blind Method; Drug Therapy, Combination; Gastrointestinal Tract; HIV Infections; Humans; Lactobacillales; Male; Maraviroc; Middle Aged; Placebos; Rectum; Triazoles; Young Adult | 2013 |
Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; DNA, Viral; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Treatment Outcome; Triazoles; Viral Load | 2014 |
Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Immunocompromised Host; Interleukin-7; Ki-67 Antigen; Male; Maraviroc; Middle Aged; RNA, Viral; Treatment Outcome; Triazoles; Viral Load | 2013 |
Dynamics of the HIV-1 latent reservoir after discontinuation of the intensification of antiretroviral treatment: results of two clinical trials.
Topics: Adult; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Pilot Projects; Pyrrolidinones; Raltegravir Potassium; Triazoles; Virus Latency | 2013 |
Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients.
Topics: Adult; CCR5 Receptor Antagonists; Cyclohexanes; Double-Blind Method; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Survival Analysis; Time Factors; Triazoles | 2014 |
A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; DNA, Viral; Drug Combinations; Endpoint Determination; HIV Infections; Humans; Longitudinal Studies; Male; Maraviroc; Middle Aged; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Triazoles; Viral Load; Viremia | 2014 |
Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals.
Topics: Anti-Retroviral Agents; Cyclohexanes; Cytokines; Enzyme-Linked Immunospot Assay; Flow Cytometry; HIV Infections; HIV-1; Humans; Immunity, Cellular; Maraviroc; Receptors, CCR5; Statistics, Nonparametric; T-Lymphocytes; Triazoles; Virus Internalization | 2014 |
Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Lipodystrophy; Male; Maraviroc; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Risk Factors; Treatment Failure; Triazoles; Viral Load | 2014 |
Virological response to short-course maraviroc monotherapy does not predict viral tropism in HIV-1-infected treatment-naive patients.
Topics: Adult; Anti-HIV Agents; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Pilot Projects; Treatment Outcome; Triazoles; Viral Load; Viral Tropism; Young Adult | 2014 |
Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Cell Count; Cyclohexanes; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Maraviroc; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Treatment Outcome; Triazoles | 2014 |
Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclohexanes; Cyclopropanes; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Treatment Outcome; Triazoles; Viral Load; Young Adult | 2014 |
Maintenance of virologic efficacy and decrease in levels of β2-microglobulin, soluble CD40L and soluble CD14 after switching previously treated HIV-infected patients to an NRTI-sparing dual therapy.
Topics: Adult; beta 2-Microglobulin; CD4-Positive T-Lymphocytes; CD40 Ligand; Cyclohexanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipopolysaccharide Receptors; Male; Maraviroc; Middle Aged; Reverse Transcriptase Inhibitors; Triazoles | 2014 |
Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; HIV Infections; HIV-1; Humans; Maraviroc; Mutation; Triazoles; Viral Tropism | 2015 |
Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; DNA, Viral; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Maraviroc; Prospective Studies; Ritonavir; Treatment Outcome; Triazoles; Viral Load | 2015 |
Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study.
Topics: Anti-HIV Agents; Chromatography, Liquid; Cyclohexanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Plasma; Raltegravir Potassium; Tandem Mass Spectrometry; Triazoles | 2015 |
Sitagliptin Reduces Inflammation and Chronic Immune Cell Activation in HIV+ Adults With Impaired Glucose Tolerance.
Topics: Adipokines; Adult; Chemokines; Endothelial Progenitor Cells; Female; Glucose Intolerance; HIV Infections; HIV-1; Humans; Hypoglycemic Agents; Inflammation; Lymphocyte Activation; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2015 |
Dynamics of adaptive and innate immunity in patients treated during primary human immunodeficiency virus infection: results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial.
Topics: Adaptive Immunity; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Dendritic Cells; Female; HIV; HIV Infections; Humans; Immunity, Innate; Lymphocyte Subsets; Male; Maraviroc; Prospective Studies; Triazoles | 2015 |
Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.
Topics: Adult; Anti-HIV Agents; Bone Density; Cyclohexanes; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Pelvic Bones; Tenofovir; Triazoles | 2015 |
Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women.
Topics: Adult; Anti-HIV Agents; Blood Chemical Analysis; Cyclohexanes; Europe; Female; HIV Infections; Humans; Maraviroc; Pregnancy; Pregnancy Complications, Infectious; Triazoles; United States; Young Adult | 2015 |
Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclohexanes; Double-Blind Method; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Lymphocyte Count; Male; Maraviroc; Middle Aged; Receptors, CCR5; Time Factors; Treatment Outcome; Triazoles | 2015 |
Missing CD4+ cell response in randomized clinical trials of maraviroc and dolutegravir.
Topics: Adult; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclohexanes; Data Interpretation, Statistical; Datasets as Topic; Double-Blind Method; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Male; Maraviroc; Models, Statistical; Oxazines; Piperazines; Pyridones; Triazoles; United States | 2015 |
A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals.
Topics: Adolescent; Adult; Anti-HIV Agents; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Male; Middle Aged; Placebos; Plasma; Pyridones; RNA, Viral; Treatment Outcome; Triazoles; Young Adult | 2016 |
Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial).
Topics: Anti-HIV Agents; Cyclohexanes; HIV Infections; HIV-1; Maraviroc; Raltegravir Potassium; Risk Factors; Treatment Failure; Triazoles; Viral Load | 2015 |
Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Prospective Studies; Treatment Outcome; Triazoles; Viral Load | 2015 |
Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; Chromatography, High Pressure Liquid; Cyclohexanes; Cyclopropanes; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; HIV Infections; HIV Integrase Inhibitors; Humans; Immunity, Mucosal; Lymphocyte Activation; Male; Maraviroc; Pilot Projects; Raltegravir Potassium; T-Lymphocyte Subsets; Triazoles | 2016 |
Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder.
Topics: Aged; AIDS Dementia Complex; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Cognition; Cyclohexanes; Double-Blind Method; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Pilot Projects; Prospective Studies; Treatment Outcome; Triazoles | 2016 |
Adherence and Acceptability of a Multidrug Vaginal Ring for HIV Prevention in a Phase I Study in the United States.
Topics: Adult; Anti-HIV Agents; Contraceptive Devices, Female; Cyclohexanes; Double-Blind Method; Drug Therapy, Combination; Feasibility Studies; Female; HIV Infections; Humans; Interview, Psychological; Maraviroc; Medication Adherence; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Program Evaluation; Pyrimidines; South Africa; Text Messaging; Triazoles | 2016 |
Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Administration Schedule; Female; HIV Infections; Humans; Inhibitory Concentration 50; Male; Middle Aged; Organophosphates; Piperazines; Prodrugs; Triazoles | 2016 |
Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 R
Topics: Adult; Comorbidity; Cyclohexanes; Female; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Male; Maraviroc; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Triazoles; Viral Load; Virus Replication | 2016 |
Differential CD4+ cell count increase and CD4+ : CD8+ ratio normalization with maraviroc compared with tenofovir.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Cyclohexanes; Darunavir; Double-Blind Method; Emtricitabine; Female; Flow Cytometry; HIV Infections; Humans; Male; Maraviroc; Placebos; Prospective Studies; Tenofovir; Treatment Outcome; Triazoles | 2016 |
Neurocognition with maraviroc compared with tenofovir in HIV.
Topics: Adult; AIDS-Related Complex; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cognition; Cyclohexanes; Double-Blind Method; Female; HIV Infections; Humans; Male; Maraviroc; Neuropsychological Tests; Placebos; Tenofovir; Treatment Outcome; Triazoles; United States | 2016 |
Pharmacodynamic correlations using fresh and cryopreserved tissue following use of vaginal rings containing dapivirine and/or maraviroc in a randomized, placebo controlled trial.
Topics: Administration, Intravaginal; Adult; Biopsy; Cervix Uteri; Contraceptive Devices, Female; Cryopreservation; Cyclohexanes; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; In Vitro Techniques; Maraviroc; Pyrimidines; Sexually Transmitted Diseases, Viral; Triazoles; United States | 2016 |
Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Maintenance Chemotherapy; Male; Maraviroc; Middle Aged; Raltegravir Potassium; Tenofovir; Treatment Outcome; Triazoles; Viral Load; Young Adult | 2016 |
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study.
Topics: Adult; Anti-HIV Agents; Cyclohexanes; Drug Administration Schedule; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Treatment Failure; Triazoles; Viral Tropism | 2016 |
Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis.
Topics: Administration, Oral; Adult; CCR5 Receptor Antagonists; Cyclohexanes; Female; Healthy Volunteers; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Intestinal Mucosa; Male; Maraviroc; Models, Biological; Pre-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Rectum; Saliva; Treatment Outcome; Triazoles; Urethra; Vagina | 2016 |
Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305).
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Disease Transmission, Infectious; Double-Blind Method; HIV Infections; Homosexuality, Male; Humans; Male; Maraviroc; Middle Aged; Pre-Exposure Prophylaxis; Prospective Studies; Triazoles; Young Adult | 2017 |
A randomized controlled clinical trial on the impact of CCR5 blockade with maraviroc in early infection on T-cell dynamics.
Topics: Adult; CCR5 Receptor Antagonists; Cyclohexanes; Double-Blind Method; Female; HIV Infections; Humans; Male; Maraviroc; T-Lymphocytes; Time Factors; Triazoles | 2016 |
Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Female; Follow-Up Studies; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Nerve Tissue Proteins; RNA, Viral; Treatment Outcome; Triazoles; Viral Load | 2016 |
Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Coinfection; Cyclohexanes; Female; Hepatitis B; Hepatitis C; HIV Fusion Inhibitors; HIV Infections; Humans; Liver; Liver Function Tests; Male; Maraviroc; Middle Aged; Treatment Outcome; Triazoles; Viral Load | 2017 |
Maraviroc for previously treated patients with R5 HIV-1 infection.
Topics: Adult; Aged; Anti-Retroviral Agents; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; RNA, Viral; Treatment Failure; Triazoles; Viral Load | 2008 |
Maraviroc approved for use in treatment-experienced CCR5-tropic HIV-1.
Topics: CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Double-Blind Method; Drug Approval; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Placebos; Triazoles; United States; United States Food and Drug Administration; Viral Load | 2009 |
A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.
Topics: Adult; Aged; Cyclohexanes; Double-Blind Method; Female; Genotype; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Least-Squares Analysis; Male; Maraviroc; Middle Aged; Patient Selection; Phenotype; Placebos; Triazoles; Viral Load; Young Adult | 2009 |
96-Week MERIT ES analysis shows efficacy of Celsentri=Selzentry.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Cyclopropanes; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Lamivudine; Maraviroc; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome; Triazoles; Zidovudine | 2009 |
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Antiviral Agents; Benzoxazines; CCR5 Receptor Antagonists; Cyclohexanes; Cyclopropanes; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Maraviroc; Middle Aged; Receptors, CCR5; Treatment Outcome; Triazoles; Viral Load; Viral Tropism; Young Adult; Zidovudine | 2010 |
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Cyclohexanes; Drug Administration Schedule; Drug Interactions; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Salvage Therapy; Triazoles; Young Adult | 2010 |
Hemodynamic effects of single-dose vardenafil in subjects receiving maraviroc.
Topics: Adolescent; Adult; Blood Pressure; Cross-Over Studies; Cyclohexanes; Erectile Dysfunction; HIV Fusion Inhibitors; HIV Infections; Humans; Imidazoles; Male; Maraviroc; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Single-Blind Method; Sulfones; Triazines; Triazoles; Vardenafil Dihydrochloride; Vasodilator Agents; Young Adult | 2010 |
Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice.
Topics: Antiviral Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Gene Expression Regulation, Viral; Genotype; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Prospective Studies; Salvage Therapy; Treatment Outcome; Triazoles; Viral Tropism; Virus Internalization; Virus Replication | 2010 |
Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclohexanes; Double-Blind Method; Female; Follow-Up Studies; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Triazoles | 2010 |
Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.
Topics: Adult; Albumins; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Central Nervous System Infections; Cross-Over Studies; Cyclohexanes; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Immunoglobulin G; Lopinavir; Male; Maraviroc; Middle Aged; Neopterin; Peptide Fragments; Polymerase Chain Reaction; Ritonavir; RNA, Viral; Triazoles; Viral Load; Viremia; Virus Replication | 2010 |
Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients.
Topics: Alkynes; Benzoxazines; Case-Control Studies; CD4 Lymphocyte Count; Cyclohexanes; Cyclopropanes; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Receptors, CCR5; Reverse Transcriptase Inhibitors; Triazoles; Viral Load | 2010 |
Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Salvage Therapy; Treatment Outcome; Triazoles; Viral Load | 2011 |
Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclohexanes; Cyclopropanes; Female; High-Throughput Nucleotide Sequencing; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Retrospective Studies; Treatment Failure; Treatment Outcome; Triazoles; Viral Tropism; Young Adult | 2011 |
CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study.
Topics: Adult; Anti-HIV Agents; Brain; Brain Chemistry; CCR5 Receptor Antagonists; Cerebrospinal Fluid; Cyclohexanes; Female; HIV Infections; Humans; Magnetic Resonance Spectroscopy; Male; Maraviroc; Middle Aged; Plasma; Triazoles | 2012 |
[Our experience with maraviroc treatment in HIV positive patients].
Topics: CD4 Lymphocyte Count; Cyclohexanes; Female; HIV Fusion Inhibitors; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Triazoles; Viral Load | 2011 |
Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bacteria; CCR5 Receptor Antagonists; CD8-Positive T-Lymphocytes; Chronic Disease; Cyclohexanes; Disease Reservoirs; DNA, Circular; Female; HIV Infections; HIV-1; Humans; Immunologic Memory; Lymphocyte Activation; Male; Maraviroc; Middle Aged; Plasmids; Receptors, CCR5; T-Lymphocyte Subsets; T-Lymphocytes; Triazoles; Viremia | 2011 |
T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity.
Topics: Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclohexanes; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; T-Lymphocyte Subsets; T-Lymphocytes; Treatment Outcome; Triazoles; Viral Load | 2012 |
HIV-1 tropism evolution after short-term maraviroc monotherapy in HIV-1-infected patients.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; CD4-Positive T-Lymphocytes; Cyclohexanes; HIV Infections; Humans; Maraviroc; Receptors, CXCR4; Triazoles; Viral Load | 2012 |
From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework.
Topics: Adenine; Anti-HIV Agents; Cyclohexanes; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Male; Maraviroc; Models, Biological; Nitriles; Organophosphonates; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; RNA, Viral; Tenofovir; Triazoles | 2012 |
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Triazoles; Viral Load; Young Adult | 2012 |
CCR5 antagonism impacts vaccination response and immune profile in HIV-1 infection.
Topics: AIDS Vaccines; CCR5 Receptor Antagonists; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Immunity; Immunity, Cellular; Immunity, Humoral; Immunophenotyping; Male; Maraviroc; Middle Aged; Receptors, CCR5; T-Lymphocytes; Treatment Outcome; Triazoles; Vaccination | 2012 |
Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study.
Topics: Aged; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Cyclohexanes; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Prospective Studies; Triazoles; Viral Load | 2012 |
A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patients.
Topics: Adult; Aged; Algorithms; Anti-HIV Agents; Biological Assay; Biomarkers, Pharmacological; CCR5 Receptor Antagonists; Cyclohexanes; Female; Genotyping Techniques; High-Throughput Nucleotide Sequencing; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Predictive Value of Tests; Receptors, CCR5; Receptors, CXCR4; Retrospective Studies; Triazoles; Viral Tropism | 2012 |
Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Cyclohexanes; Drug Combinations; Drug Therapy, Combination; Female; Genotype; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Lamivudine; Male; Maraviroc; Middle Aged; Polymerase Chain Reaction; Retrospective Studies; Sequence Analysis, DNA; Triazoles; Viral Load; Viral Tropism; Young Adult; Zidovudine | 2012 |
Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; RNA, Viral; Tenofovir; Triazoles; Viral Load; Young Adult | 2013 |
Dipeptidyl peptidase IV inhibition does not adversely affect immune or virological status in HIV infected men and women: a pilot safety study.
Topics: Adolescent; Adult; Aged; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; HIV Infections; HIV Seropositivity; Humans; Male; Middle Aged; Pilot Projects; Pyrazines; RNA, Viral; Sitagliptin Phosphate; Triazoles | 2013 |
Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; Dyslipidemias; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Hypolipidemic Agents; Intention to Treat Analysis; Male; Maraviroc; Middle Aged; Pilot Projects; Prospective Studies; Triazoles; Triglycerides; Viral Tropism | 2013 |
Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.
Topics: Adolescent; Adult; Anti-HIV Agents; Antifungal Agents; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Female; Fluconazole; Genotype; HIV Infections; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Triazoles; Voriconazole; Young Adult | 2013 |
A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc.
Topics: Adult; Algorithms; Anti-HIV Agents; CCR5 Receptor Antagonists; Computer Simulation; Cyclohexanes; Dose-Response Relationship, Drug; HIV Infections; HIV-1; Humans; Male; Maraviroc; Models, Biological; Models, Statistical; Predictive Value of Tests; RNA, Viral; Triazoles; Viral Load; Virus Replication | 2005 |
A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc.
Topics: Anti-HIV Agents; Computer Simulation; Cyclohexanes; Dose-Response Relationship, Drug; Food; HIV Infections; HIV-1; Humans; Maraviroc; Monte Carlo Method; Placebos; RNA, Viral; Triazoles; Viral Load | 2006 |
Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Cell Line; Clone Cells; Cyclohexanes; Evolution, Molecular; Genes, env; Genetic Variation; HIV Envelope Protein gp160; HIV Infections; HIV-1; Humans; Maraviroc; Phylogeny; Receptors, CCR5; Receptors, CXCR4; Recombination, Genetic; Triazoles | 2006 |
Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Statistics as Topic; Triazoles | 2008 |
Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anti-HIV Agents; CCR5 Receptor Antagonists; Contraceptives, Oral; Cyclohexanes; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Ethinyl Estradiol; Female; HIV Infections; Humans; Lamivudine; Levonorgestrel; Male; Maraviroc; Midazolam; Middle Aged; Statistics as Topic; Triazoles; Zidovudine | 2008 |
Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
Topics: Adolescent; Anti-HIV Agents; Antifungal Agents; Atazanavir Sulfate; CCR5 Receptor Antagonists; Cyclohexanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Maraviroc; Middle Aged; Oligopeptides; Pyridines; Saquinavir; Statistics as Topic; Triazoles | 2008 |
Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
Topics: Adolescent; Adult; CCR5 Receptor Antagonists; Cyclohexanes; Cytochrome P-450 CYP3A; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Maraviroc; Middle Aged; Statistics as Topic; Triazoles | 2008 |
The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Organophosphonates; Receptors, CCR5; Statistics as Topic; Tenofovir; Triazoles; Trimethoprim, Sulfamethoxazole Drug Combination | 2008 |
A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects.
Topics: Administration, Oral; Adolescent; Adult; Anti-Retroviral Agents; Area Under Curve; CCR5 Receptor Antagonists; Cyclohexanes; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Receptors, CCR5; Triazoles | 2008 |
Maraviroc: integration of a new antiretroviral drug class into clinical practice.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Double-Blind Method; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Triazoles; Virology | 2008 |
Treatment of coccidioidomycosis with SCH 39304.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antifungal Agents; Coccidioidomycosis; Dermatomycoses; Drug Administration Schedule; Female; HIV Infections; Humans; Joint Diseases; Lung Diseases, Fungal; Male; Middle Aged; Treatment Outcome; Triazoles | 1994 |
353 other study(ies) available for triazoles and HIV Infections
| Article | Year |
|---|---|
Total and Unbound Doravirine Concentrations and Viral Suppression in CSF.
Topics: HIV Infections; HIV-1; Humans; Pyridones; Triazoles; Virus Replication | 2022 |
Structure-based identification of novel scaffolds as potential HIV-1 entry inhibitors involving CCR5.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CCR5; Receptors, Chemokine; Triazoles | 2022 |
Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2021 |
Altered Env conformational dynamics as a mechanism of resistance to peptide-triazole HIV-1 inactivators.
Topics: Anti-HIV Agents; Binding Sites; Drug Resistance, Viral; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Molecular Docking Simulation; Mutation; Peptides; Protein Conformation; Triazoles; Virus Internalization | 2021 |
The Novel PKC Activator 10-Methyl-Aplog-1 Combined with JQ1 Induced Strong and Synergistic HIV Reactivation with Tolerable Global T Cell Activation.
Topics: Anti-HIV Agents; Azepines; Bryostatins; CD4-Positive T-Lymphocytes; Cell Line; HIV Infections; HIV-1; Humans; Lymphocyte Activation; Phorbol Esters; Signal Transduction; Triazoles; Virus Latency | 2021 |
Tenofovir plasma trough concentrations in people with HIV treated with doravirine versus other antiretroviral regimens.
Topics: Anti-HIV Agents; HIV Infections; Humans; Pyridones; Tenofovir; Triazoles | 2021 |
Real life use of dolutegravir doravirine dual regimen in experienced elderly PLWH with multiple comorbidities and on polypharmacy: A retrospective analysis.
Topics: Aged; Aged, 80 and over; Anti-HIV Agents; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infant; Male; Middle Aged; Oxazines; Piperazines; Polypharmacy; Pyridones; Retrospective Studies; Treatment Outcome; Triazoles; Viral Load | 2021 |
Prevalence of doravirine cross-resistance in HIV-infected adults who failed first-line ART in China, 2014-18.
Topics: Adult; Anti-HIV Agents; China; Drug Resistance, Viral; Genotype; HIV Infections; HIV-1; Humans; Mutation; Prevalence; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2022 |
Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients.
Topics: Agammaglobulinemia; Anti-HIV Agents; Drug Resistance, Viral; Genetic Diseases, X-Linked; HIV Infections; HIV-1; Humans; Mutation; Nevirapine; Poland; Prevalence; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2021 |
Doravirine/tenofovir disoproxyl fumarate/lamivudine-induced alopecia: A case report.
Topics: Alopecia; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Fumarates; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Pyridones; Tenofovir; Triazoles; Viral Load | 2022 |
Real-life use of Doravirine in treatment-experienced people living with HIV: A multicenter Italian study.
Topics: Anti-HIV Agents; DNA-Directed RNA Polymerases; Female; HIV Infections; Humans; Integrase Inhibitors; Male; Middle Aged; Pyridones; Retrospective Studies; Reverse Transcriptase Inhibitors; Triazoles | 2022 |
Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
Topics: Animals; Anti-HIV Agents; Biological Availability; CCR5 Receptor Antagonists; Cyclohexanes; HIV Infections; HIV-1; Maraviroc; Rats; Rats, Sprague-Dawley; Receptors, CCR5; Triazoles; Tropanes | 2022 |
Rational Design of Doravirine: From Bench to Patients.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Drug Design; Drug Interactions; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Pyridones; Reverse Transcriptase Inhibitors; Translational Research, Biomedical; Triazoles | 2020 |
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.
Topics: Anti-HIV Agents; Drug Resistance, Viral; France; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Italy; Mutation; Prevalence; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2020 |
The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations.
Topics: Algorithms; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; Humans; Mutation; Prevalence; Pyridones; Spain; Triazoles | 2020 |
Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HI
Topics: Amides; Anti-Retroviral Agents; Chromatography, High Pressure Liquid; Drug Monitoring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Limit of Detection; Linear Models; Piperazines; Pyridones; Reference Standards; Reproducibility of Results; Rilpivirine; Tandem Mass Spectrometry; Triazoles | 2020 |
Composition and Orientation of the Core Region of Novel HIV-1 Entry Inhibitors Influences Metabolic Stability.
Topics: Anti-HIV Agents; Azabicyclo Compounds; Azetidines; Chromatography, Liquid; HEK293 Cells; HIV Core Protein p24; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Microsomes, Liver; Organophosphates; Piperazines; Protein Binding; Pyrrolidines; Tandem Mass Spectrometry; Triazoles | 2020 |
HIV-1 infection and latency-reversing agents bryostatin-1 and JQ1 disrupt amyloid beta homeostasis in human astrocytes.
Topics: Amyloid beta-Peptides; Astrocytes; Azepines; Bryostatins; HIV Infections; HIV-1; Homeostasis; Humans; Triazoles; Virus Activation; Virus Latency | 2020 |
Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors.
Topics: Allosteric Site; Anti-HIV Agents; Binding Sites; Drug Resistance, Viral; Enzyme Assays; Gene Expression; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Kinetics; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutation; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Interaction Domains and Motifs; Pyridines; Pyridones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thermodynamics; Triazoles; Urea | 2020 |
Filgotinib suppresses HIV-1-driven gene transcription by inhibiting HIV-1 splicing and T cell activation.
Topics: CD4-Positive T-Lymphocytes; HIV Infections; HIV-1; Humans; Jurkat Cells; Lymphocyte Activation; Pyridines; RNA Splicing; Transcription, Genetic; Triazoles | 2020 |
Doravirine Use in Treatment-Experienced HIV-Positive Patients.
Topics: Anti-HIV Agents; HIV Infections; Humans; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2021 |
Structure-based non-nucleoside inhibitor design: Developing inhibitors that are effective against resistant mutants.
Topics: Anti-HIV Agents; Binding Sites; Drug Design; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Dynamics Simulation; Mutation; Pyridones; Pyrimidines; Rilpivirine; Triazoles | 2021 |
Clearance of HIV infection by selective elimination of host cells capable of producing HIV.
Topics: Animals; Antigens, CD34; Apoptosis; Autophagy; Azepines; CD4-Positive T-Lymphocytes; HIV Infections; HIV-1; Humans; Mice; Organophosphates; Piperazines; Pyridines; Pyrimidinones; RNA, Viral; T-Lymphocytes; Triazoles | 2020 |
Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor.
Topics: Animals; Anti-HIV Agents; Antibodies, Neutralizing; Antibodies, Viral; CD4 Antigens; CD4-Positive T-Lymphocytes; CHO Cells; Cricetulus; env Gene Products, Human Immunodeficiency Virus; Glycosylation; HEK293 Cells; HIV Infections; HIV-1; Humans; Immunoconjugates; Macaca mulatta; Piperazines; Protein Multimerization; Rabbits; Recombinant Proteins; Triazoles | 2020 |
Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1.
Topics: Anti-HIV Agents; Emtricitabine; Fumarates; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Tenofovir; Triazoles | 2020 |
2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0.
Topics: Age Factors; Anti-Retroviral Agents; Comorbidity; Drug Interactions; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Treatment Outcome; Triazoles | 2020 |
In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations.
Topics: Anti-HIV Agents; Clone Cells; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nitriles; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Triazoles | 2021 |
Changes in weight and BMI with first-line doravirine-based therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Mass Index; CD4 Lymphocyte Count; Darunavir; HIV Infections; Humans; Pyridones; Ritonavir; Treatment Outcome; Triazoles; Viral Load | 2021 |
Successful treatment by doravirine with cobicistat-boosted darunavir for end-stage renal failure under chronic haemodialysis.
Topics: Anti-HIV Agents; Cobicistat; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Failure, Chronic; Pyridones; Renal Dialysis; Triazoles | 2021 |
Cell culture selections reveal favourable drug resistance profiles for doravirine and islatravir.
Topics: Anti-HIV Agents; Cell Culture Techniques; Deoxyadenosines; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2021 |
Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Mutation; Pyridones; Retrospective Studies; South Africa; Triazoles | 2021 |
Real-Life Safety of Doravirine in Treatment-Experienced, Virologically Suppressed PLWHIV.
Topics: Anti-HIV Agents; HIV Infections; Humans; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2021 |
Repurposing a Bacterial Immune System to Discover Antiviral Targets.
Topics: Antiviral Agents; Cell Line; Clustered Regularly Interspaced Short Palindromic Repeats; Cyclohexanes; Gene Knockout Techniques; HIV Infections; HIV-1; Humans; Immune System; Maraviroc; RNA, Viral; T-Lymphocytes; Triazoles; Viral Proteins; Virion; Virus Replication | 2017 |
Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist Reveals Mechanisms of Chemokine Recognition and Molecular Mimicry by HIV.
Topics: Animals; CCR5 Receptor Antagonists; Chemokine CCL5; Cloning, Molecular; Crystallography, X-Ray; Cyclohexanes; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Models, Molecular; Molecular Mimicry; Protein Binding; Protein Conformation; Receptors, CCR5; Sf9 Cells; Spodoptera; Structure-Activity Relationship; Triazoles; Virus Internalization | 2017 |
Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists.
Topics: Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cell Line; Cyclohexanes; Drug Resistance, Viral; Female; HEK293 Cells; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Receptors, CCR5; Treatment Failure; Triazoles; Virus Internalization | 2017 |
Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.
Topics: Adult; Anti-HIV Agents; Body Fluids; Cervix Uteri; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Prospective Studies; Raltegravir Potassium; Rilpivirine; Semen; Triazoles; Vagina; Viral Load | 2017 |
A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
Topics: Azepines; CD4-Positive T-Lymphocytes; Cell Cycle Proteins; Gene Expression Regulation, Viral; HEK293 Cells; HeLa Cells; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Humans; Jurkat Cells; Nuclear Proteins; Protein Domains; Proto-Oncogene Proteins c-myc; Proviruses; Quinolines; Transcription Factors; Triazoles; Viral Load; Virus Activation; Virus Integration; Virus Latency | 2018 |
Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication.
Topics: Anti-HIV Agents; Autophagy; Azepines; Cell Cycle Proteins; Cells, Cultured; HIV Infections; HIV-1; Humans; Imidazoles; Macrophages; Nuclear Proteins; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors; Triazoles; Virus Replication | 2018 |
Unique Phenotypic Characteristics of Recently Transmitted HIV-1 Subtype C Envelope Glycoprotein gp120: Use of CXCR6 Coreceptor by Transmitted Founder Viruses.
Topics: Adult; Anti-HIV Agents; Antibodies, Monoclonal; Antibodies, Neutralizing; Antibodies, Viral; CCR5 Receptor Antagonists; Cell Line; Cyclohexanes; HEK293 Cells; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Infant; Maraviroc; Receptors, CXCR6; Triazoles; Virus Replication | 2018 |
Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Niacinamide; Point Mutation; Structure-Activity Relationship; Triazoles | 2018 |
HIV latency reversing agents act through Tat post translational modifications.
Topics: Amino Acid Substitution; Anti-HIV Agents; Azepines; Cell Cycle Proteins; Gene Expression Regulation, Viral; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Humans; Mutation; Nuclear Proteins; Protein Processing, Post-Translational; RNA Splicing; tat Gene Products, Human Immunodeficiency Virus; Transcription Factors; Transcription, Genetic; Triazoles; Virus Activation; Virus Latency; Virus Replication | 2018 |
Procyanidin trimer C1 reactivates latent HIV as a triple combination therapy with kansui and JQ1.
Topics: Anti-HIV Agents; Azepines; CD4-Positive T-Lymphocytes; Cell Line; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Flavonoids; HIV Infections; HIV-1; Humans; Jurkat Cells; Primary Cell Culture; Triazoles; Virus Latency | 2018 |
Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients.
Topics: Anti-HIV Agents; Drug Resistance, Viral; France; Gene Frequency; Greece; HIV Infections; HIV-1; Humans; Italy; Mutation, Missense; Prevalence; Pyridones; Triazoles | 2019 |
Population Pharmacokinetics of Doravirine and Exposure-Response Analysis in Individuals with HIV-1.
Topics: Adult; Aged; Anti-HIV Agents; Area Under Curve; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Triazoles; Young Adult | 2019 |
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Nevirapine; Nitriles; Pyridazines; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Treatment Outcome; Triazoles | 2019 |
Immune reconstitution inflammatory syndrome in an HIV-infected patient with disseminated coccidioidomycosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Antiretroviral Therapy, Highly Active; Coccidioidomycosis; Fluconazole; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Male; Prednisone; Treatment Outcome; Triazoles | 2019 |
Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV.
Topics: Anti-Retroviral Agents; Azepines; Cell Cycle Proteins; Drug Design; Female; HIV Infections; HIV-1; Humans; Male; Protein Domains; Structure-Activity Relationship; tat Gene Products, Human Immunodeficiency Virus; Transcription Factors; Triazoles | 2019 |
Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing.
Topics: Cyclohexanes; DNA, Viral; Genotype; High-Throughput Nucleotide Sequencing; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Kaplan-Meier Estimate; Leukocytes, Mononuclear; Maraviroc; Treatment Outcome; Triazoles; Viral Tropism | 2013 |
Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; CD4-Positive T-Lymphocytes; Cell Line; Cyclohexanes; Drug Resistance, Viral; env Gene Products, Human Immunodeficiency Virus; GTP-Binding Proteins; HEK293 Cells; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Pertussis Toxin; Piperazines; Pyrimidines; Receptors, CCR5; Transfection; Triazoles | 2013 |
A model of peptide triazole entry inhibitor binding to HIV-1 gp120 and the mechanism of bridging sheet disruption.
Topics: Anti-HIV Agents; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutagenesis, Site-Directed; Nuclear Magnetic Resonance, Biomolecular; Peptides; Protein Conformation; Triazoles | 2013 |
Sensitive cell-based assay for determination of human immunodeficiency virus type 1 coreceptor tropism.
Topics: Anti-HIV Agents; Cell Fusion; Cell Line; Cyclohexanes; env Gene Products, Human Immunodeficiency Virus; Genome, Viral; Genotype; HEK293 Cells; HIV Infections; HIV-1; Humans; Maraviroc; Pilot Projects; Receptors, CCR5; Receptors, CXCR4; Receptors, HIV; RNA, Viral; Saccharomyces cerevisiae Proteins; Sensitivity and Specificity; Triazoles; Viral Tropism | 2013 |
Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients.
Topics: Adult; Anti-HIV Agents; Cyclohexanes; Drug Therapy, Combination; HIV Infections; Humans; Lopinavir; Male; Maraviroc; Plasma; Ritonavir; Time Factors; Triazoles | 2013 |
Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc.
Topics: Animals; Anti-HIV Agents; CCR5 Receptor Antagonists; Cell Line; Chemokine CCL5; Cyclohexanes; Down-Regulation; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Macaca; Maraviroc; Microbial Sensitivity Tests; Receptors, CCR5; Triazoles; Virus Internalization; Virus Replication | 2013 |
Transplacental passage of etravirine and maraviroc in a multidrug-experienced HIV-infected woman failing on darunavir-based HAART in late pregnancy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Darunavir; Female; HIV Infections; Humans; Infant; Infant, Newborn; Maraviroc; Nitriles; Pregnancy; Pregnancy Complications, Infectious; Pyridazines; Pyrimidines; RNA, Viral; Sulfonamides; Treatment Failure; Triazoles; Viral Load | 2013 |
Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative study.
Topics: Anti-HIV Agents; Clinical Laboratory Techniques; Cyclohexanes; DNA, Viral; HIV Infections; HIV-1; Humans; Laboratory Proficiency Testing; Maraviroc; Proviruses; Triazoles; Viral Tropism | 2013 |
Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.
Topics: Adult; Aged; CCR5 Receptor Antagonists; Cyclohexanes; Drug Resistance, Viral; Drug Substitution; Female; Follow-Up Studies; Genotype; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Prevalence; Receptors, CCR5; Sequence Analysis, DNA; Treatment Outcome; Triazoles; Viral Load; Viral Tropism; Virus Replication; Young Adult | 2013 |
A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.
Topics: Anti-HIV Agents; Cyclohexanes; Genetic Variation; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Maraviroc; Molecular Sequence Data; Mutation, Missense; Sequence Analysis, DNA; Treatment Failure; Triazoles; Virus Internalization | 2013 |
Profile of HIV type 1 coreceptor tropism among Kenyan patients from 2009 to 2010.
Topics: Adolescent; Adult; Aged; CCR5 Receptor Antagonists; Child; Child, Preschool; Cyclohexanes; Female; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Kenya; Male; Maraviroc; Middle Aged; Molecular Sequence Data; Receptors, CCR5; Receptors, CXCR4; Sequence Analysis, DNA; Triazoles; Viral Tropism; Young Adult | 2013 |
Oral administration of the CCR5 inhibitor, maraviroc, blocks HIV ex vivo infection of Langerhans cells within the epithelium.
Topics: Administration, Oral; Adult; CCR5 Receptor Antagonists; Chromatography, Liquid; Coculture Techniques; Cyclohexanes; Drug Administration Schedule; Epithelium; HIV Fusion Inhibitors; HIV Infections; Humans; Langerhans Cells; Male; Maraviroc; Mass Spectrometry; Receptors, CCR5; Time Factors; Triazoles; Young Adult | 2013 |
Maraviroc treatment in non-R5-HIV-1-infected patients results in the selection of extreme CXCR4-using variants with limited effect on the total viral setpoint.
Topics: Anti-HIV Agents; Cohort Studies; Cyclohexanes; High-Throughput Nucleotide Sequencing; HIV Infections; HIV-1; Humans; Longitudinal Studies; Maraviroc; Receptors, CCR5; Receptors, CXCR4; Receptors, HIV; Selection, Genetic; Triazoles; Viral Tropism | 2013 |
Identifying chemicals with potential therapy of HIV based on protein-protein and protein-chemical interaction network.
Topics: 1-Deoxynojirimycin; Algorithms; Anti-HIV Agents; CCR5 Receptor Antagonists; Computer Simulation; Cyclohexanes; Databases, Chemical; Didanosine; Drug Design; Drug Discovery; HIV Infections; HIV-1; Host-Pathogen Interactions; Humans; Maraviroc; Models, Molecular; Protein Interaction Mapping; Protein Interaction Maps; Receptors, CCR5; Triazoles | 2013 |
Primary resistance of CCR5-tropic HIV-1 to maraviroc cannot be predicted by the V3 sequence.
Topics: Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; France; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Maraviroc; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation, Missense; Sequence Analysis, DNA; Triazoles | 2013 |
Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cyclohexanes; Darunavir; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Maraviroc; Pilot Projects; Ritonavir; RNA Stability; RNA, Viral; Sulfonamides; Treatment Outcome; Triazoles; Viral Load | 2013 |
Analysis of primary resistance mutations to HIV-1 entry inhibitors in therapy naive subtype C HIV-1 infected mother-infant pairs from Zambia.
Topics: Adult; Amino Acid Sequence; Cloning, Molecular; Cyclohexanes; Drug Resistance, Viral; env Gene Products, Human Immunodeficiency Virus; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Maraviroc; Molecular Sequence Data; Mutation, Missense; Piperazines; Pregnancy; Pyrimidines; Sequence Analysis, DNA; Triazoles; Young Adult; Zambia | 2013 |
[Ophthalmological alterations at the initial diagnosis of HIV infection].
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Cyclohexanes; Deoxycytidine; Drug Therapy, Combination; Early Diagnosis; Emtricitabine; Eye Infections, Viral; HIV Infections; Humans; Lopinavir; Male; Maraviroc; Organophosphonates; Retinal Diseases; Syndrome; Tenofovir; Treatment Outcome; Triazoles; Zidovudine | 2014 |
Dissimilarities in the metabolism of antiretroviral drugs used in HIV pre-exposure prophylaxis in colon and vagina tissues.
Topics: Adult; Anti-HIV Agents; Chemoprevention; Colon; Cyclohexanes; Cytochrome P-450 Enzyme System; Female; Glucuronosyltransferase; HIV Infections; Humans; Isoenzymes; Male; Maraviroc; Mucous Membrane; Organ Specificity; Pyrimidines; Triazoles; Vagina; Young Adult | 2013 |
Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: role of different tropism testing results and of concomitant treatments.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Peptide Fragments; Retrospective Studies; RNA, Viral; Survival; Triazoles; Viral Load; Viral Tropism | 2014 |
A reduced grade of liver fibro-steatosis after raltegravir, maraviroc and fosamprenavir in an HIV/HCV co-infected patient with chronic hepatitis, cardiomyopathy, intolerance to nelfinavir and a marked increase of serum creatine phosphokinase levels probab
Topics: Adult; Carbamates; Cardiomyopathies; Chemical and Drug Induced Liver Injury; Creatine Kinase; Cyclohexanes; Drug Substitution; Drug Therapy, Combination; Fatty Liver; Furans; Hepatitis C, Chronic; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Liver Cirrhosis; Male; Maraviroc; Organophosphates; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Triazoles | 2012 |
Maraviroc-induced decrease in circulating bacterial products is not linked to an increase in immune activation in HIV-infected individuals.
Topics: CD4-Positive T-Lymphocytes; Cyclohexanes; Female; Graft vs Host Disease; HIV Infections; HIV-1; Humans; Male; Triazoles; Viral Load | 2013 |
Response: Maraviroc intensification and microbial translocation.
Topics: CD4-Positive T-Lymphocytes; Cyclohexanes; Female; Graft vs Host Disease; HIV Infections; HIV-1; Humans; Male; Triazoles; Viral Load | 2013 |
Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068.
Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Molecular Sequence Data; Organophosphates; Piperazines; Prodrugs; Reverse Genetics; Sequence Analysis, DNA; Triazoles | 2014 |
HIV-1 coreceptor tropism in India: increasing proportion of X4-tropism in subtype C strains over two decades.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Child, Preschool; Cyclohexanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; India; Male; Maraviroc; Middle Aged; Polymorphism, Genetic; Receptors, HIV; Triazoles; Viral Tropism; Young Adult | 2014 |
Oral CCR5 inhibitors to prevent HIV transmission: the new "morning-before pill"?
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Epithelium; HIV Fusion Inhibitors; HIV Infections; Humans; Langerhans Cells; Male; Maraviroc; Receptors, CCR5; Triazoles | 2013 |
In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.
Topics: Anti-HIV Agents; Drug Synergism; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; In Vitro Techniques; Macrophages; Monocytes; Pyridones; Triazoles; Virus Replication | 2014 |
Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection.
Topics: Cyclohexanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Mutation, Missense; Pyrrolidinones; Raltegravir Potassium; Treatment Failure; Triazoles; Viral Load | 2014 |
Innate immunity cell activation in virologically suppressed HIV-infected maraviroc-treated patients.
Topics: Adult; Anti-Retroviral Agents; Antigens, CD; Biomarkers; Case-Control Studies; Cross-Sectional Studies; Cyclohexanes; Female; HIV Infections; HLA Antigens; Humans; Killer Cells, Natural; Male; Maraviroc; Middle Aged; Monocytes; Treatment Outcome; Triazoles | 2014 |
A validated HPLC-MS method for quantification of the CCR5 inhibitor maraviroc in HIV+ human plasma.
Topics: Calibration; CCR5 Receptor Antagonists; Chromatography, High Pressure Liquid; Cyclohexanes; HIV Infections; Humans; Limit of Detection; Maraviroc; Mass Spectrometry; Receptors, CCR5; Reference Standards; Sensitivity and Specificity; Triazoles | 2014 |
Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting.
Topics: Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Male; Maraviroc; Middle Aged; Retrospective Studies; Ritonavir; RNA, Viral; Sulfonamides; Triazoles | 2014 |
Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides.
Topics: Administration, Intravaginal; Anti-Infective Agents, Local; Anti-Retroviral Agents; Cellulose; Cyclohexanes; Delayed-Action Preparations; Female; Gels; HIV Infections; HIV-1; Humans; Hydrophobic and Hydrophilic Interactions; Maraviroc; Silicone Elastomers; Triazoles; Vagina; Vaginal Creams, Foams, and Jellies | 2014 |
Maraviroc reduces the regulatory T-cell frequency in antiretroviral-naive HIV-infected subjects.
Topics: Adult; CD4 Lymphocyte Count; Cyclohexanes; Dose-Response Relationship, Drug; Female; Flow Cytometry; HIV Fusion Inhibitors; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Receptors, CCR5; Retrospective Studies; T-Lymphocytes, Regulatory; Triazoles | 2014 |
New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.
Topics: Anti-HIV Agents; Azepines; Bryostatins; CD4-Positive T-Lymphocytes; Cell Cycle Proteins; Depsipeptides; Disulfiram; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Humans; Hydroxamic Acids; Indoles; Ionomycin; Lymphocyte Activation; Nuclear Proteins; Panobinostat; Tetradecanoylphorbol Acetate; Transcription Factors; Triazoles; Virus Latency; Vorinostat | 2014 |
Reactivation of hepatitis B virus infection associated with maraviroc use in an HIV-infected patient.
Topics: Aged; Anti-HIV Agents; Cyclohexanes; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Male; Maraviroc; Triazoles; Virus Activation | 2014 |
Potential anti-inflammatory effects of maraviroc in HIV-positive patients: a pilot study of inflammation, endothelial dysfunction, and coagulation markers.
Topics: Adult; Anti-Inflammatory Agents; Biomarkers; Case-Control Studies; CCR5 Receptor Antagonists; Cyclohexanes; Cytokines; Female; HIV Fusion Inhibitors; HIV Infections; Humans; Inflammation; Male; Maraviroc; Middle Aged; Pilot Projects; Thrombophilia; Triazoles | 2014 |
Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression.
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cell Proliferation; Cyclohexanes; Female; Gene Expression; Gene Expression Profiling; HIV Infections; Humans; Male; Maraviroc; Microarray Analysis; Middle Aged; Treatment Outcome; Triazoles; Tumor Necrosis Factor-alpha; Viremia | 2014 |
HIV-2 viral tropism influences CD4+ T cell count regardless of viral load.
Topics: Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclohexanes; Female; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-2; Humans; Male; Maraviroc; Middle Aged; Peptide Fragments; RNA, Viral; Spain; Triazoles; Viral Load; Viral Tropism; Viremia | 2014 |
Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Cyclohexanes; HIV Infections; Humans; Lopinavir; Male; Maraviroc; Middle Aged; Plasma; Ritonavir; Semen; Triazoles | 2014 |
Extravirologic modulation of immune response by an NRTI-sparing antiretroviral regimen including darunavir and maraviroc.
Topics: Anti-HIV Agents; Apoptosis; Cells, Cultured; Cyclohexanes; Darunavir; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Maraviroc; Neutrophils; Sulfonamides; Triazoles | 2014 |
Exposure to entry inhibitors alters HIV infectiousness and sensitivity to broadly neutralizing monoclonal antibodies.
Topics: Antibodies, Monoclonal; Cell Line; Cyclohexanes; Drug Synergism; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Maraviroc; Neutralization Tests; Regression Analysis; Triazoles; Virus Replication | 2014 |
Electrospun solid dispersions of Maraviroc for rapid intravaginal preexposure prophylaxis of HIV.
Topics: Administration, Intravaginal; Anti-HIV Agents; Anti-Infective Agents, Local; Cell Line; Cell Survival; Cyclohexanes; Electrochemical Techniques; Excipients; Female; HIV Infections; Humans; Kinetics; Maraviroc; Nanofibers; Polyethylene Glycols; Polysorbates; Povidone; Suspensions; Triazoles; Vaginal Creams, Foams, and Jellies; Wettability; Wetting Agents | 2014 |
Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy.
Topics: Adult; Alkynes; Area Under Curve; Benzoxazines; Cyclohexanes; Cyclopropanes; Drug Administration Schedule; Drug Substitution; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Reverse Transcriptase Inhibitors; Treatment Outcome; Triazoles; Viral Load | 2015 |
CCR5 as a treatment target in pulmonary arterial hypertension.
Topics: Animals; CCR5 Receptor Antagonists; Cell Proliferation; Cells, Cultured; Cyclohexanes; Disease Models, Animal; Familial Primary Pulmonary Hypertension; HIV Fusion Inhibitors; HIV Infections; Humans; Hypertension, Pulmonary; Hypoxia; Macaca mulatta; Macrophages; Male; Maraviroc; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Smooth, Vascular; Pulmonary Artery; Receptors, CCR5; Simian Acquired Immunodeficiency Syndrome; Triazoles | 2014 |
HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.
Topics: Adenine; Animals; Anti-HIV Agents; Cyclohexanes; Disease Models, Animal; Female; HIV Infections; HIV-1; Humans; Maraviroc; Mice; Mucous Membrane; Organophosphonates; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Tenofovir; Triazoles; Virus Internalization | 2014 |
The utility of genotypic tropism testing in clinical practice.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; DNA, Viral; Drug Prescriptions; Female; Genotype; HIV Infections; HIV-1; Humans; London; Male; Maraviroc; Medical Audit; Practice Patterns, Physicians'; Retrospective Studies; RNA, Viral; Sequence Analysis, DNA; Triazoles; Viral Tropism | 2015 |
HIV-2 X4 tropism is associated with lower CD4+ cell count in treatment-experienced patients.
Topics: CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Disease Progression; Drug Resistance, Viral; Genotype; HIV Infections; HIV-2; Humans; Maraviroc; Prevalence; Receptors, CCR5; Retrospective Studies; Triazoles; Viral Load; Viral Tropism | 2014 |
Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes.
Topics: Amino Acid Substitution; Drug Resistance, Viral; Genotype; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Mutation, Missense; Piperazines; Polymorphism, Genetic; Triazoles | 2015 |
Computational study on the interaction between CCR5 and HIV-1 entry inhibitor maraviroc: insight from accelerated molecular dynamics simulation and free energy calculation.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; HIV Infections; HIV-1; Humans; Hydrogen Bonding; Maraviroc; Models, Molecular; Molecular Dynamics Simulation; Protein Conformation; Receptors, CCR5; Thermodynamics; Triazoles | 2014 |
Treatment. Maraviroc dosing not effective in half of blacks.
Topics: Black People; Cyclohexanes; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Triazoles | 2014 |
Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response.
Topics: Adult; Aged; Anti-Retroviral Agents; Cyclohexanes; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; RNA, Viral; Treatment Outcome; Triazoles; Viral Load; Young Adult | 2015 |
Models for predicting effective HIV chemoprevention in women.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Cell Culture Techniques; Cell Survival; Chemoprevention; Chromatography, Liquid; Cyclohexanes; Disease Transmission, Infectious; Dose-Response Relationship, Drug; Female; HIV Infections; Humans; Maraviroc; Middle Aged; Organ Culture Techniques; Organophosphonates; Tandem Mass Spectrometry; Tenofovir; Triazoles; Vagina; Viral Load; Young Adult | 2015 |
FT-IR and FT-Raman spectroscopic signatures, vibrational assignments, NBO, NLO analysis and molecular docking study of 2-{[5-(adamantan-1-yl)-4-methyl-4H-1,2,4-triazol-3-yl]sulfanyl}-N,N-dimethylethanamine.
Topics: Adamantane; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Molecular Docking Simulation; Quantum Theory; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; Triazoles | 2015 |
Therapeutic use of CCR5 antagonists is supported by strong expression of CCR5 on CD8(+) T cells in progressive multifocal leukoencephalopathy-associated immune reconstitution inflammatory syndrome.
Topics: Anti-Retroviral Agents; CCR5 Receptor Antagonists; CD8-Positive T-Lymphocytes; Cyclohexanes; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Leukoencephalopathy, Progressive Multifocal; Maraviroc; Microscopy, Confocal; Receptors, CCR5; Triazoles | 2015 |
Antiretroviral blood levels in HIV/HCV-coinfected patients with cirrhosis after liver transplant: a report of three cases.
Topics: Anti-Retroviral Agents; Coinfection; Cyclohexanes; Darunavir; Drug Monitoring; Female; Hepatitis C; HIV Infections; Humans; Liver Cirrhosis; Liver Transplantation; Male; Maraviroc; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Triazoles | 2015 |
Virological failure of patients on maraviroc-based antiretroviral therapy.
Topics: Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Retrospective Studies; Treatment Failure; Triazoles; Viral Load; Viral Tropism | 2015 |
Reliable genotypic tropism tests for the major HIV-1 subtypes.
Topics: Algorithms; Amino Acid Sequence; CCR5 Receptor Antagonists; Computational Biology; Cyclohexanes; Genotype; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Maraviroc; Mutation; Peptide Fragments; Phenotype; Receptors, CCR5; Triazoles; Viral Tropism | 2015 |
Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia.
Topics: Anti-HIV Agents; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclohexanes; Female; HIV Infections; Humans; Lymphocyte Activation; Male; Maraviroc; Middle Aged; Monocytes; Raltegravir Potassium; RNA, Viral; Treatment Outcome; Triazoles; Viral Load; Viremia | 2015 |
Highly efficient synthesis of HIV NNRTI doravirine.
Topics: Aldehydes; HIV Infections; HIV Reverse Transcriptase; Molecular Structure; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2015 |
A prospective evaluation of maraviroc administration in patients with advanced HIV disease and multiple comorbidities: focus on efficacy and tolerability issues.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Comorbidity; Cyclohexanes; Female; Follow-Up Studies; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Prospective Studies; Treatment Outcome; Triazoles; Viral Load | 2015 |
Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.
Topics: Adult; Anti-HIV Agents; Azepines; Bryostatins; CD4-Positive T-Lymphocytes; Cells, Cultured; Disulfiram; Drug Evaluation, Preclinical; Drug Synergism; Female; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Humans; Lymphocyte Activation; Lymphokines; Male; Middle Aged; Phorbol Esters; Protein Kinase C; RNA, Messenger; RNA, Viral; Transcription, Genetic; Triazoles; Virion; Virus Latency | 2015 |
Triple combination of carbosilane dendrimers, tenofovir and maraviroc as potential microbicide to prevent HIV-1 sexual transmission.
Topics: Adenine; Animals; Anti-HIV Agents; Anti-Infective Agents; Antiviral Agents; Cell Survival; Cyclohexanes; Dendrimers; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Maraviroc; Mice; Mice, Inbred BALB C; Mucous Membrane; Organophosphonates; Silanes; Software; Tenofovir; Triazoles; Vagina | 2015 |
Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
Topics: 3T3 Cells; Animals; Antiviral Agents; Benzylamines; Cell Death; Cell Line; Cyclams; Cyclohexanes; Flow Cytometry; Heterocyclic Compounds; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Membrane Fusion; Mice; Receptors, CCR5; Receptors, CXCR4; Triazoles; Virus Internalization; Virus Replication | 2015 |
Preclinical discovery and development of maraviroc for the treatment of HIV.
Topics: Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Maraviroc; Triazoles | 2015 |
Development of maraviroc, a CCR5 antagonist for treatment of HIV, using a novel tropism assay.
Topics: Anti-HIV Agents; Biological Assay; Clinical Trials as Topic; Cyclohexanes; Drug Design; Drug Evaluation, Preclinical; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CCR5; Triazoles; Viral Tropism | 2015 |
Ineffective central nervous system HIV suppression of once-a-day maraviroc and ritonavir-boosted darunavir dual therapy: four case reports.
Topics: Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Darunavir; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Maraviroc; Middle Aged; Nervous System; Ritonavir; RNA, Viral; Treatment Outcome; Triazoles; Viral Load | 2016 |
Parameters Influencing Baseline HIV-1 Genotypic Tropism Testing Related to Clinical Outcome in Patients on Maraviroc.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cyclohexanes; Female; Genes, Viral; Genetic Association Studies; Genotype; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Treatment Outcome; Triazoles; Viral Tropism; Young Adult | 2015 |
Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Retrospective Studies; RNA, Viral; Salvage Therapy; Treatment Outcome; Triazoles; Viral Load | 2015 |
The efficacy and safety of maraviroc addition to a stable antiretroviral regimen in subjects with suppressed plasma HIV-RNA is not influenced by age.
Topics: Adult; Age Factors; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; Cyclohexanes; HIV; HIV Infections; Humans; Maraviroc; Middle Aged; Multivariate Analysis; Retrospective Studies; RNA, Viral; Treatment Outcome; Triazoles; Viral Load | 2015 |
HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc.
Topics: Adult; Algorithms; Antiretroviral Therapy, Highly Active; Area Under Curve; Cyclohexanes; Female; High-Throughput Nucleotide Sequencing; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Peptide Fragments; RNA, Viral; ROC Curve; Sequence Analysis, RNA; Software; Triazoles; Viral Tropism | 2015 |
Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 Prevention.
Topics: Administration, Topical; Anti-HIV Agents; Cell Survival; Cervix Uteri; Colon; Cyclohexanes; Drug Combinations; Drug Liberation; Female; Gels; HIV Fusion Inhibitors; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; In Vitro Techniques; Maraviroc; Mucous Membrane; Pyrimidines; Rectum; Rheology; Triazoles | 2015 |
Maraviroc Clinical Test (MCT) as an alternative tool to decide CCR5-antagonists prescription in naïve HIV-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Cyclohexanes; Female; Genotype; Genotyping Techniques; HIV; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Retrospective Studies; RNA, Viral; Time Factors; Treatment Outcome; Triazoles; Viral Load; Viral Tropism; Young Adult | 2015 |
Impact of the Maraviroc-Resistant Mutation M434I in the C4 Region of HIV-1 gp120 on Sensitivity to Antibody-Mediated Neutralization.
Topics: Antibodies, Monoclonal; Antibodies, Neutralizing; Antibodies, Viral; CD4-Positive T-Lymphocytes; Cell Line; Cyclohexanes; Drug Resistance, Viral; Gene Expression; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Immune Sera; Immunoglobulin G; Maraviroc; Mutation; Neutralization Tests; Receptors, CCR5; Triazoles | 2016 |
Maraviroc modifies gut microbiota composition in a mouse model of obesity: a plausible therapeutic option to prevent metabolic disorders in HIV-infected patients.
Topics: Animals; Bacterial Translocation; Bacteroidetes; CCR5 Receptor Antagonists; Cecum; Cyclohexanes; Diet, High-Fat; Drug Evaluation, Preclinical; Firmicutes; HIV Fusion Inhibitors; HIV Infections; Humans; Insulin Resistance; Male; Maraviroc; Metabolic Diseases; Mice; Mice, Inbred C57BL; Microbiota; Non-alcoholic Fatty Liver Disease; Obesity; Proteobacteria; Random Allocation; Species Specificity; Triazoles; Weight Gain | 2015 |
Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation.
Topics: Azepines; Diterpenes; HIV Infections; HIV-1; Humans; I-kappa B Proteins; NF-kappa B; NF-KappaB Inhibitor alpha; Positive Transcriptional Elongation Factor B; Signal Transduction; T-Lymphocytes; Triazoles; Virus Activation; Virus Latency | 2015 |
Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Cells, Cultured; Coculture Techniques; Cyclohexanes; HIV Infections; HIV-2; Humans; Imidazoles; Leukocytes, Mononuclear; Maraviroc; Phenotype; Phytohemagglutinins; Receptors, CCR2; Receptors, CCR5; Sulfoxides; Triazoles; Virus Replication | 2015 |
Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.
Topics: Amino Acid Sequence; Base Sequence; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Drug Resistance, Viral; Glycosylation; HIV Envelope Protein gp120; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Molecular Sequence Data; Protein Structure, Tertiary; Receptors, CCR5; Receptors, CXCR4; Sequence Alignment; Sequence Analysis, RNA; Signal Transduction; Treatment Failure; Triazoles; Virus Internalization; Virus Replication | 2015 |
Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Cell Line; Cyclohexanes; Drug Synergism; Flow Cytometry; HIV Infections; HIV-1; Humans; Immunoglobulin G; Maraviroc; Receptors, CCR5; Receptors, CXCR4; Recombinant Fusion Proteins; Triazoles; Virus Internalization | 2016 |
Role of Semen on Vaginal HIV-1 Transmission and Maraviroc Protection.
Topics: Administration, Intravaginal; Animals; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cyclohexanes; Disease Models, Animal; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Mice; Mice, Transgenic; Semen; Triazoles; Vagina; Viral Load | 2015 |
Differences in the variability of cerebral proton magnetic resonance spectroscopy (1H-MRS) measurements within three HIV-infected cohorts.
Topics: Adult; Antiretroviral Therapy, Highly Active; Aspartic Acid; Basal Ganglia; Brain; Brain Chemistry; Cohort Studies; Creatine; Cyclohexanes; Female; Hepatitis C; HIV Fusion Inhibitors; HIV Infections; Humans; Inositol; Magnetic Resonance Imaging; Male; Maraviroc; Middle Aged; Proton Magnetic Resonance Spectroscopy; Protons; Triazoles; Young Adult | 2015 |
Single oral dose of maraviroc does not prevent ex-vivo HIV infection of rectal mucosa in HIV-1 negative human volunteers.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Biopsy; Cyclohexanes; Healthy Volunteers; HIV Infections; HIV-1; Humans; Intestinal Mucosa; Maraviroc; Models, Biological; Organoids; Treatment Failure; Triazoles | 2015 |
Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Off-Label Use; Retrospective Studies; Salvage Therapy; Treatment Outcome; Triazoles; Viral Load; Young Adult | 2015 |
Clinical outcome of maraviroc-containing therapy in heavily pre-treated HIV-1-infected patients.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cyclohexanes; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Retrospective Studies; Treatment Outcome; Triazoles; Viral Load; Viral Tropism; Young Adult | 2016 |
Position-specific automated processing of V3 env ultra-deep pyrosequencing data for predicting HIV-1 tropism.
Topics: Amino Acid Sequence; Cyclohexanes; Genotype; High-Throughput Nucleotide Sequencing; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Host-Pathogen Interactions; Humans; Maraviroc; Molecular Sequence Data; Peptide Fragments; Phenotype; Point Mutation; Receptors, CCR5; Receptors, CXCR4; Reproducibility of Results; Triazoles; Viral Tropism | 2015 |
Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activation.
Topics: Adult; Antiretroviral Therapy, Highly Active; Biomarkers; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Lymphocyte Activation; Macrophages; Male; Maraviroc; Middle Aged; Monocytes; Triazoles; Viral Load | 2016 |
Is there a role for maraviroc to treat HIV-associated central nervous system white matter disease?
Topics: Anti-HIV Agents; Cyclohexanes; HIV Infections; Humans; Infant; Infant, Newborn; Leukoencephalopathies; Male; Maraviroc; Treatment Outcome; Triazoles | 2016 |
Short Communication: Limited Anti-HIV-1 Activity of Maraviroc in Mucosal Tissues.
Topics: Anti-HIV Agents; Cells, Cultured; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Maraviroc; Models, Biological; Mucous Membrane; Organ Culture Techniques; Treatment Outcome; Triazoles | 2016 |
Durability and Effectiveness of Maraviroc-Containing Regimens in HIV-1-Infected Individuals with Virological Failure in Routine Clinical Practice.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cyclohexanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Treatment Outcome; Triazoles; Viral Load | 2015 |
Short Communication: Preferential Killing of HIV Latently Infected CD4(+) T Cells by MALT1 Inhibitor.
Topics: Acetanilides; Bryostatins; Caspases; CD4-Positive T-Lymphocytes; Cell Line, Tumor; HIV Infections; HIV-1; Humans; Jurkat Cells; Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein; Neoplasm Proteins; Ribonucleases; Transcription Factors; Triazoles; Virus Activation; Virus Latency; Virus Replication | 2016 |
No selection of CXCR4-using variants in cell reservoirs of dual-mixed HIV-infected patients on suppressive maraviroc therapy.
Topics: Anti-HIV Agents; Cyclohexanes; Genotype; High-Throughput Nucleotide Sequencing; HIV; HIV Infections; Humans; Leukocytes, Mononuclear; Maraviroc; Selection, Genetic; Triazoles; Viral Tropism | 2016 |
Maraviroc contributes to the restoration of the homeostasis of regulatory T-cell subsets in antiretroviral-naive HIV-infected subjects.
Topics: CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Forkhead Transcription Factors; HIV Infections; Homeostasis; Humans; Immunophenotyping; Leukocyte Common Antigens; Longitudinal Studies; Maraviroc; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Triazoles | 2016 |
Laryngotracheal mucormycosis: Report of a case.
Topics: Antifungal Agents; Burkitt Lymphoma; Debridement; Dysphonia; Echinocandins; Hepatitis C, Chronic; HIV Infections; Humans; Hyperbaric Oxygenation; Laryngitis; Laryngoscopy; Lipopeptides; Male; Micafungin; Middle Aged; Mucormycosis; Neurosyphilis; Respiratory Distress Syndrome; Respiratory Sounds; Tracheitis; Tracheotomy; Triazoles | 2016 |
Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients.
Topics: Animals; CCR5 Receptor Antagonists; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Triazoles | 2016 |
Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates.
Topics: Anti-HIV Agents; Cells, Cultured; Chemoprevention; Cyclohexanes; Disease Transmission, Infectious; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Maraviroc; Models, Biological; Organ Culture Techniques; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Triazoles | 2016 |
Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Argentina; Cryptococcosis; Cryptococcus neoformans; Drug Resistance, Fungal; Epidemiologic Methods; Fluconazole; Flucytosine; HIV Infections; Humans; Itraconazole; Meningitis, Cryptococcal; Microbial Sensitivity Tests; Triazoles; Voriconazole | 2016 |
A comparison of two post-processing analysis methods to quantify cerebral metabolites measured via proton magnetic resonance spectroscopy in HIV disease.
Topics: Biomarkers; Brain; Brain Diseases; CCR5 Receptor Antagonists; Cyclohexanes; HIV Infections; Humans; Maraviroc; Proton Magnetic Resonance Spectroscopy; Triazoles | 2016 |
Immune Responses to HIV.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Cytomegalovirus; Hepacivirus; HIV Antibodies; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CCR5; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Triazoles | 2016 |
Reduced Frequencies and Activation of Regulatory T Cells After the Treatment of HIV-1-Infected Individuals with the CCR5 Antagonist Maraviroc Are Associated with a Reduction in Viral Loads Rather Than a Direct Effect of the Drug on Regulatory T Cells.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Receptors, CCR5; T-Lymphocytes, Regulatory; Triazoles; Viral Load; Virus Replication | 2016 |
Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model.
Topics: Administration, Intravaginal; Animals; Anti-HIV Agents; Contraceptive Devices, Female; Cyclohexanes; Delayed-Action Preparations; Drug Combinations; Female; HIV Infections; Humans; Maraviroc; Models, Animal; Primary Prevention; Sheep; Tenofovir; Triazoles; Vagina | 2016 |
Author's reply.
Topics: Animals; CCR5 Receptor Antagonists; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Triazoles | 2016 |
Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.
Topics: Dose-Response Relationship, Drug; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Inhibitory Concentration 50; Models, Molecular; Mutation; Pyridones; Reverse Transcriptase Inhibitors; Rilpivirine; Triazoles; Virus Replication | 2016 |
Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients.
Topics: Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Treatment Outcome; Triazoles; Viral Load | 2016 |
Etiologic Agents and Antifungal Susceptibility of Oral Candidosis from Romanian patients with HIV-infection or type 1 diabetes mellitus.
Topics: Antifungal Agents; Candida; Candidiasis, Oral; Diabetes Complications; Diabetes Mellitus, Type 1; Drug Resistance, Fungal; Fluconazole; HIV Infections; Humans; Microbial Sensitivity Tests; Romania; Triazoles | 2016 |
Maraviroc Reduces Arterial Stiffness in PI-Treated HIV-infected Patients.
Topics: Atherosclerosis; Carotid Intima-Media Thickness; Case-Control Studies; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Male; Maraviroc; Risk Factors; Treatment Outcome; Triazoles; Vascular Stiffness | 2016 |
Prevention. Raltegravir, maraviroc show promise as PrEP drugs in studies.
Topics: Cyclohexanes; HIV Infections; Humans; Maraviroc; Raltegravir Potassium; Triazoles | 2016 |
Characterization of impurities of HIV NNRTI Doravirine by UHPLC-high resolution MS and tandem MS analysis.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Drug Contamination; HIV Infections; Humans; Molecular Structure; Pyridones; Reverse Transcriptase Inhibitors; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Triazoles | 2016 |
Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization.
Topics: Anti-HIV Agents; Cyclohexanes; Dimerization; Dose-Response Relationship, Drug; HIV Infections; HIV-1; Humans; Ligands; Maraviroc; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Naltrexone; Receptors, CCR5; Receptors, Opioid, mu; Structure-Activity Relationship; Triazoles | 2016 |
Addition of maraviroc to antiretroviral therapy decreased interferon-γ mRNA in the CD4+ T cells of patients with suboptimal CD4+ T-cell recovery.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Interferon-gamma; Leukocytes, Mononuclear; Male; Maraviroc; Middle Aged; RNA, Messenger; RNA, Viral; Triazoles; Viral Load | 2017 |
Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.
Topics: Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; CD4 Antigens; Cyclohexanes; HEK293 Cells; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Maraviroc; Mutagenesis; Peptide Fragments; Receptors, CCR5; Triazoles; Virus Internalization | 2016 |
Short Communication: Lack of Effect of Maraviroc Intensification on Blood and Gut Reservoir.
Topics: Blood; CCR5 Receptor Antagonists; Cyclohexanes; Gastrointestinal Tract; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Pilot Projects; Prospective Studies; Treatment Outcome; Triazoles | 2017 |
Off-licence use of once-daily maraviroc in children and adolescents with perinatally acquired HIV-1 infection.
Topics: Adolescent; CCR5 Receptor Antagonists; Child; Cyclohexanes; Female; HIV Infections; Humans; Male; Maraviroc; Off-Label Use; Retrospective Studies; Treatment Outcome; Triazoles | 2017 |
Effects of Therapy with Maraviroc on the Carotid Intima Media Thickness in HIV-1/HCV Co-infected Patients.
Topics: Biomarkers; Carotid Intima-Media Thickness; CCR5 Receptor Antagonists; Coinfection; Cyclohexanes; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Liver Cirrhosis; Male; Maraviroc; Middle Aged; Pilot Projects; Polymerase Chain Reaction; Prospective Studies; Triazoles; Ultrasonography, Doppler, Color | 2017 |
Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation.
Topics: Adolescent; Cell Proliferation; HIV Infections; HIV-1; Humans; Interleukin-2; Lymphocyte Activation; Small Molecule Libraries; STAT5 Transcription Factor; Sumoylation; T-Lymphocytes; Triazoles; Virus Activation; Virus Latency | 2017 |
Strategic use of dual regimens of boosted protease inhibitors plus maraviroc in poorly adherent subjects in view of long-acting drugs: A retrospective study.
Topics: Adult; Cyclohexanes; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; Humans; Male; Maraviroc; Medication Adherence; Middle Aged; Protease Inhibitors; Retrospective Studies; Triazoles; Young Adult | 2017 |
Can incentives reduce the barriers to use of antenatal care and delivery services in Kenya?: Results of a qualitative inquiry.
Topics: Delivery, Obstetric; Female; Health Expenditures; Health Knowledge, Attitudes, Practice; Health Services Accessibility; HIV Infections; Humans; Kenya; Maternal Health Services; Mothers; Motivation; Nurses; Patient Acceptance of Health Care; Patient Satisfaction; Pregnancy; Prenatal Care; Qualitative Research; Quality of Health Care; Syphilis; Transportation; Triazoles | 2017 |
Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; Cyclohexanes; Drug Approval; Drug Resistance, Multiple; Drug Resistance, Viral; Europe; HIV Infections; Humans; Randomized Controlled Trials as Topic; Treatment Failure; Triazoles; United States | 2008 |
Maraviroc: in vitro assessment of drug-drug interaction potential.
Topics: Area Under Curve; Atazanavir Sulfate; Cyclohexanes; Cytochrome P-450 CYP3A; Drug Interactions; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ketoconazole; Liver; Male; Maraviroc; Microsomes, Liver; Oligopeptides; Predictive Value of Tests; Pyridines; Ritonavir; Saquinavir; Triazoles | 2008 |
Anti-HIV agents. Is PF-232798 a possible successor to maraviroc?
Topics: Azabicyclo Compounds; CD4 Lymphocyte Count; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; Humans; Imidazoles; Maraviroc; Piperidines; Triazoles; Tropanes; Viral Load | 2008 |
An in-depth look at the challenges of prescribing maraviroc.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Dose-Response Relationship, Drug; Drug Interactions; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Triazoles | 2008 |
A new class of anti-HIV therapy and new challenges.
Topics: Anti-Retroviral Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Resistance, Viral; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Triazoles | 2008 |
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
Topics: Adult; Aged; Anti-Retroviral Agents; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Double-Blind Method; Drug Therapy, Combination; Enfuvirtide; Ethnicity; Female; Genotype; Hepatitis B; Hepatitis C; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Odds Ratio; Peptide Fragments; Receptors, CCR5; RNA, Viral; Transaminases; Treatment Outcome; Triazoles; Viral Load | 2008 |
Immune reconstitution syndrome after voriconazole treatment for cryptococcal meningitis in a liver transplant recipient.
Topics: Adrenal Cortex Hormones; Anti-Retroviral Agents; Antifungal Agents; Female; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Immune System; Inflammation; Liver Transplantation; Magnetic Resonance Imaging; Meningitis, Cryptococcal; Middle Aged; Pyrimidines; Recurrence; Triazoles; Voriconazole | 2008 |
[Pretreated HIV patients profit from Maraviroc. Oral HIV fusion inhibitor opens new therapy chances].
Topics: Administration, Oral; Cyclohexanes; Drug Resistance, Viral; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Randomized Controlled Trials as Topic; Triazoles; Viral Load | 2008 |
New insights into missed endpoint trial.
Topics: CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Endpoint Determination; HIV Infections; HIV-1; Humans; Maraviroc; Patient Selection; Receptors, CXCR4; Triazoles | 2008 |
Antiretroviral treatment update from the 17th International AIDS Conference.
Topics: Anti-HIV Agents; Cardiovascular Diseases; CCR5 Receptor Antagonists; Cyclohexanes; HIV Infections; HIV Integrase Inhibitors; Humans; Maraviroc; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Triazoles | 2008 |
[Introduction. A brief history of AIDS].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; Cyclohexanes; Drug Design; History, 20th Century; History, 21st Century; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Receptors, CCR5; Triazoles | 2008 |
1-Amido-1-phenyl-3-piperidinylbutanes--CCR5 antagonists for the treatment of HIV: part 2.
Topics: Animals; Anti-HIV Agents; Butanes; Caco-2 Cells; CCR5 Receptor Antagonists; Cell Line; Dogs; HIV Infections; Humans; Piperidines; Rats; Receptors, CCR5; Stereoisomerism; Triazoles | 2009 |
1,3,4-Oxadiazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 2: SAR of the C5 position.
Topics: Amino Acid Motifs; Anti-HIV Agents; Chelating Agents; Chemistry, Pharmaceutical; Drug Design; HIV Infections; HIV Integrase Inhibitors; Humans; Metals; Models, Chemical; Molecular Structure; Naphthyridines; Oxadiazoles; Structure-Activity Relationship; Triazoles | 2009 |
The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophore.
Topics: Amino Acid Motifs; Anti-HIV Agents; Chelating Agents; Chemistry, Pharmaceutical; Drug Design; HIV Infections; HIV Integrase Inhibitors; Humans; Models, Chemical; Molecular Structure; Naphthyridines; Oxadiazoles; Structure-Activity Relationship; Triazoles; Virus Replication | 2009 |
Report from the 2008 joint ICAAC/IDSA meeting. Maraviroc vs. efavirenz: a reanalysis of MERIT.
Topics: Alkynes; Benzoxazines; CCR5 Receptor Antagonists; Cyclohexanes; Cyclopropanes; HIV Infections; Humans; Maraviroc; Reverse Transcriptase Inhibitors; Triazoles | 2008 |
Maraviroc and CD4+ cell count recovery in patients with virologic suppression and blunted CD4+ cell response.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; Drug Interactions; HIV Infections; HIV-1; Humans; Maraviroc; Triazoles; Viral Load | 2009 |
Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients.
Topics: Anti-HIV Agents; Cyclohexanes; HIV Infections; HIV-1; Humans; Maraviroc; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles | 2009 |
In vitro activity of voriconazole against Mexican oral yeast isolates.
Topics: Adult; Antifungal Agents; Candida; Candidiasis, Oral; Fluconazole; HIV Infections; Humans; Mexico; Microbial Sensitivity Tests; Mouth; Pharynx; Pyrimidines; Triazoles; Voriconazole | 2010 |
Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing.
Topics: Cyclohexanes; DNA, Viral; Drug Resistance, Viral; Evolution, Molecular; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Phenotype; Phylogeny; Receptors, CXCR4; Sequence Alignment; Sequence Analysis, DNA; Triazoles | 2009 |
CCR5 pharmacology methodologies and associated applications.
Topics: Animals; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Discovery; HIV Infections; Humans; Maraviroc; Receptors, CCR5; Triazoles | 2009 |
Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women.
Topics: Adolescent; Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; Cervix Uteri; Cyclohexanes; Female; HIV Infections; HIV Seronegativity; HIV-1; Humans; Maraviroc; Middle Aged; Protein Binding; Triazoles; Vagina; Young Adult | 2009 |
Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery.
Topics: Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; Drug Evaluation; Endotoxins; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Retrospective Studies; RNA, Viral; Treatment Outcome; Triazoles | 2009 |
Concurrent use of statins does not influence efficacy of maraviroc in Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients 1 and 2 trials.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Drug Interactions; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Maraviroc; Treatment Outcome; Triazoles | 2009 |
Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Cyclohexanes; Female; HIV; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Receptors, HIV; Triazoles; Viral Load; Young Adult | 2009 |
Effects of antifungal agents in sap activity of Candida albicans isolates.
Topics: Antifungal Agents; Aspartic Acid Proteases; Candida albicans; Candidiasis; Culture Media; DNA, Fungal; Drug Resistance, Fungal; Fluconazole; HIV Infections; Humans; Microbial Sensitivity Tests; Mouth Mucosa; Polymerase Chain Reaction; Pyrimidines; Triazoles; Voriconazole | 2010 |
Optimizing care for patients on maraviroc salvage therapy.
Topics: Adult; Cyclohexanes; Drug Interactions; Drug Therapy, Combination; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Middle Aged; Salvage Therapy; Triazoles | 2009 |
Maraviroc modelling strategy: use of early phase 1 data to support a semi-mechanistic population pharmacokinetic model.
Topics: Administration, Oral; Anti-HIV Agents; Clinical Trials, Phase I as Topic; Cyclohexanes; Dose-Response Relationship, Drug; Female; HIV Infections; Humans; Injections, Intravenous; Male; Maraviroc; Metabolic Clearance Rate; Models, Biological; Models, Statistical; Triazoles | 2009 |
[New antiretroviral drug classes in HIV therapy].
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Maraviroc; Piperazines; Pyrimidines; Pyrrolidinones; Quinolones; Raltegravir Potassium; Succinates; Triazoles; Triterpenes; Viral Load | 2009 |
Voriconazole use and pharmacokinetics in combination with interferon-gamma for refractory cryptococcal meningitis in a patient receiving low-dose ritonavir.
Topics: Anti-HIV Agents; Antifungal Agents; Cerebrospinal Fluid; Dideoxynucleosides; Drug Monitoring; HIV Infections; Humans; Interferon-gamma; Lamivudine; Male; Meningitis, Cryptococcal; Pyrimidines; Ritonavir; Serum; Triazoles; Voriconazole; Young Adult | 2010 |
[Immunorecovery after prolonged HIV-related immunosuppression: opportunities of the new antiretroviral classes].
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclohexanes; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Immunocompetence; Interleukin-2; Male; Maraviroc; Middle Aged; Reverse Transcriptase Inhibitors; Sulfonamides; T-Lymphocyte Subsets; Triazoles; Viral Load | 2009 |
Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients.
Topics: Adult; CCR5 Receptor Antagonists; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; Humans; Male; Maraviroc; Mass Spectrometry; Middle Aged; Pilot Projects; Triazoles | 2009 |
Is maraviroc beneficial in paradoxical progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome management?
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Immune Reconstitution Inflammatory Syndrome; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Maraviroc; Triazoles | 2009 |
Satisfactory cross-cultural validity of the ACTG symptom distress module in HIV-1-infected antiretroviral-naive patients.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cultural Competency; Cyclohexanes; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Language; Male; Maraviroc; Middle Aged; Multicenter Studies as Topic; Psychometrics; Randomized Controlled Trials as Topic; Reproducibility of Results; Stress, Psychological; Surveys and Questionnaires; Triazoles; Zidovudine | 2009 |
FDA advisory committee approves Selzentry.
Topics: Advisory Committees; CCR5 Receptor Antagonists; Cyclohexanes; Drug Approval; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CCR5; Triazoles; United States; United States Food and Drug Administration | 2009 |
Molecular docking and 3D-QSAR studies on triazolinone and pyridazinone, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
Topics: Computer Simulation; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Models, Molecular; Molecular Structure; Pyridazines; Quantitative Structure-Activity Relationship; Reverse Transcriptase Inhibitors; Triazoles | 2010 |
A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients.
Topics: CCR5 Receptor Antagonists; Chromatography, High Pressure Liquid; Cyclohexanes; Drug Monitoring; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Reproducibility of Results; Triazoles | 2010 |
Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir.
Topics: Adult; Area Under Curve; Chromatography, Liquid; Cyclohexanes; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV Seronegativity; Humans; Male; Maraviroc; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Tandem Mass Spectrometry; Triazoles | 2010 |
Maraviroc for treatment-naive patients with HIV-1 infection: is the glass half empty or half full?
Topics: Antiviral Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Maraviroc; Triazoles | 2010 |
Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cyclohexanes; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Maraviroc; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Salvage Therapy; Triazoles; Viral Load | 2010 |
Tether influence on the binding properties of tRNALys3 ligands designed by a fragment-based approach.
Topics: Binding Sites; HIV; HIV Infections; Ligands; Models, Molecular; Nuclear Magnetic Resonance, Biomolecular; Reverse Transcription; RNA, Transfer, Amino Acyl; RNA, Viral; Triazoles | 2010 |
Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc.
Topics: Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; Genotype; HIV Infections; HIV-2; Humans; Maraviroc; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Treatment Outcome; Triazoles | 2010 |
Are the proposed env mutations actually associated with resistance to maraviroc?
Topics: Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; env Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV-1; Humans; Maraviroc; Mutation, Missense; Triazoles | 2010 |
Antifungal susceptibility, serotyping, and genotyping of clinical Cryptococcus neoformans isolates collected during 18 years in a single institution in Madrid, Spain.
Topics: Amplified Fragment Length Polymorphism Analysis; Antifungal Agents; Comorbidity; Cryptococcosis; Cryptococcus neoformans; Drug Resistance, Fungal; Female; HIV Infections; Hospitals; Humans; Immunocompromised Host; Male; Microbial Sensitivity Tests; Serotyping; Spain; Triazoles | 2010 |
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.
Topics: Adult; CCR5 Receptor Antagonists; Cyclohexanes; Female; Genotype; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Male; Maraviroc; Middle Aged; Molecular Sequence Data; Phenotype; Receptors, CCR5; Receptors, HIV; Sensitivity and Specificity; Sequence Analysis, DNA; Treatment Outcome; Triazoles; Tropism | 2010 |
Shift in phenotypic susceptibility suggests a competition mechanism in a case of acquired resistance to maraviroc.
Topics: Adult; Cyclohexanes; Drug Resistance, Viral; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Phenotype; Triazoles | 2010 |
Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms.
Topics: Adult; Anti-HIV Agents; Central Nervous System Diseases; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Triazoles | 2010 |
Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor.
Topics: Administration, Intravaginal; Animals; Anti-HIV Agents; Cyclohexanes; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Macaca mulatta; Maraviroc; Receptors, CCR5; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Treatment Outcome; Triazoles; Vaginal Diseases; Virus Internalization; Virus Replication | 2010 |
Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; Female; Hepatitis C, Chronic; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Maraviroc; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Retrospective Studies; Spain; Time; Triazoles; Viral Load | 2010 |
The active core in a triazole peptide dual-site antagonist of HIV-1 gp120.
Topics: Amino Acid Sequence; Anti-HIV Agents; Catalytic Domain; CD4 Antigens; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Kinetics; Molecular Sequence Data; Peptides; Surface Plasmon Resonance; Thermodynamics; Triazoles | 2010 |
A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5.
Topics: Base Sequence; Binding Sites; CCR5 Receptor Antagonists; Cell Line; Cohort Studies; Cyclohexanes; DNA Primers; Drug Resistance, Viral; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; In Vitro Techniques; Maraviroc; Models, Biological; Mutant Proteins; Mutation; Peptide Fragments; Protein Structure, Tertiary; Receptors, CCR5; Triazoles | 2010 |
Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Chromatography, Liquid; Cyclohexanes; Didanosine; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Organophosphonates; Polymerase Chain Reaction; Tandem Mass Spectrometry; Tenofovir; Triazoles; Viral Load | 2010 |
Analysis of co-receptor usage of circulating viral and proviral HIV genome quasispecies by ultra-deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment.
Topics: Adult; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; Cyclohexanes; Female; Genome, Viral; HIV; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Receptors, CCR5; Receptors, HIV; Sequence Analysis, DNA; Sequence Analysis, RNA; Triazoles; Viral Load | 2011 |
Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies.
Topics: Adult; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclohexanes; Female; Genotype; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Male; Maraviroc; Receptors, HIV; RNA, Viral; Sequence Analysis, DNA; Triazoles; Viral Load; Viral Tropism | 2010 |
Development and application of a simple LC-MS method for the determination of plasma maraviroc concentrations.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Chemical Analysis; CCR5 Receptor Antagonists; Chromatography, Liquid; Cyclohexanes; Drug Monitoring; HIV Infections; HIV-1; Humans; Male; Maraviroc; Mass Spectrometry; Triazoles | 2010 |
Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.
Topics: Amides; Amino Acid Sequence; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Resistance, Viral; Evolution, Molecular; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Maraviroc; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Peptide Fragments; Piperazines; Pyrimidines; Quaternary Ammonium Compounds; Receptors, CCR5; Triazoles | 2010 |
Hepatic safety and tolerability in the maraviroc clinical development program.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; HIV Infections; HIV-1; Humans; Maraviroc; Triazoles | 2010 |
Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients.
Topics: Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; HIV Envelope Protein gp120; HIV Infections; HIV Seropositivity; HIV-1; Humans; Maraviroc; Mutation; Peptide Fragments; Receptors, CCR5; Sequence Analysis, DNA; Triazoles; Viral Tropism | 2010 |
TROCAI (tropism coreceptor assay information): a new phenotypic tropism test and its correlation with Trofile enhanced sensitivity and genotypic approaches.
Topics: Adult; Anti-HIV Agents; Cyclohexanes; Female; HIV; HIV Infections; Humans; Male; Maraviroc; Microbial Sensitivity Tests; Middle Aged; Triazoles; Viral Tropism; Virus Cultivation | 2010 |
Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease.
Topics: Cell Line; Cells, Cultured; Enzyme Activation; Gene Products, gag; HIV Infections; HIV Protease; HIV-1; Humans; Leukocytes, Mononuclear; Nitriles; Reverse Transcriptase Inhibitors; Sulfonamides; Triazoles | 2010 |
Posaconazole cerebrospinal concentrations in an HIV-infected patient with brain mucormycosis.
Topics: Africa, Western; AIDS-Related Opportunistic Infections; Antifungal Agents; Brain; CD4 Lymphocyte Count; Central Nervous System Fungal Infections; Cerebrospinal Fluid; HIV Infections; Humans; Inhibitory Concentration 50; Magnetic Resonance Imaging; Mucormycosis; Radiography; Triazoles | 2011 |
Maraviroc does not affect humoral response to the pandemic influenza A-H1N1v 2009 adjuvanted vaccine in HIV-1-infected patients.
Topics: Adult; Aged; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclohexanes; Disease Outbreaks; Female; HIV Infections; HIV-1; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Maraviroc; Middle Aged; Triazoles | 2010 |
Evaluation of primary resistance to HIV entry inhibitors among brazilian patients failing reverse transcriptase/protease inhibitors treatment reveal high prevalence of maraviroc resistance-related mutations.
Topics: Adult; Ambulatory Care Facilities; Anti-HIV Agents; Brazil; Cyclohexanes; DNA, Viral; Drug Resistance, Viral; Enfuvirtide; env Gene Products, Human Immunodeficiency Virus; Female; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Male; Maraviroc; Middle Aged; Molecular Sequence Data; Mutation, Missense; Peptide Fragments; Piperazines; Prevalence; Proviruses; Sequence Analysis, DNA; Treatment Failure; Triazoles | 2010 |
The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects.
Topics: Algorithms; Computer Simulation; Cyclohexanes; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Models, Statistical; Research Design; Software; Triazoles; Viral Load | 2011 |
Cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals in Mexico.
Topics: Computer Simulation; Cost-Benefit Analysis; Cyclohexanes; Female; HIV Fusion Inhibitors; HIV Infections; Humans; Male; Maraviroc; Mexico; Middle Aged; Models, Biological; Quality-Adjusted Life Years; Triazoles | 2010 |
New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection.
Topics: Allosteric Regulation; Chemokine CCL3; Cyclohexanes; Guanosine Triphosphate; HEK293 Cells; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Ligands; Maraviroc; Protein Binding; Receptors, CCR5; Triazoles | 2011 |
Discordance rates between Trofile test and short-term virological response to maraviroc.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Treatment Outcome; Triazoles; Viral Tropism; Young Adult | 2011 |
The evolutionary analysis of emerging low frequency HIV-1 CXCR4 using variants through time--an ultra-deep approach.
Topics: Algorithms; Computational Biology; Cyclohexanes; Genetic Variation; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CXCR4; Sequence Alignment; Sequence Analysis, RNA; Software; Triazoles; Viral Tropism | 2010 |
Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment.
Topics: Cyclohexanes; Genotype; HIV Infections; HIV-1; Humans; Maraviroc; Phenotype; Receptors, CCR5; Receptors, CXCR4; Triazoles; Viral Tropism | 2011 |
Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model.
Topics: Administration, Oral; Animals; Anti-HIV Agents; Cyclohexanes; Disease Models, Animal; Female; Flow Cytometry; HIV Infections; HIV-1; Humans; Maraviroc; Mice; Mice, Transgenic; Post-Exposure Prophylaxis; Pyrrolidinones; Raltegravir Potassium; Triazoles; Vagina | 2010 |
It's official...but not infallible.
Topics: Cyclohexanes; Drug Approval; Europe; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Off-Label Use; Triazoles; United States | 2010 |
Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Cyclohexanes; env Gene Products, Human Immunodeficiency Virus; Genotype; High-Throughput Nucleotide Sequencing; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CCR5; Receptors, HIV; Retrospective Studies; RNA, Viral; Triazoles; Viral Tropism; Virology; Virus Attachment | 2011 |
Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia.
Topics: Anti-Retroviral Agents; Aspergillosis; Aspergillus; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Male; Nitriles; Pneumonia, Aspiration; Pyridazines; Pyrimidines; Ritonavir; Triazoles; Voriconazole | 2011 |
Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.
Topics: Adult; Aged; Anti-HIV Agents; CCR5 Receptor Antagonists; Cost-Benefit Analysis; Cyclohexanes; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Markov Chains; Middle Aged; Models, Economic; National Health Programs; Quality-Adjusted Life Years; Spain; Triazoles; Young Adult | 2010 |
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
Topics: Anti-HIV Agents; Cell Line; Cyclohexanes; High-Throughput Nucleotide Sequencing; HIV Envelope Protein gp120; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Maraviroc; Molecular Sequence Data; Receptors, Virus; Triazoles; Viral Tropism; Virus Attachment; Virus Replication | 2011 |
Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
Topics: Animals; Anti-HIV Agents; Benzeneacetamides; CCR5 Receptor Antagonists; Cell Line; Chemokine CCL5; Chemokines; Chemotaxis; Cricetinae; Cyclohexanes; DNA Replication; Drug Resistance, Multiple, Viral; HEK293 Cells; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Macrophages; Maraviroc; Protein Binding; Receptors, CCR5; Receptors, CXCR4; Sulfonamides; Triazoles; Virus Replication | 2011 |
Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.
Topics: Anti-HIV Agents; Cell Line; Cyclohexanes; Genotype; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Treatment Outcome; Triazoles; Viral Tropism | 2011 |
Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CCR5; Triazoles | 2011 |
Oral Candida isolates among HIV-infected subjects in Nigeria.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Candida; Candidiasis, Oral; Drug Resistance, Fungal; Female; Fluconazole; Flucytosine; HIV Infections; Humans; Itraconazole; Male; Microbial Sensitivity Tests; Middle Aged; Mycological Typing Techniques; Nigeria; Pyrimidines; Triazoles; Voriconazole | 2011 |
Mutations in gp41 are correlated with coreceptor tropism but do not improve prediction methods substantially.
Topics: Algorithms; Amino Acid Sequence; Anti-HIV Agents; Cyclohexanes; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Maraviroc; Molecular Sequence Data; Mutation; Predictive Value of Tests; Receptors, CCR5; Receptors, CXCR4; Reverse Transcriptase Inhibitors; Treatment Outcome; Triazoles; Tropism | 2011 |
Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Cyclohexanes; Drug Resistance, Viral; Genotype; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Logistic Models; Maraviroc; Microbial Sensitivity Tests; Phenotype; Predictive Value of Tests; RNA, Viral; T-Lymphocytes; Treatment Outcome; Triazoles; Viral Load | 2011 |
Maraviroc intensification for suboptimal CD4⁺ T cell response in a perinatally HIV-infected adolescent.
Topics: Adolescent; CD4-Positive T-Lymphocytes; Cyclohexanes; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Male; Maraviroc; Pregnancy; Pregnancy Complications, Infectious; Triazoles | 2011 |
[CCR5 antagonist Maraviroc: effective and well tolerated. "A very promising substance"].
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Therapy, Combination; Genotype; HIV Infections; HIV-1; Humans; Maraviroc; Medication Adherence; Triazoles | 2011 |
[Utilizing the potential of maraviroc early. "Clear in second line therapy" (interview by Dr. Felicitas Zorn)].
Topics: Anti-HIV Agents; Cyclohexanes; Drug Therapy, Combination; Early Diagnosis; Genotype; HIV Infections; HIV-1; Humans; Maraviroc; Triazoles | 2011 |
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Salvage Therapy; Triazoles | 2011 |
A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice.
Topics: Animals; Anti-Infective Agents, Local; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Chemistry, Pharmaceutical; Cyclohexanes; Disease Models, Animal; DNA-Binding Proteins; Female; Gels; HIV Infections; HIV-1; Homeodomain Proteins; Humans; Maraviroc; Mice; Placebos; Triazoles; Vagina | 2011 |
Virological response after short-term CCR5 antagonist exposure in HIV-infected patients: frequency of subjects with virological response and associated factors.
Topics: Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cell Line; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Receptors, CXCR4; RNA, Viral; Triazoles; Viral Load | 2011 |
Deep sequencing of plasma and proviral HIV-1 to establish coreceptor usage: what is the clinical impact of the quasispecies distribution?
Topics: Anti-HIV Agents; Cyclohexanes; HIV Infections; HIV-1; Humans; Receptors, HIV; Triazoles; Viral Tropism; Virology | 2011 |
Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc.
Topics: Administration, Intravaginal; Animals; Cyclohexanes; Delayed-Action Preparations; Female; Gels; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Macaca mulatta; Maraviroc; Silicone Elastomers; Triazoles; Vagina; Vaginal Creams, Foams, and Jellies | 2011 |
Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
Topics: Acetamides; Anti-HIV Agents; Cell Line; HIV Infections; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazoles; Virus Replication | 2011 |
Maraviroc concentrations in seminal plasma in HIV-infected patients.
Topics: Adult; Anti-Retroviral Agents; CCR5 Receptor Antagonists; Chromatography, Liquid; Cyclohexanes; HIV Infections; HIV-1; Humans; Male; Maraviroc; Mass Spectrometry; Middle Aged; Semen; Triazoles | 2010 |
In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells.
Topics: CCR5 Receptor Antagonists; Chemokine CCL2; Chemokine CCL4; Chemokine CCL5; Chemotaxis; Chemotaxis, Leukocyte; Cyclohexanes; Dendritic Cells; HIV Fusion Inhibitors; HIV Infections; Humans; Macrophages; Maraviroc; Monocytes; N-Formylmethionine Leucyl-Phenylalanine; Receptors, CCR5; Triazoles | 2011 |
Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120.
Topics: Animals; Blotting, Western; CCR5 Receptor Antagonists; Cell Survival; Cells, Cultured; Cyclohexanes; Cytokines; Dinoprostone; DNA Primers; HIV Envelope Protein gp120; HIV Infections; Inflammation; Interferon-gamma; Macrophage Activation; Maraviroc; Microglia; Nitric Oxide; Rats; Real-Time Polymerase Chain Reaction; RNA, Messenger; Triazoles | 2012 |
Rescue of HIV-1 long-time archived X4 strains to escape maraviroc.
Topics: Antiretroviral Therapy, Highly Active; Base Sequence; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Genotype; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Maraviroc; Microbial Sensitivity Tests; Molecular Sequence Data; Phylogeny; Receptors, CCR5; Receptors, CXCR4; Sequence Alignment; Treatment Failure; Triazoles; Viral Load; Viral Tropism | 2011 |
Penicillium marneffei infection presenting as vulv-ulcer in an HIV-infected woman.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Diagnosis, Differential; Female; HIV; HIV Infections; Humans; Mycoses; Penicillium; Pyrimidines; Triazoles; Ulcer; Voriconazole; Vulvar Diseases; Young Adult | 2011 |
HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry.
Topics: CCR5 Receptor Antagonists; Cell Line; Cyclohexanes; Drug Resistance, Viral; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Protein Binding; Receptors, CCR5; Triazoles; Virus Internalization | 2011 |
[Pulmonary aspergillosis and HIV infection: about two cases].
Topics: Adult; Antifungal Agents; Aspergillosis; Bronchoalveolar Lavage; HIV Infections; Humans; Lung Diseases, Fungal; Male; Middle Aged; Prognosis; Pulmonary Aspergillosis; Pyrimidines; Radiography; Risk Factors; Triazoles; Voriconazole | 2012 |
In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Cells, Cultured; Cyclohexanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; HIV-2; Humans; Inhibitory Concentration 50; Leukocytes, Mononuclear; Lymphocyte Activation; Male; Maraviroc; Models, Biological; Phytohemagglutinins; Receptors, CCR5; Receptors, CXCR4; Species Specificity; Triazoles; Virus Replication | 2012 |
Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods.
Topics: Adult; Algorithms; CCR5 Receptor Antagonists; Chromatography, High Pressure Liquid; Cyclohexanes; Female; Genotype; High-Throughput Nucleotide Sequencing; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Molecular Typing; Receptors, CCR5; RNA, Viral; Tandem Mass Spectrometry; Treatment Outcome; Triazoles; Viral Load; Viral Tropism | 2012 |
Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg.
Topics: Adult; Anti-HIV Agents; Cyclohexanes; Darunavir; Drug Interactions; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Retrospective Studies; Ritonavir; Sulfonamides; Triazoles | 2012 |
In vitro downregulation of matrix metalloproteinase-9 in rat glial cells by CCR5 antagonist maraviroc: therapeutic implication for HIV brain infection.
Topics: Animals; Astrocytes; Brain; CCR5 Receptor Antagonists; Cell Death; Cell Shape; Cell Survival; Cells, Cultured; Cyclohexanes; Down-Regulation; Gene Expression Regulation, Enzymologic; HIV Infections; Humans; Lipopolysaccharides; Maraviroc; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Neuroglia; Rats; Receptors, CCR5; RNA, Messenger; Tetradecanoylphorbol Acetate; Triazoles | 2011 |
Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival.
Topics: Aminopyridines; Animals; CCR5 Receptor Antagonists; Clinical Trials, Phase II as Topic; Cyclohexanes; Drug Evaluation; HIV Infections; Humans; Maraviroc; Morpholines; Neuralgia; Pharmaceutical Preparations; Pharmacokinetics; Receptors, Dopamine D3; Sexual Dysfunction, Physiological; Triazoles | 2012 |
Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.
Topics: Amino Acid Sequence; Amino Acid Substitution; Anti-HIV Agents; Antibodies, Blocking; Antibodies, Monoclonal; CCR5 Receptor Antagonists; Cyclohexanes; Drug Resistance, Viral; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Piperazines; Pyrimidines; Receptors, CCR5; Triazoles | 2012 |
Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Cyclohexanes; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Maraviroc; Matrix Metalloproteinase 2; Middle Aged; Pilot Projects; Prospective Studies; RNA, Viral; Serum; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta; Triazoles | 2012 |
Responses to switching to maraviroc-based antiretroviral therapy in treated patients with suppressed plasma HIV-1-RNA load.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Ki-1 Antigen; Lymphocyte Activation; Male; Maraviroc; Middle Aged; Plasma; RNA, Viral; Treatment Outcome; Triazoles; Viral Load; Viral Tropism | 2012 |
Baseline susceptibility of primary HIV-2 to entry inhibitors.
Topics: Amides; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; HIV-2; Humans; Inhibitory Concentration 50; Male; Maraviroc; Microbial Sensitivity Tests; Peptide Fragments; Quaternary Ammonium Compounds; Triazoles | 2012 |
Antiviral effect of maraviroc in semen: a case report.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Semen; Sperm Count; Triazoles; Viral Load | 2012 |
Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration.
Topics: Adult; CCR5 Receptor Antagonists; Chromatography, Reverse-Phase; Cross-Sectional Studies; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Male; Maraviroc; Middle Aged; RNA, Viral; Tandem Mass Spectrometry; Triazoles | 2012 |
Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques.
Topics: Administration, Intravaginal; Animals; Anti-HIV Agents; Biopsy; CCR5 Receptor Antagonists; Chromatography, High Pressure Liquid; Contraceptive Devices, Female; Cyclohexanes; Delayed-Action Preparations; Female; HIV Infections; HIV-1; Humans; Longitudinal Studies; Macaca mulatta; Maraviroc; Medroxyprogesterone Acetate; Pyrazoles; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tissue Distribution; Triazoles; Vagina; Valine; Virus Internalization | 2012 |
Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy.
Topics: Adult; Anti-HIV Agents; Cyclohexanes; DNA, Viral; Evolution, Molecular; Female; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Proviruses; Selection, Genetic; Triazoles; Viral Tropism | 2012 |
Impaired maraviroc and raltegravir clearance in a human immunodeficiency virus-infected patient with end-stage liver disease and renal impairment: a management dilemma.
Topics: Adult; Cyclohexanes; Disease Management; End Stage Liver Disease; Fatal Outcome; HIV Infections; Humans; Male; Maraviroc; Metabolic Clearance Rate; Pyrrolidinones; Raltegravir Potassium; Renal Insufficiency; Triazoles | 2012 |
Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia.
Topics: Aspergillosis; Female; HIV Infections; Humans; Male; Pneumonia, Aspiration; Pyridazines; Pyrimidines; Ritonavir; Triazoles | 2012 |
CCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cell-mediated infection, and a resistant variant.
Topics: Amides; Anti-HIV Agents; Binding Sites; CCR5 Receptor Antagonists; Cell Line; Cyclohexanes; HIV Infections; HIV-1; Humans; Maraviroc; Protein Structure, Secondary; Quaternary Ammonium Compounds; Receptors, CCR5; Sulfonamides; Triazoles; Tropanes; Virus Internalization; Virus Replication | 2012 |
Genetically encoded photo-cross-linkers map the binding site of an allosteric drug on a G protein-coupled receptor.
Topics: Allosteric Site; CCR5 Receptor Antagonists; Cross-Linking Reagents; Cyclohexanes; HEK293 Cells; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Models, Molecular; Mutagenesis, Site-Directed; Mutation; Receptors, CCR5; Triazoles; Ultraviolet Rays; Virus Internalization | 2012 |
[Cerebral aspergillosis in an human immunodeficiency virus infected patient].
Topics: Adult; AIDS Serodiagnosis; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Brain Edema; Cytomegalovirus Infections; Female; HIV Infections; Humans; Magnetic Resonance Imaging; Morocco; Neuroaspergillosis; Serratia Infections; Toxoplasmosis, Cerebral; Triazoles | 2012 |
Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission.
Topics: Administration, Intravaginal; AIDS Vaccines; Animals; Anti-Infective Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Macaca mulatta; Maraviroc; RNA, Viral; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Treatment Outcome; Triazoles; Viral Load | 2012 |
Immune recovery and T cell subset analysis during effective treatment with maraviroc.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Antigens; Cyclohexanes; Female; HIV Infections; Humans; Immunophenotyping; Male; Maraviroc; Middle Aged; Receptors, CCR5; Receptors, CXCR4; T-Lymphocyte Subsets; Treatment Outcome; Triazoles | 2012 |
Levels of soluble endothelial protein C receptor are associated with CD4+ changes in Maraviroc-treated HIV-infected patients.
Topics: Adult; Aged; Antigens, CD; Biomarkers; Blood Coagulation; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Endothelial Protein C Receptor; Endothelium, Vascular; Female; Follow-Up Studies; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Receptors, Cell Surface; Triazoles | 2012 |
Long-term maraviroc use as salvage therapy in HIV-2 infection.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Cyclohexanes; Drug Monitoring; HIV Infections; HIV-2; Humans; Maraviroc; Salvage Therapy; Treatment Outcome; Triazoles | 2012 |
Patients on a combined antiretroviral therapy after maraviroc clinical test show no immunovirological impairment.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Cyclohexanes; Female; Follow-Up Studies; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Treatment Outcome; Triazoles; Viral Load; Viral Tropism; Young Adult | 2012 |
Pharmacokinetic interaction between maraviroc and etravirine in HIV-infected patients receiving regimens containing both drugs and no ritonavir-boosted protease inhibitor.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Drug Interactions; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Multicenter Studies as Topic; Nitriles; Plasma; Pyridazines; Pyrimidines; Ritonavir; Triazoles | 2012 |
High prevalence of X4/DM-tropic variants in children and adolescents infected with HIV-1 by vertical transmission.
Topics: Adolescent; Anti-HIV Agents; CCR5 Receptor Antagonists; Child; Cross-Sectional Studies; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Male; Maraviroc; Prevalence; Receptors, HIV; Salvage Therapy; Triazoles; Viral Tropism | 2012 |
An expanded model of HIV cell entry phenotype based on multi-parameter single-cell data.
Topics: Amino Acid Sequence; Benzylamines; CCR5 Receptor Antagonists; Computational Biology; Cyclams; Cyclohexanes; Genetic Vectors; HEK293 Cells; Heterocyclic Compounds; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Models, Biological; Molecular Sequence Data; Multivariate Analysis; Phenotype; Receptors, CCR5; Receptors, CXCR4; Transfection; Triazoles; Virus Internalization | 2012 |
Stochastic model of in-vivo X4 emergence during HIV infection: implications for the CCR5 inhibitor maraviroc.
Topics: CCR5 Receptor Antagonists; CD4-Positive T-Lymphocytes; Cyclohexanes; HIV Infections; Humans; Maraviroc; Models, Theoretical; Triazoles | 2012 |
Maraviroc observational study: the impact of expanded resistance testing and clinical considerations for antiretroviral regimen selection in treatment-experienced patients.
Topics: Adult; Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Male; Maraviroc; Microbial Sensitivity Tests; Salvage Therapy; Treatment Failure; Triazoles | 2013 |
Effect of maraviroc on HIV disease progression-related biomarkers.
Topics: Adult; Antiretroviral Therapy, Highly Active; Biomarkers; CCR5 Receptor Antagonists; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclohexanes; Disease Progression; Female; Fibrin Fibrinogen Degradation Products; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Lipopolysaccharide Receptors; Lymphocyte Activation; Lymphocyte Count; Male; Maraviroc; Middle Aged; Receptors, CCR5; RNA, Viral; Triazoles; Viral Load | 2012 |
Prevalence and antifungal susceptibility of Candida parapsilosis complex isolates collected from oral cavities of HIV-infected individuals.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis, Oral; Caspofungin; Echinocandins; Female; Fluconazole; HIV Infections; Humans; Lipopeptides; Male; Microbial Sensitivity Tests; Mouth; Mycological Typing Techniques; Polymorphism, Restriction Fragment Length; Pyrimidines; Triazoles; Voriconazole | 2012 |
Successful salvage therapy of refractory HIV-related cryptococcal meningitis with the combination of liposomal amphotericin B, voriconazole, and recombinant interferon-γ.
Topics: Adult; Amphotericin B; Antifungal Agents; Drug Therapy, Combination; HIV Infections; Humans; Interferon-gamma; Male; Meningitis, Cryptococcal; Middle Aged; Pyrimidines; Salvage Therapy; Treatment Outcome; Triazoles; Voriconazole | 2012 |
The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression.
Topics: Adult; Anti-Retroviral Agents; Bacterial Translocation; CD4-CD8 Ratio; Clinical Trials, Phase II as Topic; Cross-Sectional Studies; Cyclohexanes; Female; HIV Infections; Host-Pathogen Interactions; Humans; Lymphocyte Activation; Male; Maraviroc; Middle Aged; Multivariate Analysis; Pyrrolidinones; Raltegravir Potassium; Risk Factors; Statistics, Nonparametric; T-Lymphocytes; Triazoles; Viral Load | 2013 |
Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brazil; CD4 Lymphocyte Count; Cyclohexanes; Drug Resistance, Viral; Enfuvirtide; Follow-Up Studies; Genotyping Techniques; HIV Envelope Protein gp41; HIV Infections; HIV Integrase; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Maraviroc; Mutation; Peptide Fragments; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Salvage Therapy; Treatment Outcome; Triazoles; Viral Load; Virus Replication | 2012 |
HIV-1 dynamics and coreceptor usage in Maraviroc-treated patients with ongoing replication.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Drug Resistance, Viral; Evolution, Molecular; Genotype; High-Throughput Nucleotide Sequencing; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Peptide Fragments; Receptors, CCR5; Receptors, CXCR4; Selection, Genetic; Sequence Analysis, RNA; Triazoles; Viral Tropism | 2013 |
Non-natural peptide triazole antagonists of HIV-1 envelope gp120.
Topics: Amino Acid Sequence; Anti-HIV Agents; Calorimetry; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Peptides; Peptidomimetics; Protein Binding; Triazoles | 2013 |
Pharmacokinetic interaction of maraviroc with tacrolimus in a patient coinfected with HIV and hepatitis B virus following hepatic transplant due to hepatocellular carcinoma.
Topics: Anti-HIV Agents; Carcinoma, Hepatocellular; Cyclohexanes; Drug Interactions; Hepatitis B; HIV Infections; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Maraviroc; Middle Aged; Plasma; Tacrolimus; Treatment Outcome; Triazoles | 2013 |
BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism.
Topics: Azepines; Benzodiazepines; CD4-Positive T-Lymphocytes; Cell Cycle Proteins; Cells, Cultured; HEK293 Cells; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Jurkat Cells; Nuclear Proteins; Positive Transcriptional Elongation Factor B; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; RNA Interference; RNA, Small Interfering; tat Gene Products, Human Immunodeficiency Virus; Transcription Factors; Transcription, Genetic; Triazoles; Virus Latency | 2013 |
A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action.
Topics: Calorimetry, Differential Scanning; CCR5 Receptor Antagonists; Contraceptive Devices, Female; Cyclohexanes; Delayed-Action Preparations; Drug Combinations; Drug Delivery Systems; Drug Stability; Drug Storage; HIV Infections; HIV Reverse Transcriptase; Hot Temperature; Maraviroc; Mechanical Phenomena; Pyrimidines; Reverse Transcriptase Inhibitors; Silicone Elastomers; Solubility; Triazoles | 2013 |
Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.
Topics: CCR5 Receptor Antagonists; CD4-Positive T-Lymphocytes; Cell Line; Cyclohexanes; env Gene Products, Human Immunodeficiency Virus; HEK293 Cells; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CCR5; Triazoles; Virus Attachment; Virus Internalization | 2013 |
Impact of antiretroviral pressure on selection of primary human immunodeficiency virus type 1 envelope sequences in vitro.
Topics: Amino Acid Sequence; Anti-HIV Agents; Base Sequence; Cyclohexanes; DNA, Viral; Genetic Variation; Genotype; Glycosylation; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Lamivudine; Maraviroc; Molecular Sequence Data; Phylogeny; Pyrrolidinones; Raltegravir Potassium; Receptors, CCR5; Receptors, CXCR4; Saquinavir; Sequence Analysis, DNA; Triazoles; Viral Tropism | 2013 |
Long-term suppressive combined antiretroviral treatment does not normalize the serum level of soluble CD14.
Topics: Adult; Aged; Anti-Retroviral Agents; Case-Control Studies; CD4 Lymphocyte Count; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Lipopolysaccharide Receptors; Longitudinal Studies; Male; Maraviroc; Middle Aged; RNA, Viral; Solubility; Time Factors; Treatment Outcome; Triazoles; Viral Load | 2013 |
Pharmacokinetics of maraviroc, raltegravir, darunavir, and etravirine in the semen of HIV-infected men.
Topics: Anti-HIV Agents; Area Under Curve; Cyclohexanes; Darunavir; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Nitriles; Prospective Studies; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Semen; Sulfonamides; Triazoles | 2013 |
Impact of antiretroviral therapy duration and intensification on isolated shedding of HIV-1 RNA in semen.
Topics: Amino Acid Sequence; Anti-Retroviral Agents; Base Sequence; Case-Control Studies; Cyclohexanes; HIV Infections; HIV-1; Humans; Incidence; Male; Maraviroc; Molecular Sequence Data; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Semen; Sequence Analysis, RNA; Sexual Behavior; Time Factors; Treatment Outcome; Triazoles; Viral Load; Viremia; Virus Shedding | 2013 |
Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.
Topics: Adult; Antiretroviral Therapy, Highly Active; Area Under Curve; CD4 Lymphocyte Count; Cyclohexanes; Darunavir; Drug Therapy, Combination; Female; Half-Life; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Male; Maraviroc; Middle Aged; Prospective Studies; Ritonavir; RNA, Viral; Sulfonamides; Triazoles | 2013 |
Frequency of amino acid changes associated with resistance to attachment inhibitor BMS-626529 in R5- and X4-tropic HIV-1 subtype B.
Topics: Amino Acid Sequence; Amino Acid Substitution; Anti-HIV Agents; CD4 Antigens; Drug Resistance, Viral; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Piperazines; Real-Time Polymerase Chain Reaction; Triazoles; Viral Tropism; Virus Attachment | 2013 |
Changes in susceptibility to posaconazole in clinical isolates of Candida albicans.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candida albicans; Candidiasis, Oral; Drug Resistance, Fungal; Genes, Viral; HIV Infections; Humans; Microbial Sensitivity Tests; Mutation; Triazoles | 2004 |
[Successful treatment with voriconazol of a Pseudallescheria boydii fungus ball in a HIV positive patient and previous tuberculosis].
Topics: Adult; Antifungal Agents; Female; HIV Infections; Humans; Lung Diseases, Fungal; Pseudallescheria; Pyrimidines; Remission Induction; Triazoles; Tuberculosis, Pulmonary; Voriconazole | 2003 |
Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360.
Topics: Anti-HIV Agents; Cells, Cultured; Clone Cells; Drug Resistance, Viral; Furans; HIV Infections; HIV Integrase; HIV-1; Humans; Mutation; Phenotype; Polymerase Chain Reaction; Triazoles; Virus Replication | 2004 |
What does "culture of life" mean for an undocumented immigrant?
Topics: Adult; Antifungal Agents; Clinical Trials as Topic; Coccidioidomycosis; Emigration and Immigration; Ethics, Medical; HIV Infections; Humans; Male; Mexico; Transients and Migrants; Triazoles; United States | 2005 |
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.
Topics: Anti-HIV Agents; Area Under Curve; CCR5 Receptor Antagonists; Clinical Trials, Phase II as Topic; Cyclohexanes; Dose-Response Relationship, Drug; HIV Infections; HIV-1; Humans; Maraviroc; Randomized Controlled Trials as Topic; RNA, Viral; Time Factors; Treatment Outcome; Triazoles; Viral Load | 2005 |
Organic chemistry at the interface to biology.
Topics: Awards and Prizes; Biology; CCR5 Receptor Antagonists; Chemistry, Organic; Cyclohexanes; DNA; Drug Design; Drug Evaluation, Preclinical; HIV Infections; Humans; Maraviroc; Photochemistry; Signal Transduction; Solar Energy; Triazoles | 2006 |
First case of Penicillium marneffei fungemia in Greece and strain susceptibility to five licensed systemic antifungal agents and posaconazole.
Topics: Antifungal Agents; Drug Resistance, Bacterial; Fungemia; Greece; HIV Infections; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillium; Triazoles | 2006 |
A modified Christensen's urea and CLSI broth microdilution method for testing susceptibilities of six Malassezia species to voriconazole, itraconazole, and ketoconazole.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Culture Media; Dermatomycoses; HIV Infections; Humans; Itraconazole; Ketoconazole; Malassezia; Microbial Sensitivity Tests; Polysorbates; Pyrimidines; Triazoles; Urea; Voriconazole | 2006 |
A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
Topics: Administration, Oral; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Dogs; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Mutation; Reverse Transcriptase Inhibitors; Triazoles | 2007 |
The latest in antiretroviral therapy.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Antibodies, Monoclonal; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Cyclohexanes; Darunavir; Drugs, Investigational; HIV Infections; HIV-1; Humans; Maraviroc; Nitriles; Organic Chemicals; Piperazines; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Receptors, Chemokine; Sulfonamides; Treatment Outcome; Triazoles | 2006 |
Rapid discovery and structure-activity profiling of novel inhibitors of human immunodeficiency virus type 1 protease enabled by the copper(I)-catalyzed synthesis of 1,2,3-triazoles and their further functionalization.
Topics: Catalysis; Combinatorial Chemistry Techniques; Computer Simulation; Copper; Crystallography, X-Ray; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Triazoles; Virus Replication | 2006 |
Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
Topics: Amino Acid Sequence; Amino Acid Substitution; CCR5 Receptor Antagonists; Cell Line; Cyclohexanes; Drug Resistance, Viral; Genes, env; Genetic Variation; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; In Vitro Techniques; Lymphocytes; Maraviroc; Molecular Sequence Data; Mutagenesis, Site-Directed; Peptide Fragments; Phenotype; Receptors, CXCR4; Triazoles; Virus Cultivation; Virus Replication | 2007 |
Researchers buoyed by novel HIV drugs: will expand drug arsenal against resistant virus.
Topics: Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; Drugs, Investigational; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; Humans; Maraviroc; Organic Chemicals; Pyrrolidinones; Raltegravir Potassium; Triazoles | 2007 |
Anti-HIV agents. New drugs, new hope, old lessons.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Cyclopropanes; HIV Infections; HIV Integrase Inhibitors; Humans; Lipodystrophy; Maraviroc; Organic Chemicals; Pyrrolidinones; Raltegravir Potassium; Triazoles; Viral Load | 2007 |
New HIV drug classes on the horizon.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Cyclohexanes; Drug Resistance, Viral; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Receptors, CCR5; Receptors, CXCR4; Triazoles | 2007 |
Acquired resistance to echinocandins in Candida albicans: case report and review.
Topics: Adult; Amino Acid Sequence; Amino Acid Substitution; Amphotericin B; Antifungal Agents; Candida albicans; Candidiasis; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Genotype; HIV Infections; HIV-1; Humans; Lipopeptides; Lipoproteins; Male; Micafungin; Microbial Sensitivity Tests; Molecular Sequence Data; Peptides, Cyclic; Pyrimidines; Treatment Failure; Triazoles; Voriconazole | 2007 |
Identifying safety concerns from genetic data: lessons from the development of CCR5 inhibitors.
Topics: Arthritis, Rheumatoid; CCR5 Receptor Antagonists; Cyclohexanes; Drug Design; Genotype; Hepatitis C; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Meta-Analysis as Topic; Multiple Sclerosis; Mutation; Pharmacogenetics; Receptors, CCR5; Research Design; Risk Assessment; Risk Factors; Triazoles | 2007 |
Pivotal moments in HIV treatment: the 14th CROI.
Topics: Anti-Retroviral Agents; Clinical Trials as Topic; Congresses as Topic; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Maraviroc; Multicenter Studies as Topic; Organic Chemicals; Pyrimidinones; Pyrrolidinones; Raltegravir Potassium; Treatment Outcome; Triazoles; United States | 2007 |
Advances in HIV therapeutics: the 14th CROI.
Topics: Acyclovir; Anti-HIV Agents; Circumcision, Male; Cyclohexanes; Dideoxynucleosides; Drug Interactions; Female; Hepatitis C; HIV Fusion Inhibitors; HIV Infections; Humans; Male; Maraviroc; Multicenter Studies as Topic; Nitriles; Organic Chemicals; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Triazoles | 2007 |
More data on maraviroc in treatment-experienced patients.
Topics: Cyclohexanes; Drugs, Investigational; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Treatment Outcome; Triazoles | 2007 |
FDA panel backs HIV drug.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Drug Approval; HIV Infections; Humans; Maraviroc; Triazoles; United States; United States Food and Drug Administration | 2007 |
Posaconazole for the management of mucosal candidiasis.
Topics: Antifungal Agents; Antiretroviral Therapy, Highly Active; Candidiasis, Oral; HIV Infections; Humans; Molecular Structure; Randomized Controlled Trials as Topic; Triazoles | 2007 |
Images in HIV/AIDS. Invasive aspergillosis presenting as a neck mass in a person with HIV/AIDS.
Topics: Adult; Antifungal Agents; Antiretroviral Therapy, Highly Active; Aspergillosis; Fatal Outcome; HIV Infections; Humans; Male; Neck; Pyrimidines; Tomography, X-Ray Computed; Triazoles; Voriconazole | 2007 |
Report from the XVI International HIV Drug Resistance Workshop.
Topics: Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; Humans; Lopinavir; Maraviroc; Nitriles; Piperazines; Pyridazines; Pyrimidines; Pyrimidinones; Triazoles | 2007 |
First medication in new class of ARTs poised to be available for salvage therapy. Tropism testing helps determine best patients for drug.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; HIV Infections; Humans; Maraviroc; Salvage Therapy; Triazoles; Tropism; Viral Load | 2007 |
Novel HIV treatment approved.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Drug Approval; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Triazoles | 2007 |
FDA approves maraviroc tablets.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Drug Approval; HIV Infections; Humans; Maraviroc; Tablets; Triazoles; United States; United States Food and Drug Administration | 2007 |
Changes in HIV-1 tropism: clinical and prognostic consequences.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; HIV Infections; HIV-1; Humans; Maraviroc; Prognosis; Receptors, CCR5; Receptors, CXCR4; Triazoles | 2007 |
Maraviroc reduces viral load in naive patients at 48 weeks.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclohexanes; Cyclopropanes; HIV Infections; HIV-1; Humans; Maraviroc; Triazoles; Viral Load | 2007 |
Maraviroc approved in the European Union.
Topics: Anti-HIV Agents; Controlled Clinical Trials as Topic; Cyclohexanes; Drug Approval; European Union; HIV Infections; Humans; Maraviroc; Triazoles | 2007 |
Post-exposure prophylaxis with a maraviroc-containing regimen after occupational exposure to a multi-resistant HIV-infected source person.
Topics: Adult; Anti-HIV Agents; Cyclohexanes; Drug Resistance, Multiple, Viral; Health Personnel; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Patient-to-Professional; Male; Maraviroc; Middle Aged; Needlestick Injuries; Occupational Exposure; Triazoles | 2008 |
Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Canada; CD4 Lymphocyte Count; Cyclohexanes; Drug Approval; Drug Resistance, Viral; Europe; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Lymphocytes; Randomized Controlled Trials as Topic; Receptors, CCR5; Receptors, CXCR4; Treatment Outcome; Triazoles; Tropism; United States; Viral Load | 2007 |
Two new drugs for HIV infection.
Topics: Administration, Oral; CCR5 Receptor Antagonists; Cyclohexanes; Drug Administration Schedule; Drug Costs; Drug Interactions; Drug Resistance, Viral; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Maraviroc; Organic Chemicals; Pyrrolidinones; Raltegravir Potassium; Treatment Outcome; Triazoles | 2008 |
A review of the clinical pharmacology of maraviroc. Introduction.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Maraviroc; Triazoles | 2008 |
A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive antagonist maraviroc.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Computer Simulation; Cyclohexanes; HIV Infections; Humans; Maraviroc; Models, Biological; Models, Statistical; Triazoles; Viral Load | 2008 |
Report from the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Maraviroc in treatment-experienced and treatment-naive patients.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; HIV Infections; Humans; Maraviroc; Treatment Outcome; Triazoles | 2007 |
FDA notifications. Maraviroc approved as a CCR5 co-receptor antagonist.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Drug Approval; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Triazoles; United States; United States Food and Drug Administration; Viral Load | 2007 |
[New drugs for HIV infection].
Topics: Anti-HIV Agents; Contraindications; Cyclohexanes; Darunavir; Drug Monitoring; HIV Infections; Humans; Maraviroc; Nitriles; Organic Chemicals; Patient Education as Topic; Patient Selection; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Triazoles | 2008 |
Multifocal squamous cell carcinomas in an HIV-infected patient with a long-term voriconazole therapy.
Topics: Antifungal Agents; Carcinoma, Squamous Cell; HIV; HIV Infections; Humans; Male; Middle Aged; Pyrimidines; Skin Neoplasms; Triazoles; Voriconazole | 2008 |
[CCR5 antagonists: a new class of antiretrovirals].
Topics: Benzoates; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Diketopiperazines; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Piperazines; Pyrimidines; Spiro Compounds; Triazoles | 2008 |
[Clinical pharmacokinetic of maraviroc].
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Drug Interactions; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Triazoles | 2008 |
[Maraviroc: clinical trials results].
Topics: Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Triazoles | 2008 |
In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection.
Topics: Antifungal Agents; Candida albicans; Candidiasis, Oral; Drug Resistance, Microbial; Fluconazole; HIV Infections; Humans; Microbial Sensitivity Tests; Mouth; Pyrimidines; Triazoles; Voriconazole | 1997 |
Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Candida; Candidiasis, Oral; Fluconazole; Genotype; HIV Infections; Humans; Itraconazole; Microbial Sensitivity Tests; Mouth; North America; Pharynx; Phenotype; Pyrimidines; Triazoles; Voriconazole | 1998 |
Is there in vivo-in vitro correlation between antifungal susceptibility, species of Candida spp. and clinical outcome?
Topics: Antifungal Agents; Candida; Candidiasis; Clinical Trials as Topic; HIV Infections; Humans; Microbial Sensitivity Tests; Neoplasms; Statistics as Topic; Treatment Outcome; Triazoles | 2000 |
Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candida albicans; Candidiasis; Drug Resistance, Microbial; Drug Synergism; HIV Infections; Humans; Microbial Sensitivity Tests; Naphthalenes; Pharyngitis; Pyrimidines; Terbinafine; Triazoles; Voriconazole | 2001 |
Genotyping and antifungal susceptibility of human subgingival Candida albicans isolates.
Topics: Adult; Amphotericin B; Antifungal Agents; Candida albicans; Dental Plaque; DNA, Fungal; Drug Resistance, Fungal; Female; Fluconazole; Genetic Heterogeneity; HIV Infections; Humans; Itraconazole; Karyotyping; Male; Microbial Sensitivity Tests; Mycological Typing Techniques; Triazoles | 2002 |
Researchers explore new anti-HIV agents.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclic N-Oxides; Drugs, Investigational; Enfuvirtide; Furans; HIV; HIV Envelope Protein gp120; HIV Envelope Protein gp41; HIV Infections; HIV Integrase Inhibitors; Humans; Nitriles; Oximes; Peptide Fragments; Piperazines; Piperidines; Pyridazines; Pyridines; Pyrimidines; Reverse Transcriptase Inhibitors; Triazoles | 2002 |
In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles.
Topics: Antifungal Agents; Azoles; Candida; Dose-Response Relationship, Drug; Fluconazole; HIV Infections; Humans; Itraconazole; Laboratories; Microbial Sensitivity Tests; Mouth; Naphthalenes; Pyrimidines; Quality Control; Terbinafine; Triazoles; Voriconazole | 2002 |
Pharmacokinetics of SCH-39304 in human immunodeficiency virus-infected patients following chronic oral dosing.
Topics: Administration, Oral; Adult; Antifungal Agents; Candidiasis, Oral; Drug Administration Schedule; HIV Infections; HIV-1; Humans; Male; Middle Aged; Triazoles | 1992 |